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Cystic Fibrosis is a life-shortening, autosomal recessive disease caused by mutations in
the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Cystic Fibrosis
is the most common lethal genetic disorder among Caucasians, and occurs at a rate of 1 in
every 3,400 births in the United States. The CFTR gene codes an anion channel expressed
on the mucosal side of the epithelia of multiple organ systems, including the digestive tract,
reproductive organs, pancreas, and airways. Loss of CFTR expression or function results in
an osmotic imbalance due to defective ion and water transport. In the respiratory tract, this
leads to airway surface liquid hyperabsorption and mucus dehydration causing decreased
mucociliary clearance rates. Failure to clear mucus and other inhaled debris favors the
development of mucus plugs and the prolonged colonization of harmful pathogens. These
conditions lead to a sustained, unregulated inflammatory response that results in severe tissue
damage and, ultimately, respiratory failure, the leading cause of Cystic Fibrosis mortality.
Cystic Fibrosis therapeutic development is largely dependent on the availability of model
systems that can be used to test and optimize therapies ahead of clinical use. These sys-
tems include networks of interactive elements that can be overly complex to exhaustively
explore experimentally. The work described here, focuses on the development of cell-scale,
mechanistic, and biologically relevant mathematical models that provide information about
the contribution of individual mechanisms to experimental outcomes.
The models were trained and validated with data obtained from human bronchial and
nasal epithelial cell cultures from donors with Cystic Fibrosis, non-Cystic Fibrosis controls,
and carriers of a single disease-causing allele. Within this context, we have use these models
as tools to explore the underlying mechanisms behind Cystic Fibrosis pathophysiology not
easily accessible experimentally. These predictions were further enhanced through the inclu-
sion of similar estimates generated from separately developed models of in vivo lung-scale
iv
function, as well as standard clinical measurements of airway function. Model predictions
provide us with unique and novel parametric descriptions of mechanistic and physiological
differences between the three populations and across multiple spatiotemporal scales. We
envision using these models as means to facilitate the deployment of personalized treat-
ment protocols, where cells sampled and cultured from individuals could be use to generate
patient-specific in silico predictors of lung-scale disease state and therapeutic response.
v
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1.0 Introduction
1.1 Airway Epithelial Structure and Function
Epithelia are inherently interfacial tissues. They exist ubiquitously across the entire
body, and serve a myriad of different specialized functions depending on their location. The
skin, for example, primarily serves as the outermost protective layer of the body. Stomach
epithelia regulate pH and facilitates digestion; intestinal epithelia facilitate water and nutri-
ent absorption; proximal tubules facilitate the secretion of excess solutes and fluids; while
lung epithelia hydrate the airway and facilitate gas exchange during breathing.
Regardless of their various functions, all epithelial tissues share a general structural for-
mula: a group of cells joined laterally through a junctional space that facilitates intercellular
communications and establishes a tight, mesh-like layer. This conformation creates two
distinct interfacial membranes: the apical (or mucosal) membrane that interacts with the
lumen, and the basolateral (or serosal) membrane where the epithelium attaches to other
tissue in the body. Figure 1.1 depicts the general structure of all epithelial tissues.
Transport in epithelial tissue can occur through transcellular pathways, or across the
the paracellular pathway along the junctional space in between the cells. The paracellular
pathway is delimited by tight junctions that connect the individual cells in the apical side
and act as a physical boundary that regulates the permeability of the epithelial tissue. More
permeant tight junctions lead to “leakier” tissue (e.g. airway, intestine), while the reverse
(e.g. kidney, stomach) leads to significantly reduced paracellular liquid and solute transport.
Changes in “leakiness” can therefore cause drastic differences in the hydraulic permeability,
electrical resistance and conductivity of an epithelial tissue.
The characterization of epithelial transport has been historically complex [106]. Transcel-
lular ionic permeability is traditionally assessed through electrophysiological measurements
of channel and cellular conductivity. However, the membrane structure of the epithelia re-
sults in a more physiologically complex system than dispersed cells, and thus requires more
technical nuance and careful examination.
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Figure 1.1: Diagram of the general structure of epithelial membranes. Epithelial cells adhere
to a basement membrane of connective tissue. Transcellular transport occurs in all epithelia
via channels and pumps in the apical and basolateral membranes. Paracellular transport
occurs through the tight junctions.
1.2 Fundamentals of Human Airway Electrophysiology
When considering the transport of ions across a cellular membrane, the electrochemical
potential (µˆ) represents the main driving force behind ionic transport. The total change in
potential energy behind this transport (∆µˆ) is the resulting driving force after the inclusion
of both the membrane potentials across the membrane (Em) and the chemical potentials (µ).
Em is affected by the changes in the distribution of electrical charges across the membrane
regardless of the chemical species, and is typically described through the Nernst equation.
In contrast, µ is dependent on the concentrations ([Xi]) and activity coefficients (yi) of each
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species i in each compartment. If we considered a single-ion system, equation 1.1 defines
∆µˆ, such that R is the gas constant, T is the temperature of the system, z is the valence of
ion i, and F is the Faraday constant.
∆µˆ = ∆µ+ zFEm = RT ln
(
[Xi]in
[Xi]out
)
+
RT
zF
ln
(
[Xi]in
[Xi]out
)
(1.1)
However, most biological systems of relevance are not single-ion systems. Therefore,
depending on the molar and charge distribution and the permeability of the membrane to
each individual ion, it is possible for the conditions that lead to electrical equilibrium (Vm =
0) to not also lead to chemical equilibrium (∆µ = 0), and vice versa. For example, imagine
a two reservoir system divided by a semipermeable membrane, where each compartment
contains two ionic species (i and j) of the same valence. Each compartment has equimolar
concentrations of each ion, but one compartment has a lower overall molarity. At time zero
this system is in neither chemical nor electrical equilibrium. If we define the membrane to
be permeable to both ions, then the system will reach equilibrium when the net change of
ion transport is zero (i.e. both species become equimolar across the two compartments).
However, if the membrane is only permeable to one species (i), electrochemical equilibrium
is reached when the net transport of species i is zero. In other words, when the chemical
gradient is offset by the charge distributions, without the need for species i to reach equimolar
conditions across the two compartments.
This example highlights the need to account for the electrostatic contributions to ionic
transport when dealing with polyionic solutions. In the case of airway epithelial electrophys-
iology, the electrolytes considered in the system are Na+, Cl−, and K+. This redefines Em
through the Goldman-Hodgkins-Katz equation to account for the three different ionic species
(equation 1.2), where Pi is the permeability of ion i, and Vm replaces the Em in equation
1.1.
Vm =
RT
F
ln
(
PNa[Na
+
out] + PK [K
+
out] + PCl[Cl
−
in]
PNa[Na
+
in] + PK [K
+
in] + PCl[Cl
−
out]
)
(1.2)
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In equation 1.1, the two terms on the right hand side can be described as the diffusive and
electrical driving forces, respectively. From these expressions, Goldman derived the single-
ion flux relationship across a cellular membrane, assuming a negligible membrane thickness
and constant electromagnetic field [66], as shown in equation1.3. Here, Γ+ and Γ− are the
upper and lower bounds on the feasible flux conductivities, respectively. It is clear from
equation 1.3 that ionic transport is inherently nonlinear in biological systems. This also
implies that common linear transport relationships such as Fick’s law (chemical diffusion) or
Ohm’s law (electrical conductivity) cannot single-handedly described this type of transport,
at least not under non-asymptotic behavior.
Ji =
zF 2Vm
RT
(
Γ+ − Γ− expRTVmF
1− expRTVmF
)
(1.3)
Having defined a physically relevant way to described ionic transport across biological
membranes, it is possible to extrapolate these flux equations to explain ionic transport dy-
namics in biological systems in a compartmental fashion. If, for example, we define our
system to be a single cell, the intracellular molar dynamics for a solute i (Ni) can be de-
scribed through an ordinary differential equation by considering the different influx and eﬄux
pathways relevant to that cell, as seen in equation 1.4. There, AC is the surface area of the
cell membrane, and K is the vector of all distinct pathways that conduct solute i across the
cell membrane. This general structure can be use to defined systems of transepithelial ion
transport for multiple species across multiple pathways, expressed in distinct membranes.
dNi
dt
= Ac
∑
K
Ji,k (1.4)
The Ussing Chamber can be applied to study individual membrane potentials. Figure 1.2
shows the simplest equivalent circuit diagram of the epithelial ion transport system. From
this representation it is easily observed that the three general transport pathways (apical and
basolateral membranes and the paracellular junction) are individual resistors that provide a
measurable electrical effect and can be studied individually.
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Figure 1.2: Diagram of the circuit abstraction of a epithelial monolayer. Ion channels and
transporters are considered resistors that regulate ion displacement. The plasma membranes
are taken to be slow-charging capacitors that inhibit flux of ions through non-physiological
pathways, and the electrochemical potential for each ionic species is considered as a potential
drop.
From this structure, we can derive an expression to assess the total epithelial resistance
(RT ), as seen in equation 1.5. Here RP and RC represents the paracellular and cellular
resistances, respectively. RP is due to the occluding effect of junction proteins like actin,
claudins, and connexins [36, 84].
RT =
[
1
RP
+
1
RC
]−1
=
[
1
RP
+
1
RAp +RBl
]−1 (1.5)
The density and structure of these proteins is what largely determines the leakiness of
an epithelial tissue type, where tighter epithelia have increased electrical resistance. The
apical (RAp) and basolateral (RBl) resistances are related to the density of channels and
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transporters in the apical and basolateral membranes, respectively. Higher densities and
transport rates correlate with lower resistances. If we assumed a relatively even channel
expression per surface area, the relatively smaller interfacial area of the lumen means the
apical membrane acts as the transport limiting step. [84].
1.3 Cystic Fibrosis: A Multi-Scale Disease
Cystic Fibrosis (CF) is an autosomal recessive disease that arises from a defect in the
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene [112]. It is the most
common lethal recessive autosomal disease among populations of Caucasian descent, affecting
around 70,000 patients worldwide, and with roughly 1,000 new cases diagnosed every year
[58, 143]. CF is a systemic disease, affecting multiple organs, with the most deleterious
effects taking place in the airways [141].
The CFTR gene codes for an anion channel expressed primarily on the apical membrane
of epithelial cells [151]. The absence or dysfunction of this channel and the associated loss of
Cl− and HCO−3 transport result in an electroosmotic imbalance of the epithelial membrane.
These disruptions can have broad consequences in the homeostatic function of multiple
tissues. For example, liquid hyperabsorption in the proximal ducts of the pancreas leads
to a drastic increase in the viscosity of exocrine secretions, decreasing the flow of multiple
digestive enzymes [101]. This build up induces a chronic inflammatory response, pancreatitis,
which leads to pancreatic insufficiency (∼ 90% of the CF population) [61]. In more severe
cases, this also causes the destruction of islet cells, triggering the development of CF-related
diabetes mellitus [61]. Similarly, liquid hyperabsorption in the intestines tends to manifest
as Meconium ileus, a blockage of the small intestine during the infancy of CF patients [112].
Meconium ileus in patients with Cystic Fibrosis is widely accepted as the leading cause of
bowel obstruction among newborns [185]. Similarly, congenital bilateral absence of the vas
deferens is responsible for approximately 2% of cases of male infertility [107], see Figure 1.3.
6
Figure 1.3: Description of primary organs affected by Cystic Fibrosis. The ubiquitous ex-
pression of CFTR across multiple epithelia leads to disruption in multiple organ systems.
However, the pathogenesis and the subsequent progression of CF airway disease, the
primary cause of morbidity for patients with CF [179], is not entirely understood. General
consensus suggests that lung disease starts to develop within the first few months of life for
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human infants with Cystic Fibrosis. Much of this knowledge has been derived from physio-
logical studies of neonatal CF animal models. These studies have highlighted the presence of
multiple physiological hallmarks of CF airway disease, including airway malformation, dys-
functional MCC, increased airway surface liquid (ASL) acidity, dehydration of the periciliary
liquid (PCL), and reduced pathogenic killing potential [23, 81, 88, 89, 148]. Furthermore,
in silico predictions of lung-level mucocilliary clearance (MCC) and absorption (ABS) dy-
namics informed with radiological studies in pediatric patients with CF suggest a possible
absorptive defect prior to adulthood [120].
1.3.1 Cystic Fibrosis Airway Disease
CF lung pathophysiology is characterized by liquid hyperabsorption, ASL depletion,
and mucus accumulation. This, in turn, creates the perfect environment for opportunistic
pathogens to thrive in, further compromising the integrity of the membrane and, possibly,
reducing the MCC rate [111]. The inability to clear pathogens will then lead to a vicious
cycle of chronic infection and further airway damage that eventually leads to premature
respiratory failure (see Figure 1.4). These elements of CF progression have been identified
and characterized through a multitude of methods, including in vivo functional lung imaging
studies [15, 30], in vitro characterization of fully differentiated primary airway cell lines [32],
and the development of multiple CF animal models, including ferret, mouse, pig, and rat
[93, 188, 194]. These combined approaches have provided a wealth of knowledge regarding
CF disease; they have also led to the development of multiple therapeutics that aim to both
ameliorate symptoms and correct the underlying anion channel defect, nearly quadrupling
of the average life expectancy of a person with CF over the last fifty years [114].
Most commonly, the progression of CF airway disease is tracked through longitudinal
spirometric measurements. Forced expiratory volume in 1 second (FEV1) and the rate of
pulmonary exacerbations (rate at which the patient requires hospitalization or treatment
with IV antibiotics) are some of the primary outcomes in clinical trials of pulmonary ther-
apies for CF [1, 53]. A decrease in FEV1 is indicative of a loss of lung function and the
possible worsening of bronchial obstruction [157, 162]. However, the rate of progression of
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CF airway disease can vary significantly. For instance, one study of 4,923 CF patients aged
6 to 17 in the US and Canada from 1994 to 2005 tried to estimate mean rates of change
of %FEV1. The study found several factors predictive of increased decline in FEV1 across
age-stratified groups, including age, gender (female), presence of crackles, FEV1 baseline,
as well as pseudomonas aeruginosa colonization, amount of sputum production, and use of
antibiotic to treat pulmonary exacerbation among all the groups [97].
Figure 1.4: Flowchart depicting the multi-scale nature of disease progression in Cystic Fi-
brosis, starting from the underlying genetic mutation and leading to osmotic imbalances,
airway obstruction, chronic inflammation, and eventual respiratory failure.
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However, the multi-scale, complex, and highly heterogeneous nature of the disease makes
it particularly difficult to study. As a genetic disease, CF disease phenotype is obviously re-
lated to the genotype of patients, but the relationship between a patient’s CFTR genotype
and their phenotype is not clear. In fact, recent studies have shown that CF disease phe-
notype is related to more than just CFTR genotype. Genome-wide association studies have
linked five non-CFTR gene loci that display significant correlation with variations in CF
airway disease severity [5, 35], response to CFTR-targeted therapeutics [34, 182], and the
incidence rates of other CF comorbidities [67]. Furthermore, these studies have helped iden-
tify meaningful variations of DNA methylation patterns present within previously identified
modifier genes of CF lung disease severity [115]. There is significant work left to do in or-
der to understand the full scope of CF airway disease pathophysiology across the different
physiological scales.
1.3.2 Cell Level Pathophysiology
At its most basic level, Cystic Fibrosis is a disease that disrupts the normal ion transport
functions of the cell. In healthy tissue, water, ions, and other solutes are transported in and
out of cells through a complex network of active and passive pathways, with the goal of
regulating and controlling several aspects of intracellular and pericellular function [190].
In epithelial cells, this network is particularly complex due to the polarized conformation
that these cells adopt. Epithelial cells differentiate as membranes made of adjacent cells
that develop distinct potential differences across each end of the cellular compartment. The
intracellular compartment acts as a central reservoir that interacts with both the basolateral
(serosal) and apical (lumenal) compartments through the transport of ion, water, and other
molecules across each respective membrane. Similarly, the apical and basolateral sides can
also interact through the paracellular pathway. The highly dynamic nature of the airway, as
well as the unique liquid/air interface at which these cells operate, makes them particularly
difficult to characterize.
The cystic fibrosis transmembrane conductance regulator (CFTR) is a transmembrane
anion channel that, under regular circumstances, is known to favor the secretion of Cl−
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and HCO−3 ions. CFTR is also involved, either directly or indirectly, in the regulation of
other ion channels and transporters, including the epithelial sodium channel (ENaC) [76],
the solute carrier family 26 member 9 (SLC26A9) [8], and aquaporin 3 (AQP3) [90, 171]. In
CF, CFTR is absent or dysfunctional. In the airway, this eliminates a key pathway for apical
Cl− secretion, and creates an electroosmotic imbalance that favors the hyperabsorption of
water from the lumenal to the serosal compartment.
Airway epithelium includes apical chloride transport as facilitated by both CFTR and
alternative channels, such as calcium-activated chloride channels (CaCCs) and SLC26A9 [8,
9, 84]. Apical Na+ and K+ transport occurs through ENaC and the large conductance Ca2+
activated K+ (BKCa) channels, respectively [84]. Basolateral Na+, Cl−, and K+ transport
occurs primarily through mechanisms including the Sodium-Potassium-2-Chloride (NaKCC)
co-transporter and Na+-K+-ATPase, as well as a series of basolateral Cl− and K+ channel and
co-transporters [84]. Water transport will also occur through multiple aquaporin channels
expressed at the apical, AQP5, and the basolateral, AQP4 and AQP3, membranes [200].
Paracellular transport of all major ionic and nonionic solutes is also relevant [32, 84, 211].
The reduction in Cl− secretion and overactive Na+ absorption generates osmotic condi-
tions that cause dehydration of the ASL, including the periciliary liquid layer (PCL) and
mucus layer [190]. The Cl−, Na+, and K+ concentrations act as the primary regulators of
lumenal composition and volume [190, 198]. Water transport is also affected in CF. Passive
water and solute transport also occurs in the paracellular space and is regulated by osmo-
larity and tight junction integrity [56, 128]. In vitro studies have shown that tight junctions
chronically exposed to cytokine profiles common to the CF airway exhibit profound changes
to their ion and liquid permeability [36]. Similarly, apical mucus accumulation has been
shown to affect transepithelial solute permeabilities [110]. A comparison of ASL conditions
between healthy and CF airway epithelium is depicted in Figure 1.5.
The absence, or dysfunction, of CFTR at the apical membrane also affects several com-
ponents of the upstream protein maturation cascade. For example, cells expressing ∆F508
CFTR, the most common CF-causing genetic mutation, can’t produce fully maturated
CFTR. The immature protein fails to clear one of several maturation checkpoints along
this cascade and gets tagged for degradation. This accumulation of misfolded protein may
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create a strain on the translational and protein maturation apparatus [156]. This strain can
in turn affect the expression of other proteins. Studies have shown decreased levels of the
soft palate, lung, and nasal epithelium clone 1 (SPLUNC1) in chronic CF disease [19, 71].
SPLUNC1 binds to ENaC, inhibiting its activation, thus, suggesting that the reduction of
SPLUNC1 in chronic CF may contribute to the increased Na+ flux typical of CF [184]. A
similar mechanism has been proposed to explain the role of defective CFTR protein in the
dysregulation of SLC26A9 through the Na+/H+ Exchange Regulatory Co-factor (NHERF1)
[8].
Figure 1.5: Normal PCL and MCC homeostatic behavior is maintained with normal func-
tion levels of CFTR at the apical membrane of the airway epithelium (left). In CF (right)
ASL hyperabsorption due to the absence of CFTR and subsequent dysregulation of elec-
trolyte balance causes mucus dehydration, and thickening, leading to chronic infections and
subsequent inflammation and tissue damage [119].
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1.3.3 System Level Pathophysiology
The liquid hyperabsorptive phenotype described in in vitro studies of CF cell cultures
is reflected in several organ level phenotypes. For example, the increased concentration
and/or differential production of different MUC proteins in the airway’s lumen alters the
rheological properties of mucus, making its clearance more challenging [79, 190]. Similarly,
PCL dehydration leads to ciliary stasis, which further prevents the elimination of mucus, as
well as the clearance of any inhaled pathogens or debris. These functional changes in the
airway create the perfect conditions for pathogenic colonization, which over the lifetime of
patients with CF leads to advanced airway damage and eventual respiratory failure.
CF airway disease is the primary cause of CF-related patient mortality [112]. The pro-
gression of airway disease is traditionally measured through spirometric tests [1, 53]. These
techniques, however, lack the resolution necessary to better understand the pathophysio-
logical changes occurring within the airway. CT studies have been used to provide insight
into the structural changes that occur as a consequence of airway obstruction and disease
progression [42]. Similarly, functional imaging through nuclear scans of the clearance of
inhaled radio-labeled pharmaceutical probes has been used to assess temporal changes of
MCC along the airway tree. This method commonly uses Tc99m Sulfur Colloid (Tc-SC) as
the probe. Tc-SC is a large particle designed to be too large for it to be absorbed across the
lung epithelium (see Figure 1.6 left panel), so a decrease in background- and decay-corrected
signal across the particular region of interest is attributed to MCC of the inhaled Tc-SC.
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Figure 1.6: Left panel: Tc-SC, and DTPA are delivered to the airways via inhaled aerosol. Both probes are cleared through
MCC at the same rate, however, only the smaller of the probes, DTPA, can also be absorbed through the epithelium. Right
panel: DTPA retention (green) can be subtracted from the Tc-SC retention (blue) to calculate the amount of absorption (red).
Modified from Markovetz, et al [120].
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MCC measurements have been extended through the use of an additional radiopharma-
ceutical, In111-DTPA (In-DTPA). DTPA is a small molecule, relative to Tc-SC, that can be
absorbed through the epithelial membrane’s paracellular pathways, as well as being cleared
through MCC (see Figure 1.6 left panel) [33, 111]. The size difference between DTPA and
Tc-SC is of great importance. It is assumed that the two molecules are cleared at identical
MCC rates, meaning any difference in In-DTPA and Tc-SC retention curves is due to ab-
sorption of In-DTPA across the airway epithelium, see Figure 1.6. Furthermore, In-DTPA
absorption has been shown to be directly proportional to in vitro liquid absorption measure-
ments in primary human bronchial epithelial (HBE) cell cultures, as well as being increased
in CF HBE cultures compared to non-CF HBE cultures [33, 111]. In-DTPA absorption mea-
surements (ABS) have been used as a surrogate biomarker of system level liquid absorption
as they are affected by both the paracellular component of liquid absorption and likely by
tight junction integrity. Consequentially, ABS measurements can be used to show increased
liquid absorption rates in patients with CF[33, 111, 120]. They also have the potential to
be used as an experimental assessment of airway hydration and the effect that different
therapeutic agents have on the absorption defect present in patients with CF.
At the system scale, MCC also acts as a host defense mechanisms against inhaled
pathogens [14]. In CF patients, the possible reduced efficacy, or absence, of MCC function
allows for opportunistic pathogens to colonize the airways and establish perennial biofilms
[109, 118]. The immune system responds to this chronic invasion with a strong, unregu-
lated inflammatory response characterized by a prolonged accumulation of neutrophils, high
proteolytic activity and elevated levels of multiple cytokines and chemokines [36, 87]. The
nature of this exaggerated inflammatory response is not entirely understood, and multi-
ple mechanisms have been suggested in the literature. For example, TRPA1 Ca+ channels,
among other functions, facilitate the fine-tuning of expression levels of multiple transcription
factors relevant within the inflammatory cascade, and have been shown to have highly dif-
ferent expression levels in primary cells harvested from CF patients [152]. Similarly, CFTR
is thought to play a direct role in the immune function of the epithelium [87]. This might
also explain why several inflammatory mechanisms such as the IL17/TH17 signalling cas-
cade and neutrophilic chemotaxis appear to be dysregulated in CF patients [6, 127]. The
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persistence of this type of inflammatory response results in tissue damage, epithelial fibrosis,
and bronchiectasis [6, 36, 51].
1.4 Mathematical Modeling of the Airway across Biological Scales: A Cystic
Fibrosis Case study
As described so far, CF affects a wide variety of functions with vastly different spa-
tiotemporal scales. Similarly, current therapies for CF span all pathophysiological scales
from inhaled antibiotics to combat chronic airway infections, inhaled osmotic agents that
transiently rehydrate the ASL and promote MCC, as well as small molecules that target
CFTR and attempt to restore and potentiate its functionality [53, 126, 162, 195, 196]. Many
of these approaches show high degrees of variability across the patients. It is true that some
of this variability is to be expected given a disease that can be caused by approximately 281
unique genetic mutations, affecting different aspects of CFTR structure and function [25].
However, this also highlights a clear need to better understand the consequent pathophysio-
logical differences that are likely to also play a role. In other words, there is an importance
of establishing coherent protocols of longitudinal personalized care that properly address the
unique needs of all CF patients.
It is important to point out that the multi-scale nature of CF presents a series of im-
portant challenges when attempting to identify possible biomarkers that can reliably inform
the relationship between cell or tissue level function and system-level clinical outcomes.
Mathematical models have gained significant interest within this field and present a novel
alternative to study the complex biophysics of CF airway physiology. Through the inclusion
of available experimental data, as well as relevant biological and clinical knowledge, math-
ematical models are designed to abstract the mechanisms responsible for different aspects
of airway function by deconstructing experimental outcomes into physiologically meaningful
components. From there, they provide a simple, reusable platform for experimentation and
to parametric descriptions and dynamic estimates of important system components. From
an engineering perspective, these model predictions and analysis can be combined with tradi-
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tional process control and design techniques in order to better address the unique challenges
of clinical applications.
The primary goal of process control is to maintain desired process operation conditions
in light of external perturbations. Translating this into medicine, the desired operating
condition would be to maintain or achieve stable patient health in the presence of various
disturbances such as trauma, disease or even clinical intervention. Traditionally, medicine
has operated as an open loop system where the physician manually closes the loop by mak-
ing treatment decisions informed by patient examination and charts. However, the inherent
complexities of all biological systems can produce unexpected deviations that obfuscate their
behavior and response to intervention. A fundamental assumption of this methodology is
that physicians’ decisions are accurate most of the time, but are usually based on linear
disease-treatment expectations that could be improved if personalized, model-based predic-
tions of patient response to treatment are available to support clinical actions. A proposed
work flow for such a framework is shown in Figure 1.7.
In this framework, final treatment decisions are solely in the hands of the physician,
but they are informed by rigorous, quantitative predictions of a course of therapy that is
optimal within measurement error and timing. Thus, mathematical models are effectively
used as a supplementary experimental tool, not unlike a mass spectrometer or CT-scan, to
generate valuable insights derived from experimental conditions that are either too expensive,
impractical, or unethical to carry out in the laboratory or clinic [134]. These ideas have been
explored in a number of medical application, such as: cancer chemotherapy and neutropenia
[57, 72, 80]; glucose control in diabetes and critical care [95, 96, 105, 146, 166, 202]; sepsis
[45, 219]; and CF [120, 174, 176].
1.4.1 Cellular Scale: Ion and Liquid Transport
There have been multiple attempts to mathematically model different aspects of cell
physiology relevant to CF disease, particularly liquid and ion transport. Among these, it is
important to mention the seminal work of David E. Goldman who, in 1943, published the
first comprehensive mathematical description of the relationship between the electrical and
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Figure 1.7: Top: Standard-of-care Physician-Patient treatment feedback loop. Bottom: A
clinical decision support system for treatment using model-informed physician decisions for
patient care.
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chemical natures of transmembrane ion flux [66]. This mathematical description has be-
come a cornerstone of mathematical modelling across multiple fields including neuroscience,
cardiology, and more recently, epithelial electrophysiology. The first work attempting to
model the dynamics of airway epithelium ion transport was published by Cook and Young
[29], and quickly followed by Hartmann and Verkman [75]. Both models presented slight
variations of the airway epithelium based on its electrochemical driving forces, but failed
to described the impact that liquid transport would have on the system [29, 75]. Novotny
and Jakobssen [136] published the first work to describe the interaction between ion and
liquid transport. This model was expanded by Falkenberg and Jakobssen to include the
possible effect that pH regulation would have on ion flux [54]. The expanded model included
almost every major channel expressed in the airway, but suffered from numerical instability
problems over timeframes relevant to system-level analysis [54]. Similarly, models developed
by Warren et al [207], and Herschlag et al [78] attempted to describe the effect that Ca2+
and purinergic signals, respectively, have on ASL homeostasis, but suffered from similar
numerical issues. More recently, Garcia et al [62], and O’Donoghue et al [138] developed
similar models of HBE to identify electrochemical transport parameters in CF and non-CF
cell cultures. These models have been used to assess the different electrophysiological trends
present under flooded conditions. Lastly, Sandefur et al improved upon the model developed
by Garcia and colleagues to include a simplified version of purinergic and Ca2+ signalling
and its role within ion and fluid transport across the epithelium [168].
1.4.2 Organ Scale: Clearance Dynamics
At the system level, the human airway has inspired a myriad of models that have at-
tempted to described different aspects of its physiology. Some examples include models that
attempt to mathematically describe the structure of the bronchial tree [21, 55], gas exchange
[104, 108] and its role in multiple chemical interactions [86], as well as linking disease states
with mathematically generated structural differences [49]. More generally, Burrowes and col-
leagues published a comprehensive multiscale description of lung physiology that attempts
to provide insight into possible strategies to provide a mathematical bridge between cellular
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and organ function [22]. In the realm of CF, mathematical models describing the pathophys-
iology behind the MCC and absorptive defects of the disease have taken precedence. Sturm
modeled the MCC mechanism as a set of stochastic differential equations that describe the
clearance of particles through a geometric abstraction of the airway. This model succeeds
in capturing decreased MCC rates in CF, but fails to identify an exact mechanism [183].
Similarly, Kuratova et. al developed a model that successfully described the potential role
that mucus rheology plays on the reduced MCC in CF patients [100]. Lastly, Markovetz
and colleagues developed a compartment-based model that follows a pharmacokinetics-type
approach to describe the MCC and liquid absorption of both CF and non-CF subjects. Their
model suggests the presence of areas of diminished MCC rate in patients with CF, as well
as the transient rescue of these areas with inhaled osmotic therapy [120].
1.5 Dissertation Overview
The work described in this manuscript outlines the first steps in the development of a
platform for the use of biophysically-inspired mathematical models of cell and tissue airway
physiology to improve our understanding of disease pathophysiology and treatment decisions,
eventually leading to the establishment of a framework for personalized treatment of CF.
Airway epithelial electrophysiology represents a complex system to model biophysically.
There exist several experimental techniques that allow for the characterization of the gov-
erning mechanisms. However, they cannot provide simultaneous information about the indi-
vidual dynamics of multiple network elements without the need to significantly perturb the
nature of the epithelium.
With this in mind, Chapter 2 focuses on the development and validation of a gen-
eralized, compartment-based model describing the mechanisms involved in primary human
airway epithelial cell cultures under common experimental conditions. The model allows for
the exploration of key interactive elements of the epithelial network, the description of elec-
trochemical ion transport, and the system’s response to common pharmacological stimuli.
The chemical and electrical components of the system required the inclusion of both alge-
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braic and differential states resulting in a largely non linear and heavily constrained model
with a discontinuous parameter space that spans multiple orders of magnitude. This also
leads to a high degree of parameter correlation due to tightly coupled transport dynamics
and pathway complexity. The model development process was further complicated by the
inherent data sparsity of the experimental results used to inform the model. Chapter 2
also describes the development of a parameter space exploration algorithm that combines the
robustness of a large scale, non linear optimizer, with the necessary reliability to satisfy the
constraints of our system. This algorithm was used to establish a simple, iterable workflow
where experimental data from primary cell cultures were used to inform the generation of
parametric distributions describing the population level physiology of both CF and non-CF
in vitro populations.
Lastly, Chapter 2 outlines two applications of this model: (1) the generation of para-
metric descriptions of the pharmacodynamic profile of CF HBE cell cultures following the
treatment with common CFTR corrector and potentiators; and (2) the evaluation and char-
acterization of physiological differences between two different in vitro models of CF, HBEs
and human nasal epithelial (HNE) cell cultures.
The lumenal side of airway epithelium is commonly lubricated by a ”thin film”, a small
volume of liquid called the airway surface liquid (ASL). The ASL is composed of a complex
mixture of protein, electrolytes, water, and other solutes that profoundly affect the function
of the epithelium. In CF, the ASL is severely depleted. Chapter 3 develops a thin film
variation of the electrophysiology model described in Chapter 2 that includes mechanisms
involved in the regulation of ASL homeostasis and paracellular solute and liquid transport,
allowing us to explore airway epithelial dynamics more akin to tissue level function.
Modeling the phenomena that underlie the regulation of ASL volume would provide
critical insights into the mechanisms that play a major role in the pathophysiology of CF.
A three compartment model will represent the dynamic volumes of the cells, the ASL, and
the basolateral bath. Both in vivo and in vitro ASL volumes were osmotically controlled via
the directed transport of solutes and liquid fluxes, both transcellularly and paracellularly.
Our model provides a novel platform to evaluate data obtained from patient-matched in
vitro experiments analogous to commonly used in vivo measurements of airway function in
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CF; thus proving a first step towards a multi-scale, personalized medicine platform in CF, see
figure 1.8. Furthermore, this allows us to longitudinally assess liquid transport dysregulation
and therapeutic response to treatment strategies like inhaled osmotic therapies.
Figure 1.8: A clinical decision support system for treatment design using model-informed
physician decisions for patient care.
Chapter 4 incorporates the mechanistic and parametric descriptions generated from
the models in Chapter 2 and Chapter 3 with in vitro and in vivo measurements. This
work highlights the development and implementation of a database that identifies novel
relationships between in silico predictions of airway physiology, common cell and tissue level
experimental assessments, and organ-level clinical data obtained from individuals with CF
lung disease, carriers of a single CFTR mutations, and healthy controls.
The three groups provided samples of HNE cells, performed a nuclear imaging study
to measure MCC and DTPA/airway surface liquid absorption (ABS), an in vivo pulmonary
function test, and inert gas washout studies. CF subjects also performed a second ABS/MCC
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imaging day that included inhalation of osmotic agents in order to characterize their thera-
peutic response. This data set was used to develop patient-specific descriptions that helped
us identify key physiological differences across all three cohorts. These differences provided
valuable insight into the high degree of variability seen among patients with CF.
Similarly, we leveraged this information to identify parameters that correlate dynamics
observed during in vitro experiments with organ-level behavior. Under the current paradigm
of CF airway pathogenesis and disease progression, sustained restoration of airway hydration
and MCC will prevent chronic infections and decrease the incidence of inflammation, poten-
tially halting disease progression. Therefore, the establishment of clear, minimally-invasive
strategies to assess individualized therapeutic response could represent a breakthrough in
CF treatment.
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2.0 Compartment-based model of human airway epithelial electrophysiology
under Ussing chamber conditions
2.1 Introduction
Healthy epithelial tissue maintains a very tightly regulated electrochemical balance of
Na+, Cl-, and K+ ions across the polarized membrane. Due to the ionic nature of their cargo,
chemical and electrical forces simultaneously drive these processes. These electrolytes, along
with water and other molecules, are transported through a complex network of trancellular
and paracelluar pathways to maintain physiologically homeostatic concentration gradients
between the apical, intracellular, and basolateral compartments for each electrolyte.
Herein we present a generalized, cell-scale, compartment-based model of ion and liquid
transport across the human airway epithelium that uses volume regulation and electrophys-
iological data from primary airway epithelial cells to quantitate parameter values. Our goal
in developing this model is to better resolve the specific physiological mechanisms that con-
tribute to CF disease pathophysiology. We believe that the mechanism-specific predictions
that our model generates can provide valuable insights that streamline the design of more
specific experimental protocols, as well as potentially help in the evaluation of the therapeu-
tic efficacy. The challenge is to construct a mathematical representation of the physiology
that can resolve the underlying mechanisms and their interactions.
In CF epithelial tissue, the absence or dysfunction of CFTR affects multiple interactive
elements of the airway epithelium electrophysiological network. The loss of Cl− secretion
across the apical membrane leads to cell and tissue-level dysregulation and ASL hyperab-
sorption. Characterization of the possible mechanisms responsible for this type of multi-scale
pathophysiological linkage is inherently difficult. These difficulties are further compounded
in epithelial cell lines when we attempt to emulate realistic airway conditions.
Several experimental techniques allow for the characterization of the interactions gov-
erning such mechanisms. However, they generally cannot provide simultaneous information
about the individual dynamics of multiple network elements without perturbing the condi-
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tions of the epithelial membrane. A relevant mathematical description of cell-scale epithelial
physiology requires the inclusion of key mechanisms that regulate ion and liquid transport
2.2 Methods and Protocols
2.2.1 Cell Culture
This study used primary HBE cell cultures harvested from non-CF (13 donors, n=70
filters), and CF (9 donors, n=37 filters) subjects, and HNE cell cultures from non-CF (11
donors, n=44 filters), CF (11 donors, n=34 filters), and carriers (3 donors, n=8 filters). The
HBE cells were cultured from excess pathological tissue removed after lung transplantation
and organ donation under a protocol approved by the University of Pittsburgh Investigational
Review Board (UPIRB), as described previously [43]. The non-CF donors presented with
different airway pathologies but were deemed homozygous for wild-type CFTR. All HNE
samples were obtained from either healthy individuals over 18 years of age with no known
history of airway pathology or smoking and a %FEV1 greater than 70%, patients with a
genetically verified CF diagnosis, or the biological parents of these CF patients, accordingly.
All donors of HNE samples were screened for CF-causing mutations and their respective
group assignment verified. The HNE samples were collected under a protocol approved by
the UPIRB. For more detailed information about the cell culture protocol see Appendix A.
2.2.2 Ussing Chamber
Primary airway epithelial monolayers cultured on filter supports (0.33-cm2 Costar Tran-
swell filters) were mounted in Ussing chambers, and the cultures were continuously short
circuited with a VCC MC6 automatic voltage clamp (Physiologic Instruments, San Diego,
CA) in order to measure their transepithelial short-circuit current (ISC). Transepithelial
resistance (TER), an indicator of monolayer integrity, was measured by applying a 2mV
bipolar pulse every 90s at the start and end of the experiments and calculated using Ohms
law. A TER measurement of 200Ωcm2 was used as a minimum threshold for inclusion of
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a ISC trace into the training data set, and 150Ωcm
2 for validation experiments. Ringers
solution composed of 115 mM NaCl, 25 mM NaHCO3, 5 mM KCl, 10 mM HEPES, 1 mM
MgCl2, 1.5 mM CaCl2, and 5 mM glucose was used to fill both the apical and basolateral
chambers for experiments containing bicarbonate. Chambers were constantly gassed with a
mixture of 95% O2 and 5% CO2, which guarantees proper mixing and maintains extracel-
lular pH at 7.4. For bicarbonate-free experiments, NaHCO3 was replaced with 25 mM of
Na-Gluconate, pH was adjusted with NaOH to 7.4, and chambers were gassed with air. All
experiments were performed at 37 C. Following voltage clamping and chamber flooding, the
ISC was allowed to stabilize until a steady state was reached (∼ 10 − 30min). Depending
on the experiment, different stimulants or blockers of ion transporters/channels were added
to either the apical or basolateral chambers: Amiloride (10µM , added apically) to block the
flow of Na+ through ENaC; Forskolin (10, µM , added basolaterally) to stimulate the flow
of Cl- through CFTR; Bumetanide (10µM , added basolaterally) to inhibit the flux through
the basolateral Na+-K+-2 Cl− co-transporter (NKCC); and CF Inhibitor-172 (10µM , added
apically) to block the CFTR-related current. Sufficient time was given to allow for a new
steady state to be reached after each addition.
2.2.3 Model Development
In the human airway apical Cl− transport is facilitated by both CFTR and alternative
Cl− channels (ACC), such as calcium-activated chloride channels (CaCCs) and SLC26A9
[84, 94, 138]. Apical Na+ and K+ transport occurs through ENaC and the large conductance
Ca2+ activated K+ channel (BKCa), respectively [84, 130, 142, 209]. Basolateral Na+, Cl−,
and K+ transport occurs primarily through mechanisms including the Na+- K+-2Cl− co-
transporter (NKCC) and Na+-K+-ATPase (NaKP), as well as a series of basolateral Cl−,
and K+ channel [84]. Water transport will also occur through multiple aquaporin channels
expressed at the apical (AQP5) and the basolateral (AQP4 and AQP3) membrane [84, 200].
In an Ussing Chamber (UC) experiment, the apical and basolateral compartments are
filled with predetermined solutions designed to mimic physiological electrolyte concentra-
tions. Due to their relatively high volume, when compared to the intracellular space, these
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Figure 2.1: Schematic of a standard Ussing chamber (UC) set up, and the corresponding
model abstraction of the airway epithelial cell culture insert used to measure short-circuit
currents. In the UC, the cell monolayers are located in between two large volume reser-
voirs representing the apical and basolateral compartments. These compartments each hold
approximately 4,000 times the volume capacity of the entire monolayer volume. Cells in
the monolayer have been differentiated under air/liquid interface conditions and maintained
consistent transepithelial resistance. The zoomed area describes the major contributors to
solute and liquid transport across the airway epithelium represented in the model equa-
tions. Cellular volume and electrolyte concentrations dynamically respond to changes in
electroosmotic driving forces.
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compartments can be mathematically modelled as infinite reservoirs, and thus need not be
included in the mass balances (Figure 2.1A). Therefore, transport of water between the
cellular and apical (Ap) or basolateral (Bl) compartments is driven solely by the osmotic
pressure difference, ∆piC,M , as described in Equation 2.1.
∆piC,M =
∑
k
γk
nk,C
VC
−OsmM (2.1)
Here, M is a set variable the includes both the Ap and Bl membranes, nk,c and VC are
the number of moles of solute k present in the cellular compartment, C, and the volume of
the same compartment, respectively. γk is the osmotic coefficient associated with solute k.
OsmM is the osmolarity of either the apical or basolateral compartment as defined by the
solutions simulated in the model. From this relation, we can then describe the intracellular
volume (VC) dynamics as:
dVC
dt
= Vm
∑
j
(LPM∆pii,j) (2.2)
Here, LPM is the hydraulic permeability of the membrane separating compartments i
and j, and Vw is the molar volume of water. In our cell cultures, the basolateral membrane
is at least 10-fold larger than the apical membrane because basolateral transport begins
immediately adjacent to tight junctions in the lateral intercellular space. As such, we allow
hydraulic permeabilities of the basolateral membrane to be an order of magnitude greater
than the apical membrane (LPB = 10LPA), similar to values previously reported in literature
[123].
Our model abstracts the transepithelial ion transport network as an electrical circuit.
This assumption allows us to describe ion channels as resistors that modulate flux and
membranes as slow charging capacitors that inhibit the transit of ions, unless through a
channel or transporter. Changes to the apical and basolateral membrane potentials due
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to ion movement are considered instantaneous and are thus modeled algebraically. For ion
channels, each flux is defined by Goldman’s rectification equation [66].
Ji→j =
zXFPYEi/j
RT
(
e
zXFPY Ei/j
RT − 1
) ([X]i − [X]j e zXFPY Ei/jRT ) (2.3)
Here, i and j represent the two compartments involved in the flux, T is the system’s
temperature, F is the Faraday constant, R is the ideal gas constant, PY is the estimated
permeability of channel Y , Ei/j is the membrane potential between compartments i and j,
zX is the valence of electrolyte X, and [X]i and [X]j are the electrolyte concentrations in
compartments i and j, respectively.
In the case of transporters and ionic pumps, the molar flux is calculated as a series of
Hill terms that modify the estimated maximum flux with predetermined stoichiometry and
directionality, based on known physiological data [54, 136].
Ji→j =
nJmaxY A∏( [X]i50
[X]j
+ 1
)h (2.4)
Here, n refers to the stoichiometric coefficient associated with each ion X for the respec-
tive transporter, JmaxY is the estimated maximum flux per ion for transporter Y , [X]
i
50 is
the required concentration of electrolyte X present in compartment i to achieve half of the
maximum flux, [X]i is the current concentration of electrolyte X in compartment i, h is the
Hill coefficient associated with ion X, and A is the area of the relevant membrane.
From the individual channel and transporter ionic fluxes, JY , we can calculate the elec-
trical current, IY , generated by the displacement of ion X through transporter Y , such
that:
IY = zxFJY (2.5)
Where F represents Faradays constant. It should be noted that currents are only cal-
culated for ion channels and electrogenic transporters (transporters with inbalanced charge
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displacement). Based on the model schematic given in Figure 2.1 B, we established the
equations governing liquid and solute transport in airway epithelia by defining an open mass
balance around the cellular compartment. Solute transport occurs via passive transport
down an electroosmotic gradient and by active, or facilitated, transport into and out of the
cell. Thus, changes in intracellular electrolyte concentrations for a given ion is described:
dXc
dt
=
∑
Y
JY +
∑
G
nxJact,G (2.6)
Here, XC is the intracellular concentration for ion X,JY is the ionic flux through ion
channel Y at time t, Jact,M is the flux due to an ionic pump or co-transporter, G, that
does not follow necessarily follow the electroosmotic gradient, and nx is any ion-specific
stoichiometry associated with G.
From the the relation between ion flux and current described in Equation 2.5, we can
describe the total apical, IAp, and basolateral, IBl, currents based on the ion channels and
transporters included at each membrane (Figure 2.1B), as follows:
IAp = IENaC + ICFTR + IACC + IBKCa (2.7)
IBl = IbCl + IbK − INaKP (2.8)
Lastly, these expressions are used to establish algebraic constraints that are used to
simulate the zero millivolts clamped transepithelial voltage, Et, conditions of the UC and
estimate the apical, EAp, and basolateral, EBl, voltages, see equations 2.9 and 2.10.
IAp − IBl ≈ 0 (2.9)
EAp + EBl = Et ≈ 0 (2.10)
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The model is able to predict intracellular electrolyte concentration changes in response
to treated with channel blockers and stimulants (see Figure 2.2, left panel), as well as predict
apical and basolateral potentials of equal magnitude but opposite value (see Figure 2.2, right
panel), thus simulating the voltage clamp conditions of the UC.
Figure 2.2: Percent change in electrolyte concentration (Left), and predicted apical and
basolateral potentials (Right) for a representative model simulation.
2.2.4 Parameter Estimation
The model was implemented in Pyomo, an open source, Python-based, object-oriented
modeling framework designed for the formulation and analysis of mathematical models for
complex optimization problems [73, 74]. Pyomo combines the advantages of a full-featured
programming language like Python and extends them to include the optimization capabil-
ities of traditional algebraic modeling languages. In particular, our model takes advantage
of methodology designed for the handling of generalized disjunctive programming and inte-
gration of dynamic differential/algebraic systems [73, 133]. Pyomo also includes a built-in
interface with multiple numerical optimizers. This work was carried out using Interior Point
Optimizer (IPOpt). IPOpt is an open source, large-scale optimization package designed to
find the local solution of optimization problems with nonlinear and/or non-convex objective
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and pathway-constraint functions [203]. Both Pyomo and IPOpt are freely available online
(http://www.pyomo.org/installation/, https://projects.coin-or.org/Ipopt, respectively).
The complex nature of the epithelial membrane’s ion and liquid transport network, and
its response within the UC poses a fairly difficult numerical problem to model. The need
to include both differential equations to model ion and water flux dynamics, and algebraic
pathway constraints to properly describe the electrical component of transport, results in a
nonlinear, highly stiff system with a discontinuous parameter hyperspace spanning multiple
orders of magnitude. These characteristics make it prohibitive to implement our model using
standard gradient-based optimization algorithms. Figure 2.3 summarizes the key differences
faced when estimating parameters for pathway-constrained models.
In order to address this, we developed an algorithm that uses a combination of a Latin
Hypercube (LHC) sampling scheme, and an a priori feasibility check to pre-screen potential
initial parametric guesses to determine if they are located within a physiologically plausible
region of the parametric hyperspace. LHC sampling is preferable for these types of appli-
cations because it guarantees a broader coverage of the parameter hyperspace by imposing
thresholds for how close two sampled points can be [145, 159, 160]. The algorithm verifies
the numerical feasibility of these guesses through the estimation and evaluation of model
constraints at time zero, and excludes parameter sets that either fail to converge (based
on a goodness of fit, Equation 2.11) or produce biophysically invalid results (based on a
feasibility criterion, Equation 2.12 ). The approved guesses are then used to initialize a full
implementation of the model previously described. 2.4 shows the summary work flow of this
algorithm.
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Figure 2.3: Summary of parameter estimation differences for differential algebraic equation (DAE) systems relative to traditional
ordinary differential equations (ODE) systems. An ODE system (Top row) parameter estimation schemes converge when the
simulated observable states approached the available data set, essentially minimizing an objective function χ. This, however,
does not guarantee that unobservable states will remain within physiologically meaningful ranges, since the model is dynamically
unconstrained. DAE pathway constraint models (Bottom row) include both χ and a feasibility criterion, , that guarantee the
model minimizes the error but also satisfies pathway constraints imposed on it. This can lead to a trade-off in goodness of fit
for overall system feasibility.
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Figure 2.4: Workflow diagram describing the psudocode for the parametric search algorithm we developed. The diagram
highlights the importance of incorporating a feasibility check prior to the optimization run in order to guarantee that physical
constrains are met at time zero, while still sampling large portions of the physiological parameter space.
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The objective function (χ2) is a mathematical representation of the agreement of exper-
imental data with observable predicted by the model. This model uses the weighted sum of
squared residuals as our objective function, defined as:
χ2(θ) =
m∑
k=1
d∑
i=1
(
y∗k,i − yk(, ti)
σ∗k,i
)2
(2.11)
Here, y∗k,i refers to the ISC data point recorded for each individual filter for donor k,
measured at time point ti, σ
∗
k,i denotes the standard error of the mean for all filters from
donor k recorded at the same time point, and yk(θ, ti) is the corresponding model-simulated
value of yk,i as predicted by a given parameters set, θ. The objective function will be
minimized according to:
θˆ =argmin
{
χ2(θ)
}
s. t. fmin ≤f(X, θ, t,X0) ≤ fmax
and θmin ≤ θ ≤ θmax
(2.12)
Here θˆ represent the parameter values that corresponds to the identified local solution to
the optimization problem, f the constraints functions as defined in the Model Development
section, θ are free model parameters, and fmin/max and θmin/max are the lower and upper
bounds defined for all constraint function and free parameters.
This algorithm was designed to establish a simple, iterable work flow, where experimen-
tal data from primary HBE and HNE cell cultures are used to inform the generation of
parametric distributions describing the population level physiology of both CF and non-CF
cell cultures. Constant values for cellular volume regulation, electrolyte-transporter affini-
ties, and other airway epithelium physiology descriptors were obtained from literature and
previously models of human airway electrophysiology [54, 62, 123, 138, 168, 174, 209, 211],
for more details please see Table S3.
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2.3 Results
2.3.1 Model Validation against known experimental outcomes
The algebraic nature of many of the system components, and the lack of direct exper-
imental data for any of the states describing intracellular dynamics, restricts our ability
to validate some of the model predictions. To address this issue, we chose to validate the
model through the simulation of known experimental protocols, and compare the results with
known trends found in literature. This can be done through the assessment of changes in
the model-predicted permeabilities of different transporters that should correlate to changes
in either the expression levels or functionality of the same channels.
2.3.1.1 Evaluation of in vitro pharmacodynamic response to CFTR modulators
CF HBE cultures (p=1, n=3) were treated with VX809 or a vehicle control for 24, 72, 120,
168, 240, or 336 hours. Short circuit current (ISC) measurements were collected to assess
CFTR channel activity. This was done in order to establish the optimal treatment protocol
to maximize cell culture response to modulator therapy. Results showed a steady dose-
dependent response profile to the magnitude of ∆IForskolin stimulated response up to 120 hrs
of chronic VX809 treatment. Treatment beyond this threshold, resulted in a complete loss
of the modulator’s corrective action. The lack of response to CFTR stimulation after 120
hours + of VX809 treatment is likely due to DMSO poisoning. DMSO is used to dissolve
the correctors, and its prolonged exposure can be cytotoxic. See Figure 2.5.
We verified the model’s ability to describe the rescue of mutated CFTR ISC through
treatment with small molecule correctors and potentiators. The model was informed with
UC data from CF HBE cell cultures (n = 5, filters = 20) treated with a vehicle control
(DMSO), or with the combination of corrector (VX809) for 24 hours and potentiator (VX770)
during the UC recording. CFTR rescue was simulated by opening the permitted parameter
range for predicted CFTR permeability in the model. Figure 2.6 shows the changes in
predicted parameters between the two groups. A slight, but significant, increase in CFTR
permeability was predicted, as well as a nominal increase in ACC permeability. This is
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Figure 2.5: (Top) Ussing Chamber ISC traces for ∆F508 homozygous CF HBE cell cultures
treated for 24, 72, 120, 168, 240, and 336 hours with a CFTR corrector (VX809), and acutely
with a CFTR potentiator (VX770). (Bottom) Bar plots showing the summary of the change
in ISC measured following the addition of Amiloride, Foskoling+VX770 and CFInh172.
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of particular interest due to recent findings from our collaborators that suggest mutations
affecting the trafficking of CFTR to the plasma membrane may also affect the trafficking
of SLC26A9 [8]. SLC26A9 is an anion channel expressed in the apical membrane of HBEs
believed to be constitutively active in non-CF HBEs, whose function is found to be absent
in CF HBE cell cultures[8, 9]. ENaC and BKCa showed no meaningful parametric difference
between the two groups.
Figure 2.6: Model-predicted parameter changes for (Left) Short-circuit trace model predic-
tions for CF HBE cell cultures (n = 5, filters = 20) treated with corrector and potentiator
(VX809 72 hrs, and acute VX770), or vehicle control (DMSO). (Right) ENaC, CFTR, BKCa,
and ACC permeabilities generated from Ussing Chamber data. Predicted CFTR and ACC
permeabilities showed statistically significant changes between control and corrector treat-
ments (p < 0.01).
2.3.1.2 Parameter predictions in response to TGF − β1 We also wanted to test
the ability of the model to predict changes in the molar flux of different channels as a result
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of treatment with compounds believed to affect multiple members of the electrophysiology
network. Over the last few years, there has been increased evidence that the cytokine TGF−
β1 plays a significant role in the regulation of ion channels expressed in the airway epithelial.
TGF − β1 is known to be elevated in CF patients, and single nucleotide polymorphisms in
TGF − β1 gene have been linked to increased severity of lung disease [50]. More recently,
TGF −β1 has been shown to limit BKCa function through the downregulation of LRRC26y,
and auxiliary protein believed to be responsible for facilitating BKCa’s function in non-
excitable cells by lowering its Ca+2 activation thresholds [94, 213]. Similar results have been
shown for TMEM16A, a Ca+2-activated Cl− channel expressed in the apical membrane of
airway epithelia [187], and perhaps more relevant, for CFTR [180].
In order to explore this problem, we informed our model with data obtained from UC
traces of non-CF HBE cell cultures (n = 5, filters = 18) treated with TGF − β1, or vehicle
control for 24 hrs. This data was graciously provided by Dr. Agnes Swiatecka-Urban.
Through our analysis, we assume that any regulatory changes induced by TGF − β1 have
reached steady state, and that any changes to the new state through the length of the UC
recording are negligible. Figure 2.7 shows significant decrease to the predicted molar flow
across CFTR, ACC, BKCa, and ENaC. These changes are in agreement with literature trends
for CFTR, and BKCa. TGF − β1 also appears to have decreased the overall Isc baseline
of the cell, which would explain the drastic decreased in Na+ flow through ENaC. TER
measurements were not significantly different between the control and TGF − β1 treated
groups.
2.3.2 Characterizing the Electrophysiology of Primary Human Bronchial and
Nasal Epithelia, an In Vitro and In Silico Approach
Primary human bronchial epithelial (HBE) cell cultures serve as a well-established ex-
perimental in vitro model of airway physiology. Most Cystic Fibrosis (CF) related studies
with primary cell cultures have been performed in differentiated HBE cultures, which show
the same ion and liquid transport defects as the CF airway [32, 138, 195]. However, HBE
cultures are typically sourced from donated lungs not suited for transplantation, or from
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Figure 2.7: Model-predicted molar flux changes for ENaC, CFTR, ACC, and BKCa gener-
ated from Ussing Chamber data from HBE cell cultures (n = 5, filters = 18) treated TGFβ1,
or vehicle control for 24 hrs. A flux’s sign represents directionality, such that a positive flux
means influx, and a negative flux means secretion.
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explanted lungs of patients diagnosed with advance airway disease. This reality presents two
main challenges: (1) it is not well understood whether HBE cells retain any physiological
abnormality due to the underlying disease state; (2) access to explanted lung tissue is limited
and can represent an insurmountable limitation to laboratories. These concerns are partic-
ularly relevant in CF, where samples are harvested from CF patients with advance airway
disease, who are in need of a lung transplant, and may not provide a good representation of
the physiology of patients with less progressed disease states.
Primary human nasal epithelial (HNE) cell cultures are a novel, and exciting, in vitro
model of airway physiology. HNEs can be differentiated and cultured in a similar manner
to HBEs and display anatomical markers similar to those of HBE cells like ciliation, mucus
secretion, and ion and liquid transport [41, 113, 125, 129, 208, 211]. HNEs can be harvested
through minimally-invasive nasal brushings from donors with no history of airway patholo-
gies, making them a better control for the study of disease-specific physiological changes
[129]. In CF specifically, HNEs can be harvested from individual patients at all stages of
disease progression and allow for analogous in vitro measurements to those obtained from
in vivo level measurements such as functional imaging scans and nasal potential difference
(NPD).
Airway disease in CF is characterized by lung infection, inflammation, and impaired
mucociliary clearance arising from depletion of the airway surface liquid (ASL). This occurs
due to improper liquid and solute transport caused by absence or dysfunction of the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) [151]. CFTR is a transmembrane
anion channel that under normal circumstances is known to secrete Cl- and HCO3- ions
in epithelial tissue [189]. Its disruption eliminates a key pathway for apical Cl- secretion
and creates an electroosmotic imbalance that favors the hyper-absorption of water from the
luminal to the serosal compartment. CFTR is also involved, either directly or indirectly,
in the regulation of other ion channels and transporters, including the epithelial sodium
channel (ENaC) [76], the solute carrier family 26 member 9 (SLC26A9) [8, 9], and aquaporin
3 (AQP3) [90, 171]. However, the exhaustive analysis of these cell-system interactions is
experimentally complex and necessitates the use of reliable models of airway physiology, in
particular transepithelial ion transport dynamics.
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In this study, we have performed electrophysiological measurements of ion transport dy-
namics on fully differentiated epithelium monolayers harvested and cultured from primary
bronchial and nasal epithelial samples. The study included three genotypic groups: (1)
patients with a genetically confirmed CF diagnosis, (2) carriers of a single CF-causing mu-
tation, and (3) subjects homozygous for wild-type CFTR with no history of airway disease.
These cultures were used to assess ion transport dynamics under Ussing Chamber (UC) con-
ditions and for the subsequent development of a generalized, biophysically-inspired, mathe-
matical model of ion transport dynamics across the human airway epithelium. The model
is constructed to be a representation of cell electrophysiology that can resolve the under-
lying individual ionic fluxes, while guaranteeing the adherence to biological and physical
constraints relevant to the system. Values obtained from model simulation recapitulate ex-
perimental findings of transepithelial ionic transport. This combination of experimental and
computational characterization methodologies provides an avenue to increase data resolution
through the estimation of physiologically-meaningful parameters that describe processes not
measurable experimentally, thereby allowing us to identify and characterize possible under-
lying electrophysiological differences between distinct culture groups due to either cell type
or CFTR genotype.
2.3.2.1 HNE and HBE show different electrophysiological dynamics Analysis
of the UC traces revealed that non-CF and CF HNE cell cultures followed similar electro-
physiological trends with respected to each other and to their HBE counterparts, but overall
current magnitudes appeared to be distinct to each cell type. A full breakdown of these
electrophysiological studies can be found in Figure 2.8 and Table 2.1. In HNEs, ISC prior
to any drug addition (IBaseline, µA/cm
2) is statistically equivalent between CF (Figure2.8B)
and non-CF (Figure2.8A) cultures, but did show a nominal decrease in CF (p = 0.285).
ISC was increased in CF HNE (Figure 2.8B) vs. CF HBE (Figure 2.8E) (p = 0.005).
In Non-CF, there was a trend towards a decrease in HNE vs HBE (p = 0.061). The same
trends are observed when comparing Amiloride-sensitive current (∆IAmiloride, µA/cm
2), a
typical marker of ENaC-associated Na+ transport, between non-CF and CF cell cultures in
HNEs (p = 0.578) and HBEs (p = 5.9x10−10). ISC current response to Foskolin (∆IForkolin,
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µA/cm2), a common in vitro measurement of CFTR transport activity, was different between
non-CF and CF in HNE (p = 9.6x10−13) and HBE (p = 1.9x10−20) cell cultures, as would be
expected. As well as between non-CF (p = 3.9x10−12), but not CF (p = 0.304) across the two
cell types. The exact same trends as ∆IForkolin apply to post-Foskolin, Bumetanide-sensitive
current drop (∆IBumetanide, µA/cm
2) (Non-CF vs. CF, HNE: p = 0.032, HBE: p = 6.3x10−20;
HBE vs. HNE, Non-CF: p = 2.6x10−17, CF: p = 0.331). It is interesting to point out that the
percent of ∆IForkolin inhibited by Bumetanide is more than 3 times greater in Non-CF HBEs
than Non-CF HNEs (∼ 75% vs. ∼ 21%). Together, these results suggest possible differences
in the electrophysiology profiles of Non-CF HBE and HNE cellular cultures, particularly
with regards to the transcellular transport of Cl−.
Our study also included UC traces from HNE cultures harvested from 5 parent donors
carrying a single CF-causing mutation ( wt/∆F508= 4, wt/2481insA = 1, Table 2.1, Figure
2.8C). These revealed possible differences between the electrophysiological profiles of carriers
relative to both non-CF and CF HNE cell cultures. In particular, carriers exhibited decreased
Ibaseline and ∆IAmiloride currents (Table 2.1, p  0.01, compared to both CF and non-CF),
approximately a 50% decrease in ∆IForkolin relative to non-CF cell cultures (p = 1.43x10
−3),
and an increased in the percent of ∆IForkolin inhibited by Bumetanide relative to non-CF
(∼ 59% vs. ∼ 21%, p = 0.003). No meaningful TER difference was observed between any
of the groups (Table 2.1, p ≥ 0.25).
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Figure 2.8: Cultures stratified by CFTR genotype and cell type. In sections A-E, the thick
lines near the top denote drug additions, used to calculate their respective ∆ISC . Solid lines
represent mean population trace after correcting for addition times, and dotted lines repre-
sent the ± SEM for the population: A) non-CF HNE (green), B) CF HNE (red), C) Carrier
HNE (purple), D) non-CF HBE (blue), and E) CF HBE (brown). F) Bar graph showing the
population mean (± SEM) for transepithelial resistances (TER). G) Bar graphs showing ISC
measurement means (± SEM). Unpaired t-test to establish statistical significance,∗ < 0.05
and • < 0.01.
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Table 2.1: Summary of statistical analysis for the comparison of electrophysiology for HNEs and HBE cell cultures, stratified by
their CFTR genotypes: healthy donors (non-CF, wt/wt, n = 13), carriers of a single CF-causing mutation (Carrier, wt/non-wt,
n = 5) and patients with CF (CF, non-wt/non-wt, n = 14). Mean (± SEM) were calculated from all filters in a given group. At
least 3 filters were used for each line included in the data set. Unpaired t-tests were used to compare and establish statistical
significance across all different possible pairings. ISC are shown in µA/cm
2 and TER in Ωcm2.
HBE HNE HBE vs. HNE
non-CF CF non-CF non-CF CF Carrier non-CF non-CF CF non-CF CF
vs. CF vs. CF vs. Carrier vs. Carrier
IBaseline 47.88 17.16 3.1x10
−13 38.20 31.50 12.61 0.285 2.12x10−5 1.60x10−3 0.061 0.005
(± SEM) (± 2.86) (± 1.87) (± 4.31) (± 4.50) (± 3.32)
∆IAmiloride -37.51 -14.00 5.9x10
−10 -34.40 -29.74 -9.80 0.578 4.68x10−5 9.93x10−4 0.546 0.002
(± SEM) (± 2.70) (± 1.64) (± 4.33) (± 4.48) (± 3.39)
∆IForskolin 17.95 0.088 1.9x10
−20 7.33 0.21 3.78 9.6x10−13 1.43x10−3 3.44x10−4 3.9x10−12 0.304
(± SEM) (± 1.03) (± 0.06) (± 0.75) (± 0.10) (± 0.70)
∆IBumetanide -13.09 0.051 6.3x10
−20 -1.52 0.16 -2.24 0.032 0.455 1.42x10−3 2.6x10−17 0.331
(± SEM) (± 0.79) (± 0.03) (± 0.76) (± 0.10) (± 0.56)
TER 534.46 597.02 0.372 560.24 516.02 735.36 0.413 0.345 0.246 0.384 0.541
(± SEM) (± 35.8) (± 15.6) (± 25.5) (± 37.3) (± 176)
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2.3.2.2 The mathematical model captures population ion transport dynamics in
HBE and HNE samples In order to describe differences between the electrophysiological
dynamics among these groups, the data obtained from the UC studies were used to inform
a mathematical model of ion and liquid transport under UC conditions, as described in
Methods and Materials. We first examined whether model simulations were able to predict
the transepithelial transport dynamics of all cell cultures, regardless of cell type or CFTR
genotypic makeup.
Donor specific model predictions were obtained by fitting the model using the optimiza-
tion scheme described in Equation 2.8 and 2.9, for all individual cell cultures measured from
a single primary cell line. Parity plots comparing the model-predicted and experimental
measurements for all cell types were generated (Figure 2.9). Individual dots represent the
experimental data from one filter at one time point plotted against the model prediction for
that cell line at the same simulated time. Root mean square error (RMSE) and R2 val-
ues were calculated and reported in order to assess the ability of the model to describe ion
transport dynamics of all cell groups within the constraints defined. The plots demonstrated
good agreement between the model and experimental data for both cell types, regardless of
CFTR genotype.
Next, parameter fits obtained from the simulations described above where analyzed and
summarized in Table 2.2. Calculated means from all parameter distributions suggest signifi-
cant differences between HBE and HNE model-predicted permeabilities for several transport
pathways. Since the predicted parameter sets are not constructed from a population level
fit, but rather from donor-specific parametric fits, the resulting distributions are non-normal
and can present apparent multimodalities. In order to address this, 2-sample Kolmogorov-
Smirnov test, a non-parametric test of the likelihood of two sample sets belonging to the sam-
ple distribution, was used to compare the corresponding distributions between non-CF HBE
and HNE cell cultures (Figure 2.10 A). The distributions showed meaningful changes in mean
model-predicted permeabilities (m/s) for ENaC (p = 2.67x10−4), CFTR (p = 1.32x10−4),
BKCa (p = 7.24x10−3), bCl (p = 9.56x10−4), and the maximal flux (mol/m2s) for NaKP
(p = 0.0412). ACC, PbK and NKCC display similar mean predicted values between the
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Figure 2.9: Parity plots comparing measured Ussing chamber data to cell-line specific model
fits against all 5 groups of cells: (A) non-CF HNE (green); (B) CF HNE (red); (C) Carrier
HNE (purple); (D) non-CF HBE (blue); (E) CF HBE (brown). Black dashed line represents
a perfect model fit. Cell-line specific model predictions were obtained by fitting the model
using a sum of square errors objective function with an variance-weighted simultaneous fit of
all individual cell cultures in any given cell line. Individual dots represent the experimental
data from one filter at one time point plotted against model prediction for that cell line .
Root mean square error (RMSE) and R2 values are reported for the parity between observed
and simulated values for all cell groups.
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Table 2.2: Summary of averaged population-level best fit parameters for CF, non-CF and
carrier cell cultures in HBE and HNE groups. Model includes pathway constraints that
satisfy the biophysical conditions of the Ussing Chamber system (e.g. electroneutrality,
voltage clamping). Logarithmic, variance-weighted, nonlinear least-squares was used as the
objective function. Model parameters were estimated via LHS/IPOpt optimization for model
training. Abbreviations include ENaC (PENaC), CFTR (PCFTR) BKCa (PBKCa), alternative
Cl− channels (PACC), basolateral Cl− (PbCl) and basolateral K+ (PK) permeabilities in m/s,
as well as the maximum fluxes through the basolateral Na+-K+-2Cl− co-transporter (JNKCC)
and Na+-K+-ATPase (JNaKP ) in mol/m
2s.
Cell Type/ PENaC PCFTR PACC PBKCa PbCl PbK JNKCC JNaKP
CFTR genotype x10−7 x10−7 x10−8 x10−8 x10−8 x10−8 x10−7 x10−7
HBE non-CF 26.92 19.54 5.31 26.7 4.59 4.39 1.02 9.97
CF 33.4 - 1.96 9.73 0.95 4.30 0.20 6.37
non-CF 1.29 0.78 6.30 19.9 9.10 5.01 0.79 5.01
HNE CF 9.46 - 0.43 21.1 0.68 2.52 0.10 0.31
Carrier 9.82 0.054 0.38 39.1 4.51 2.44 0.10 5.81
two groups. In order to further explore these changes, joint parametric plots were generated
between PbCl and PENaC , PCFTR, PBKCa, or JNaKP (Figure 2.10 B-E, respectively). These
plots revealed an increased in the predicted basolateral Cl− permeability in non-CF HNEs
relative to their HBE counterparts. The observed change in PbCl correlates with changes
observed in ENaC, CFTR and BKCa as well. When these trends are taken into consideration
alongside the differences in ∆IForkolin and ∆IBumetanide observed between non-CF HBEs and
HNEs in Figure 2.8 A, these predictions suggest HBEs and HNEs transport Cl− at distinct
homeostatic rates in the absence of a Cl− gradient.
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Figure 2.10: Plots summarizing the model-predicted parameter distributions for non-CF
HBE (blue) and HNE (green) cell cultures. (A) Split violin plots for predicted distributions
for all free parameter in the model. A 2-sample Kolmogorov-Smirnov test was used to
compare the predicted distributions for each parameter between the two groups. ∗: p < 0.05,
• : p < 0.01. (B-E) Joint parametric scatter plots of the subject-specific, model-predicted
parameters that showed statistically significant distributions between non-CF HBEs (blue)
and HNEs (green). PbCl vs. (B) PENaC , (C) PCFTR, (D) PBKCa, or (E) JNaKP . All plots are
on a base 10 logarithmic scale to better demonstrate the parametric shift between the two
populations.
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2.3.2.3 Basolateral Cl− transport is different between HBEs and HNEs As a
way to explore any potential differences in the basolateral Cl− transport between HBEs and
HNEs and attempt to validate model predictions, a series of experiments were designed to
explore the role of NKCC in Cl− intake. UC traces for non-CF HBE and HNE filters (N
= 3, n ≥ 7) were measured with two different drug addition sequences. For the first set
of runs, the addition sequence was as follows: (1) Amiloride (blocks ENaC), (2) Forskolin
(stimulates CFTR), (3) CFIhn172 (blocks CFTR), and (4) bumetanide (blocks NKCC).
In the second set, Amiloride is still added first, followed by Bumetanide, Forskolin and
CFIhn172, in that order. The first sequence represents a fairly standard UC experiment
run designed to provides information about the baseline function levels for both cell types.
The second addition sequence was designed to explore the ability of the cells to move Cl−
following the inhibition of NKCC Cl− intake. A graphical summary of this protocol can be
found Figure 2.11.
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Figure 2.11: Protocol of Experiments to explore the role of the Na+-K+-2Cl− co-transporter in HNE and HBE cell cultures.
I. the addition sequence was as follows: (1) Amiloride (blocks ENaC), (2) Forskolin (stimulates CFTR), (3) CFIhn172 (blocks
CFTR), and (4) bumetanide (blocks NKCC). II. Amiloride is still added first, followed by Bumetanide, Forskolin and CFIhn172,
in that order. The first sequence represents a fairly standard UC experiment run designed to provides information about the
baseline function levels for both cell types. The second addition sequence was designed to explore the cells ability to move Cl−
following the inhibition of NKCC Cl− intake.
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Figure 2.12 shows representative ISC traces of non-CF HBE (A, B) and HNE (C, D)
for the two conditions listed above, respectively. Comparison between these conditions for
the same cell type showed that treatment with Bumetanide prior to the stimulation of
CFTR results in significant inhibition of ∆IForkolin for both non-CF HBE (-Bumetanide:
18.99±5.30, +Bumetanide: 8.03±1.50; p = 1.93x10−3) and HNE cell cultures (-Bumetanide:
9.62 ± 2.06, +Bumetanide: 5.27 ± 1.66, p = 0.043). Furthermore, when Bumetanide is
added prior to Forskolin, HBE cultures showed a statistically higher mean percent inhibition
of ∆IForkolin than HNEs relative to baseline ∆IForkolin measurements (HBE: ∼ 57.7% vs.
HNE: ∼ 45.2%, p = 1.34x10− 2). Figure 2.12 E shows bar plots summarizing the mean (±
SEM) from ∆IForkolin measurements from non-CF HNEs and HBEs under both experimental
conditions.
2.3.2.4 Bicarbonate is essential for HNE Cl− transport In order to further explore
the mechanism behind the Cl- transport differences we have described, non-CF HBE and
HNE (N = 3, n = 8) UC experiments were run to assess the role that bicarbonate, HCO−3 ,
transport has on electrophysiology dynamics. These experiments either included or removed
HCO−3 from the extracellular solutions and used the following drug addition sequence: (1)
Amiloride, (2) Bumetanide, (3) Forskolin, (4) CF Ihn172. Figure 2.13 shows representative
ISC traces of non-CF HBE (A) and HNE (B) for the two conditions listed above. Comparison
between these conditions for the same cell type showed that removing HCO−3 and blocking
NKCC significantly reduces the ∆IForkolin and ∆ICFIhn172 relative to baseline measurements
in non-CF HNEs (∆IForkolin; +HCO
−
3 : 1.69±0.65, -HCO−3 : 0.23±0.05; p = 2.64x10−4), but
not for their HBE counterparts (∆IForkolin; +HCO
−
3 : 6.79± 2.63, -HCO−3 : 5.63± 0.92; p =
0.134) (Figure 2.13 A-D. Similarly, we explored the effect that the addition of Bumetanide
and the removal of HCO−3 has on CF HNE cell cultures treated with a CFTR corrector and
potentiator combo. The results showed no meaningful change in ∆IForkolin between three
conditions tested (-Bumetanide/+ HCO−3 : 4.01±0.02; +Bumetanide/+ HCO−3 : 4.61±0.01;
+Bumetanide/- HCO−3 : 5.62 ± 1.42). The addition of Bumetanide or removal of HCO−3
both effectively abolished ∆ICFIhn172 measurements (-Bumetanide/+ HCO
−
3 : −7.94± 0.79;
+Bumetanide/+ HCO−3 : −1.28± 0.01; +Bumetanide/- HCO−3 : −1.16± 0.03)(Figure 2.14).
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Figure 2.12: Summary of Ussing Chamber experiments designed for validation of model
predictions. (A-D): representative short circuit current traces for HBE (A-B) and HNE (C-
D) non-CF cell cultures (N = 3, n = 7, per cell type per experiment type). Plots on the
left (A, C) were treated acutely with the following pharmacological addition: (1) Amiloride
(blocks ENaC), (2) Forskolin (stimulates CFTR), (3) CFIhn172 (blocks CFTR), and (4)
Bumetanide (blocks NKCC). Plots on the right (B, D) were treated acutely with the following
pharmacological addition: (1) Amiloride (blocks ENaC), (2) bumetanide (blocks NKCC), (3)
Forskolin (stimulates CFTR), and (4) CFIhn172 (blocks CFTR). (E) Bar graphs showing
measured ∆IForskolin, µA/cm
2(±SEM) per cell type per addition sequence. Student t-test
was used to established statistical significance between the different groups. ∗ : p < 0.05.
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Figure 2.13: Summary of Ussing Chamber experiments to asses effect of bicarbonate ion,
HCO−3 , on airway epithelial Cl- transport. (A) Representative short circuit current traces for
non-CF HBE cell cultures. (B) Representative short circuit current traces for non-CF HNE
cell cultures. Solid lines represent filters treated with Bumetanide and with HCO−3 in the
extracellular solution. Dashed lines represent filters treated with Bumetanide in the absence
of HCO−3 in the extracellular solution. (C) Bar graphs showing ∆IForkolin (µA/cm
2±SEM)
for non-CF HBEs and HNEs measured under the two conditions described above. (E)
Bar graphs showing ∆ICFIhn172 (µA/cm
2 ± SEM) for non-CF HBEs and HNEs measured
under the two conditions described above. Student t-test was used to established statistical
significance between the different groups. ∗ : p < 0.05. Three different primary lines were
used for each experimental condition (N = 3, n = 8).
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Figure 2.14: Summary of UC experiments to assess effect of Bumetanide treatment and bi-
carbonate ion, HCO−3 , on airway epithelial Cl
− transport of primary CF HNE cell cultures.
Cell cultures were treated with VX809, a CFTR corrector (10 µM) for 48 hours prior to ex-
periment. Following addition sequence was used: (1) Amiloride, (2) Bumetanide or nothing,
(3) Forskolin and VX770 (5 µM , CFTR potentiator), and (4) CFIhn172. (A) Representative
ISC traces.Dotted line represents filters with no Bumetanide added and with HCO
−
3 present
in the extracellular solution. Dashed lines represent filters treated with Bumetanide with
HCO−3 . Solid lines represent filters treated with Bumetanide in the absence of HCO
−
3 . (B)
Bar graphs showing ∆IAmiloride, ∆IForskolin, and ∆ICFIhn172 (µA/cm
2±SEM) measured un-
der the conditions described above. Student t-test was used to compare the different groups.
∗ : p < 0.05. Three different primary lines were used per experimental condition (N = 3, n
= 7).
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2.4 Discussion
HNEs represent a novel and exciting new model for the study of airway physiology
and pathologies. This is particularly underscored in a study by Tosoni and colleagues that
measured TER, transepithelial voltage, and calculated equivalent currents from 137 pseudos-
tratified HNE cultures from 18 healthy donors [193]. Their study validated the feasibility of
HNEs as a platform for common in vitro studies performed in other primary epithelial models
like HBEs. However, it also found significant inter-patient variability with positively-skewed
log normal distributions for all three measurements, suggesting the importance of initial cell
line specific baseline measurements as a set point for framing experimental results [193]. In
spite of their potential, the extent to which HNE electrophysiology may differ from that of
HBE cultures has yet to be fully characterized. Studies on ENaC expression and functional
levels in the nasal tissue, as well as the potential clinical relevance of these measurements,
serve as a great example. A study that sampled tissue from the airways of patients under-
going a lung lobectomy showed that nasal tissue expressed markedly different mRNA levels
of the α− and γ−subunits of ENaC when compared to bronchial and peripheral lung biop-
sies [140]. Similar studies have also found that these expression levels are correlated with
Benzamil-sensitive NPD measurements and ∆IAmiloride measured from nasal mucosa tissue
samples, in vivo and in vitro measurements of ENaC function, respectively. This suggests a
change in the homeostatic functional levels of ENaC as a function of depth along the airway
tree (i.e. nasal cavity vs. bronchi) [144, 216].
In an effort to develop a consistent electrophysiological dataset to asses these type of
differences, fully differentiated HBE and HNE cultures were used to perform transepithelial
short-circuit electrophysiology studies under UC conditions as described previously. Data
demonstrated that HNE filters present statistically significant decreases in ∆IForskolin and
∆IBumatanide with respect to HBE filters under the same conditions. ∆IForskolin is a commonly
used marker of in vitro CFTR function, as well as the common in vitro endpoint for CFTR
corrector and potentiator efficacy in CF. The concurrent change in both the magnitude
of∆IBumetanide and the percent of ∆IForskolin inhibited by Bumetanide suggest significant
differences in the overall Cl− transport dynamics exercised by each cell type. In fact, the
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observed differences in IBaseline (p = 0.06) between the two cell types, while not significant, do
support the notion of varied electrophysiology dynamics between the two cell types (Figure
2.8 A, D-E).
In order to further explore these observations, this dataset was used to inform a bio-
physically inspired model of airway epithelium electrophysiology (Figure 2.1 B). The model
accurately recapitulated Isc for all five groups (Figure 2.9 A-E). Interrogation of model
mechanisms corroborated the different ionic flux dynamics, particularly an overall reduced
transepithelial Cl− secretion in HNEs. The model predicted a shift in the basolateral Cl−
permeabilities and fluxes between HBEs and HNEs. Specifically, subject-specific parameter
sets were used to generate possible parameter distributions for each cell type. These dis-
tributions showed a significant decrease in JNKCC and PCFTR, and an increase in PbCl for
non-CF HNEs relative to their HBE counterparts (Figure 2.10 A). UC experiments looking
at ∆IForskolin in the presence or absence of Bumetanide revealed a significantly higher in-
hibitory effect in HBEs than HNEs (Figure 2.12 A-E), supporting the previously described
model findings.
Differences in CFTR function between nasal and lung airways have not been well de-
scribed and may affect CF pathophysiology. A previous study of CFTR expression and
function levels did not find any significant differences in ISC measurements between HNEs
and HBEs regardless of CFTR genotype in the presence of a large serosal to mucosal Cl− gra-
dient [153]. (It is important to note that a Cl− gradient could induce a saturated transport
mechanism, where the increased transport driving force inherently changes the homeostatic
behavior of the epithelium.) A separate study that looked at patient-matched, non-CF HBE
and HNE cultures found a linear relation between the CFTR-related ISC measurements, but
the relation does not appear to follow parity, which possibly indicates distinct functional
levels [17]. An earlier study also supports this claim in cultures from donors homozygous for
wild-type CFTR but reported TER measurements below 100Ωcm2 for most of their samples
[113]. Together these findings support the notion of distinct Cl− transport dynamics for the
nasal and bronchial epithelia.
In order to further explore this possibility, and to identify a possible mechanism behind
this shift, we evaluated the effect that pre-Forskolin treatment with Bumetanide, and the
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removal of HCO−3 from the extracellular solution has on HBEs and HNEs UC dynamics.
These experiments showed that while HBE cells do show a non-significant decrease in the
∆IForskolin and ∆ICFIhn172, relative to baseline, HNEs showed almost no current response
to either pharmacological event (Figure 2.13 A-B) in the absence of HCO−3 . This indicates
that HCO−3 plays a more important role in Cl
− transport in HNEs than HBEs. Together,
these findings point to an increase in Cl− flux linked to HCO−3 in HNEs relative to baseline
levels in HBEs.
Anion (Cl− and HCO−3 ) transport has been of great interest in the study of airway ep-
ithelium, particularly with regards to submucosal glands in bronchi [44]. Single cell and
monolayer electrophysiology studies in Calu-3 cells have shown that basolateral transport
of HCO−3 accounts for a large portion of basolateral Cl
− loading and that under voltage
clamp conditions the lumen favors the secretion of HCO−3 as oppose to Cl
− [172, 175]. In
fact, similar studies suggest a possible anion exchange mechanism where the simultaneous
influx of Na+ and HCO−3 through basolateral SLC4A4 (NBC) transporters leads to a cor-
responding basolateral Cl− influx and HCO−3 eﬄux through SLC4A2 (AE2)[99]. AE2 is a
Cl−-HCO−3 anion exchanger, and NBC is a unidirectional Na
+-HCO−3 co-transporter; both
are believed to be expressed in the airway epithelium [84]. This mechanism has been shown
to be serosal Bumetanide insensitive, Forskolin-stimulated, electrogenic, serosal DNDS (a
potent inhibitor of NBC) sensitive, serosal Na+ dependent, and favored under depolarized
basolateral potential conditions (EBl ≈ −40mV ) [44, 175].
Apical permeabilization studies confirmed electrogenicity due to unequivalent Na+-
HCO−3 intake through NBC, with an estimated 2:1 stoichiometry[99, 175]. Similarly, the
stable knock-down of AE2 in the same system abolished Cl−/HCO−3 basolateral exchange
and increased the fraction of ∆IForskolin sensitive to Bumetanide, suggesting a reversal to
an NKCC-dominated basolateral Cl−intake profile [85]. Lastly, activation of basolateral
Ca2+-activated CTX-sensitive K+ channels (hIK) with I-BIO (a sustained intracellular Ca2+
stimulant), hyperpolarized the basolateral potential, diminished HCO−3 intake and increased
the fraction of NKCC contribution to basolateral Cl− intake [18].
Other studies have described similar mechanisms. Murine models deficient for NKCC
exhibit a compensatory, HCO−3 -mediated Cl
− transport pathway in both airway and gut ep-
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ithelia [44, 65, 204]. Even more relevant is a different study that performed UC measurements
under isosmotic and HCO−3 free conditions on nasal tissue samples obtained from 9 non-CF
patients and observed low (less than 2µA/cm2) ISC measurements following treatment with
cAMP and IBMX, commonly used stimulants of CFTR [167]. This further suggests that
lack of HCO−3 may be sufficient to abolish transepithelial Cl
− transport in nasal epithelia.
We hypothesize that the increased basolateral Cl− flux predicted by the model is linked
to AE following a similar electrogenic transport rate through NBC, as the one described
above. It is important to mentioned that due to the anion agnostic nature of our model,
these types of anion transport would be predicted as an increase in the bCl and CFTR
permeabilities (Table 2.2), with a possible decrease of the overall flux through NKCC. This
is further confirmed by the decreased in the fraction of ∆IForskolin inhibited by Bumetanide in
HNEs relative to HBEs and the near total inhibition of ∆IAmiloride and ∆IForskolin, following
the removal of HCO−3 , but not following treatment with Bumetanide (in the ∆IForskolin case).
CFTR expression and functional levels in HNEs have been linked to several commonly
used clinical markers of airway function in CF. More recently, a study found that apical
expression levels of CFTR in HNEs correlate to lung disease progression in CF, as measured
by %FEV1 [197]. Similarly, HNEs harvested from patients with CF and treated with CFTR
correctors and potentiators showed that changes in their ∆IForskolin strongly correlates with
changes in the Forskolin-stimulated NPD and %FEV1 in patients undergoing analogous
treatments [153]. And perhaps more importantly, cells harvested from nasal brushings have
been used to identify significant H+ and HCO−3 transport rate differences between chronic
rhinosinusitis (CRS) patients with and without CF [27].
We also assessed whether treatment with Bumetanide or removal of HCO−3 affected the
response of CF HNEs cell culture CFTR correctors and potentiators in 3 ∆F508 homozygous
lines. The results showed that Bumetanide decreased both the ∆IForskolin and ∆ICFIhn172 of
CF HNEs. However, no meaningful difference was observed between the experiments with
and without HCO−3 (Figure 2.14 A-B). In fact, Bumetanide inhibited all the ∆IForskolin when
added following the CFTR stimulant, suggesting NKCC dominates basolateral Cl− intake.
It is possible that the absence of any basolateral Cl− transport is sufficient to inhibit the
action of the correctors, due to limited rescue levels of CFTR relative to wild type levels of
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function. However, there have been significant studies that have looked at the effect that
CFTR variants have on the relative Cl− and HCO−3 permeabilities the channel. Seminal
work by Reddy and colleagues, for example, identified distinct Cl−:HCO−3 CFTR selectiv-
ity in a CF human sweat gland epithelium model [161]. They showed ∆F508/R117H lost
nearly all Cl− conductance but retained significant HCO−3 conductance, while ∆F508 ho-
mozygous cultures lost both conductances [161]. It should be noted that the latter CFTR
variant combination is associated with a low likelihood of causing CF (www.cftr2.org/r117h).
Other studies have also showed that CFTR variants can impair HCO−3 transport by disrupt-
ing CFTR regulation through the WNK1-SPAK pathway [101]. Specifically, they showed
that loss of HCO−3 is linked with higher incidence of CRS, pancreatitis and vas deferens
abnormalities, even in the absence of CF airway disease [101].
Lastly, and perhaps most relevant, recently presented work by Bridges and colleagues
has identified remarkable differences in the ability of correctors to restore HCO−3 function.
Polarized cultures of FRT cells expressing ∆F508 CFTR showed no meaningful difference
in ∆IForskolin in the presence or absence of a serosal-to-mucosal HCO
−
3 gradient. Cells
expressing G551D or S549R showed higher response in the presence of the same HCO−3
gradient, with G551D cells responding nearly as well as when exposed to an equivalent
Cl− gradient [173]. The distinct selectivity and permeability described by different variants
could explain the shift from HCO−3 to NKCC driven basolateral Cl
− transport observed
between Non-CF and CF HNEs (Figures2.13 and 2.14). Specifically, the analysis must be
expanded to include cultures from a broad range of CFTR variants in order to validate the
proposed mechanism. Figure 2.15 summarizes this proposed mechanism. However, more
detailed studies are needed in order to fully explore the role that basic electrophysiological
differences between HBEs and HNEs can have in the electrophysiological profiles observed
in CF HNEs .
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Figure 2.15: Outline of proposed mechanism for anion transport in Non-CF and CF HNEs. Combined results from in vitro and
in silico experiments revealed a possible shift in basolateral anion transport. Non-CF HNEs revealed a HCO−3 -dependent, and
Bumetanide insensitive transport profile. CF HNEs treated with a CFTR modulator combination (VX770/VX809) revealed
a shift that favors basolateral Cl− intake through NKCC transport. Model results suggest that this shift could be caused by
a change in the transmembrane potential as a result of loss of CFTR function and the indirect effect that it has on other
neighboring ion channels.
61
Similarly, basic UC studies performed on HNE cultures harvested from subjects with a
CF carrier genotype (wt/non-wt) showed markedly distinct electrophysiology profiles versus
either CF or non-CF HNEs, including lower IBaseline,∆IAmiloride, and ∆IForskolin (Figure 2.8
B, Table 2.1). HNE carrier data also yielded distinct model-predicted parameters, with
predictions for ENaC, ACC, NKCC and bK trending to values similar to those predicted for
CF-subjects, the NaKP flux staying similar to that of non-CF, and values for CFTR and bCl
splitting the difference between non-CF and CF predictions (Table2.2). All subjects showed
greater than 60% inhibition of ∆IForskolin by Bumetanide in the presence of physiological
HCO−3 levels. Once again, this suggests, a possible shift towards a more NKCC-dominated
basolateral Cl− intake than their Non-CF counterparts. It is important to point out that
this study only included data from 5 distinct carrier subjects (4 with a ∆ F508/wt genotype
and 1 with a 2184insA/wt genotype).
Previously published studies have found a link between CFTR mutations and incidence
of CRS [206]. Another study, specifically found that carriers of a CF-causing mutation
have a higher prevalence of CRS than normal [205]. In fact, multiple studies have found
links between the incidence of common CF comorbidities like nasal polyps, bronchiectasis,
and pancreatitis and CF-causing mutations, even in the absence of a formal CF diagnosis
[24, 28, 150, 177]. Together, these suggest an underlying electrophysiological difference
between carriers and non-CF individuals that, while not severe enough to cause CF, can
disrupt the healthy function of the epithelia. More studies are needed to further explore
the extent of any physiological difference and to better understand the link between CFTR
mutations and possible clinical manifestations. These studies are currently underway.
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3.0 A Quantitative System Pharmacology Model of Cystic Fibrosis Liquid
and Solute Transport Dynamics across Primary Human Nasal Epithelia
Cystic Fibrosis (CF) is a life-shortening, autosomal recessive disease caused by mutations
in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. CF is the most
common lethal genetic disorder among Caucasians and occurs at a rate of 1 in every 3,400
births in the United States affecting approximately 70,000 patients worldwide [192]. The
CFTR gene codes for an anion channel (also referred to as CFTR) expressed on the mucosal
side of the epithelium of multiple organ systems, including the pancreas, intestine, repro-
ductive organs, and airway [142]. Loss of CFTR expression or function results in an osmotic
imbalance due to defective ion transport. In the respiratory tract, these conditions cause
airway surface liquid (ASL) hyperabsorption, mucus dehydration, and depressed mucociliary
clearance (MCC). Mucostasis leads to chronic infection and a sustained and unregulated in-
flammatory response that causes bronchiectasis and respiratory failure, the leading cause of
CF mortality.
Fundamentally, CF is a disease driven by dysregulation of transepithelial ion and wa-
ter transport. In healthy epithelia, water, ions, and other solutes are transported across
the epithelium via paracellular and transcellular mechanisms [190]. Water transport is pri-
marily driven by osmotic forces across tight junctions or through water channels on the
plasma membrane of epithelial cells [199]. Ions and some small molecules are transported
transcellularly through active or passive fluxes linked to a multitude of ion channels and co-
transporters [84]. Solute transport also occurs in the paracellular space, and it is mediated
by both diffusive and convective transport [110]. Cl−, Na+, and K+ concentrations are the
main determinants of ASL and cellular volume regulation [190, 198]. In CF, deficient or
absent CFTR causes decreased Cl− and HCO3− secretion [12, 151]. In CF, dysfunctional
CFTR or its downstream physiological effects have been shown to either directly or indirectly
disrupt the normal functions of multiple known members of the epithelial electrophysiology
network, including the epithelial sodium channel (ENaC) [130], the solute carrier family 26
member 9 (SLC26A9) [8], aquaporin 3 (AQP3) [90, 171], and some gap and tight junction
63
proteins [18, 19]. The combined effect of these disruptions leads to a homeostatic imbalance
that favors the hyperabsorption of ASL.
Electrophysiological measurements are taken using an Ussing Chamber (UC) to study
ion and liquid transport dynamics at the airway epithelium. The UC allows for the measure-
ment of the whole-membrane, transepithelial short-circuit current, which provides a direct
link to ion transport dynamics under conditions where the epithelium interfaces two static,
relatively infinite liquid and ion reservoirs. This technique has been particularly useful in
CF, where UC recordings are commonly used to study disease pathophysiology and assess
the efficacy of novel CFTR modulators [8, 52, 195]. Several mathematical models have been
published that explore the electrophysiological dynamics of the airway epithelium under
conditions similar to those of the UC, where apical liquid volume far exceeds physiologi-
cal conditions. These models have either focused on general descriptions of airway epithelia
function [54, 62, 135, 136]or explored possible functional differences between CF and non-CF
cell cultures [138, 174]. However, the ASL has a much smaller volume under physiological
conditions and is often described as a highly dynamic, thin-film volume responsible for ep-
ithelial hydration. Thus the conditions assumed in these previous models may limit their
applicability to predict ASL dynamics under physiological, or thin film conditions, or those
associated with ASL dehydration , a hallmark of CF pathophysiology [30, 32, 110, 120]. More
recently, Sandefur et al. published an extended model that accounts for thin-film conditions
of the airway and includes cellular regulation through both Ca2+ and purinergic signals over
a physiologically-relevant time period [168]. However, it does not account for all paracellu-
lar transport mechanisms or provide a meaningful and scalable metric to extrapolate model
predictions to clinical measurements.
Here we present a detailed model characterizing the pathways for liquid and solute trans-
port within the CF airway. The model is informed with data generated from primary human
nasal epithelial (HNE) cell cultures harvested from subjects who performed concurrent air-
way function tests. Contributions of both convective and diffusive paracellular transport on
epithelial dynamics are described. In particular, the model includes expressions to track the
transport of the radiopharmaceutical Technetium 99m-Diethylenetriamine Pentaacetic Acid
(Tc-DTPA), an in vitro analogue of the in vivo functional imaging probe Indium 111-DTPA
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(In-DTPA), which is used to measure small molecule absorption across the airway epithe-
lium [110]. Radiolabeled DTPA can only move through the paracellular pathway, and its
absorption rate characterizes paracellular flows and tight junction integrity. Radiolabeled
DTPA absorption is increased in the lungs of patients with CF [30, 110, 120], and in primary
human bronchial epithelial (HBE) CF cell cultures where it is strongly correlated with ASL
absorption [110]. Functional imaging scans measuring In-DTPA absorption were developed
with the goal of detecting changes in liquid absorption in the CF airway —a key indication
of therapeutic efficacy.
These types of in vitro to in vivo relations are of particular relevance in the study of CF.
Primary cell cultures have played an unusually important role in therapeutic development
within this disease, which lacks an easily accessible, reliable animal model that can recapit-
ulate human airway physiology, disease pathogenesis, and the genotypic variety observed in
humans [102, 170]. Biophysically-inspired computational models can further facilitate this
process by providing a physiologically-grounded bridge between novel cell culture based ex-
perimental measurements and commonly used clinical indicators of CF pathophysiology and
therapeutic efficacy. The work presented here, an in silico model that leverages knowledge
obtained from a parallel assessment of cell and organ level physiology, serves as a first step
in this direction. On a longer timeframe, this can yield a platform where in vitro mea-
surements sets can be used to informed data-driven, validated in silico model and generate
patient-tailored and phenotype-based analyses of this trans-scale disease.
3.1 Materials and Methods
3.1.1 Cell culture
HNE cells, collected under a protocol approved by the University of Pittsburgh Institu-
tional Review Board (clinicaltrial.gov number NCT02947126), were cultured from samples
obtained from minimally-invasive nasal brushings of donors. Donors either had no history of
lung disease and who were not carriers of the 144 most common CFTR mutations associated
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with CF disease, or had a genetically-confirmed CF diagnosis. In brief, cells were expanded
using conditionally reprogrammed cells, allowing for their passaging without loss of quality
decline [121, 131]. Following sufficient expansion (80-90% confluency), the cells were seeded
onto 0.33-cm2 filters (0.4-m pore size, Corning- Costar Transwell Collagen T-cols, Acton,
MA, USA). After 24 hours, apical media was removed, and cell cultures were maintained
at an air-liquid interface (ALI) thereafter. Basolateral media was changed 3 times weekly.
Filters were maintained for at least 4 weeks under ALI conditions and demonstrated active
cilia, an indicator of successful epithelial differentiation, before testing [43, 131]. For more
detailed information about the cell culture protocol see Appendix A. This study used filters
cultured from primary HNE cells from CF (14 subjects, n=36 filters) and non-CF donors
(14 subjects, n=48 filters). For a general summary of the subject demographics and basic
general experimental results see Table 3.1.
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Table 3.1: HNE donor information and summary measurements. This includes in vitro ASL and Tc- DTPA total absorption
from healthy donors (wt/wt) and donors with CF (non-wt/non-wt) following either an isotonic or an hypertonic stimuli.
Experimental measurements are reported as the percent (%) change over 24 hours . For ASL measurements, a positive values
signals a net liquid absorption, and a negative value represents a net liquid secretion over the same time period. Means (±
SEM) were calculated from all individual cell cultures from each group. N represents the number of individual primary cell
lines used for each experimental set up.
Isotonic Ringers Hypertonic Ringers
ID Group Size Age Sex Genotype ASL Tc-DTPA ASL Tc-DTPA
%± SEM %± SEM %± SEM %± SEM
∆F508/∆F508 (4) N = 14 N = 7
CF 14 38 M ∆F598/other (8) 83.2 61.2 -23.4 34.4
(±7.4) (8) other/other (2) ± 0.09 ± 8.3 ± 10.9 ± 6.3
N = 14 N = 6
non-CF 14 28 M wt/wt 64.2 37.5 -110.2 36.5
(±0.4) (9) ± 0.06 ± 8.1 ± 15.2 ± 2.9
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3.1.2 In vitro ASL and paracellular transport clearance studies
ASL volume and Tc-DTPA apical retention were measured during the 24 h following
the addition of 0.01mCi/ml Tc-DTPA in 10 µL of isotonic Ringer’s solution (IR) (115 mM
NaCl, 25 mM NaHCO3, 5 mM KCl, 10 mM HEPES, 1 mM MgCl2, 1.5 mM CaCl2, and 5 mM
glucose) to the apical surface of the HNE cell cultures (Figure 3.1A). Tc-DTPA radioactivity
was measured in the ASL and cell layer by removing the filter from the media and briefly
placing it in a well counter. Results were decay and background corrected, normalized
by starting counts, and fitted to exponential curves to generate clearance rates [30, 110].
Plates containing HNE cells cultures were imaged with an optical scanner (Epson V500,
Epson Corporation, Long Beach, CA, USA). ASL volume was measured using a previously
described optical method [76]. These images were then analyzed using an image analysis
algorithm implemented in ImageJ (https://imagej.nih.gov/ij/, NIH, Bethesda, MD, USA)
[76]. The algorithm utilizes the radial refraction patterns induced as transmitted light passes
through the meniscus of the ASL layer to predict a liquid volume from an experimentally
determined calibration curve. A diagram detailing the experimental setup for these studies
can be found in Figure 3.1A. In order to explore the behavior of HNE cell cultures under
osmotic stimuli, these studies were also performed following the apical addition of Tc-DTPA
in 10µL of hypertonic Ringer’s solution (isotonic + 200mM NaCl) (HR).
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Figure 3.1: (A) Schematic of human nasal epithelial (HNE) cell culture experimental conditions. The HNE membrane was
seeded and allowed to differentiate on porous supports in the presence of epithelial differentiation media (basolateral side) and a
5% CO2/95% O2 gas mixture (apical side). Membranes naturally develop an ASL volume. At the beginning of the experiments,
10µL of Ringers solution and Tc-DTPA were added. Tc-DTPA retention (in counts) and ASL volume (in µL) were measured
at 0, 2, 4, 6, 8, 12, and 24 h following the volumetric stimulus. The zoomed area (B) shows the major contributors to solute
and liquid transport across the airway epithelium represented in the model equations.
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3.1.3 Model Structure and Development
Based on the model schematic in Figure 3.1 B, we have developed a system of ordinary
differential equations (ODEs) governing liquid and solute transport in HNE cell cultures.
HNE cultures are grown at an ALI to mimic physiological conditions in the human airway
as closely as possible. In order to accurately describe the dynamic behavior of this system,
three compartments are included:
1. the cellular (C) compartment, which accounts for the total intracellular volume across
the entire epithelial monolayer (∼ 0.5− 1.5µL)
2. the apical (Ap) compartment consisting of the naturally occurring ASL (∼ 0− 25µL)
3. the larger basolateral (Bl) compartment, which contains cell culture media (∼ 400µL)
These compartments interface each other in the transport of water, electrolytes, and other
solutes through a complex network of ion channels, transporters, and junction proteins across
both the paracellular and transcellular pathways [84]. The model includes mathematical
expressions characterizing the different transport mechanisms of water, Na+, Cl−, K+, and
Tc-DTPA between all three compartments, as well as the electrical potential across both the
apical and basolateral membranes. A compartmental description of the model fluxes and
compartments can be found in Figure 3.2.
The model describes the geometry and dimensions of HNE cell cultures based on the
assumption that they are composed of cell monolayers, with individual cells having the
shape of rectangular prisms adjacent to one another over the entire filter plane. Accordingly,
the model definitions of effective surface area for all tight junctions (ATJ), and apical (AAp)
and basolateral (ABl) membranes are as follows: ATJ is taken to be the cross-sectional area
of the total filter area (AF = 0.33cm
2) occupied by tight junctions. AAp is the remaining part
of AF once ATJ is subtracted. Lastly, ABl is taken to include both the basal reflection of AAp
and the lateral membrane lining the paracellular space, starting immediately below the tight
junctions. Previous work from our lab has shown that when the number of cells in a filter
is sufficiently large (as is the case in fully differentiated cell cultures with physiologically-
meaningful transepithelial resistance) [119], the following relationship exists:
70
Figure 3.2: Compartmental model diagram that highlights the different pathways that affect
transcellular and paracellular solute and fluid transport. Model allows for the apical, basolat-
eral, and cellular volume and electrolyte concentrations to dynamically respond to changes in
electroosmotic driving forces (ion channels) and facilitated ion transport (co-transporters).
The model also includes paracellular transport of solutes (ions and Tc-DTPA) through both
diffusion and convection, and osmotically driven water flux through both the trans- and
paracellular pathways.
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AT,J = AF
2ATJ,1
AC,1
(3.1)
Here ATJ,1 and AC,1 are the areas of a single tight junction section and cell, respec-
tively, calculated from tight junctions cross-sectional length (average separation between
two individual cells, LTJ = 60nm) and a single cell average square face length (LC = 8µm)
[119]. Initial monolayer volume (VC) was estimated from cell height (hc) predictions under
the aforementioned geometrical basis and assuming constant total epithelial membrane area
[62, 168]. However, Vc, and thus hc, vary dynamically in response to volumetric and osmotic
effects, allowing the monolayer to regulate cellular solute concentration and membrane po-
larization in response to stimuli [123]. In order to model this behavior, the transport of
water between any two compartments (i→ j) is driven solely by osmotic pressure difference,
∆pii,j.
∆pii,j =
∑
k
(
γk
nk,i
Vi
)
−
∑
k
(
γk
nk,j
Vj
)
(3.2)
In this expression, nk,i is the number of moles of solute, k, which is divided by the
volume of compartment i and multiplied by osmotic coefficient γk. Volume changes in all
compartments can thus be caused by water transport across the paracellular pathway, or
either of the epithelial membranes, and can be described as:
dVi
dt
= Vm
∑
i,j 6=i
Pwi,j∆pii,j (3.3)
Here, i refers to any of the three compartments, Pwi,j is the water permeability between
compartment i and j, and VM is the molar volume of water (0.018
L
mol
).
The model accounts for the transport of both ionic (Na+, Cl−, K+) and uncharged (Tc-
DTPA) solutes. Tc-DTPA can only move between the Ap and Bl compartments through
the paracellular space. All ionic solutes can move both paracellularly and transcellularly.
In transcellular flux, ion transport can occur via passive transport through an ion channel
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down an electroosmotic gradient, facilitated transport through a co-transporter, or by active
transport through ion pumps. For ion channels, the directionality and driving force include
both the chemical and electrical components and are defined by Goldman’s constant field
equation [66]. In the case of transporters and ionic pumps, the molar flux is calculated as
a series of Hill terms that modify maximal solute fluxes with predetermined stoichiometry
and directionality based on relevant ionic concentrations in the source compartment at any
given time [54, 136]. Through model-estimated permeabilities (ion channels) and maximal
fluxes (co-transporters), these terms are used to describe the dynamics for each individual
transport pathway.
In the paracellular space, we include the transport of solutes through both diffusive and
convective means. It is important to note that the model applies the same paracellular trans-
port mechanisms to both ionic and uncharged solutes. With this in mind, we can describe
the diffusive (Jdiff ) and convective (Jconv) components of paracellular solute transport as
follows:
Jdiff = P
k
Ap,Bl [k]Ap,Bl (3.4)
Jconv = [k]i
dVAp↔Bl
dt
(3.5)
Here, P kAp,Bl represents the paracellular permeability of solute k, ∆[k]Ap,Bl and
dVAp↔Bl
dt
are the concentration gradient of solute k and the water flux between the Ap and Bl com-
partments, respectively, as determined by the orientation of ∆piAp,Bl, see Equation 3.2. From
these expressions, we can describe a closed system mass balance for any solute, ki, throughout
the three compartments as:
dkAp
dt
= −
C,Ap∑
Y
Jy + Jdiff + Jconv (3.6)
dkC
dt
=
C,Ap∑
Y
Jy +
C,Bl∑
Y
Jy +
∑
L
nkJact,L (3.7)
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dkBl
dt
= −
C,Bl∑
Y
Jy −
∑
L
nkJact,L − Jdiff − Jconv (3.8)
Here, dki
dt
is the change of solute k in compartment i,
∑C,i
Y JY is the summation of all
the ion channel (Y ) fluxes between the C and either the Ap or Bl compartments, and∑
L nkJact,L is the summation of any co-transporter (L) flux multiplied by their respective
stoichiometric coefficient, nk. Notice that this last term is only present between the C and
Bl compartments due to the lack of significant facilitated or active ion transport between
the Ap and C compartments in airway epithelial cells [84]. Individual ionic currents, IY , are
calculated for all electrogenic ionic fluxes, JY , such that the relation between ion flux and
current can be described as:
IY = zkFJY (3.9)
Here zk is the ionic charge of solute k, and F refers to Faradays constant. These currents
are used to derive dynamic expressions for the membrane potential across both membranes,
such that:
dEAp
dt
= C−1ApAAp
(
−
Ap∑
Y
IY +
P∑
k
Ik
)
(3.10)
dEBl
dt
= C−1Bl ABl
(
−
Bl∑
Y
IY +
P∑
k
Ik
)
(3.11)
Here Ei and Ci are the either the apical or basolateral membrane potentials and capac-
itances per area, respectively for compartment i. Where i ∈ {Ap,Bl}. Membrane capaci-
tances are considered constants for both membranes, and are based on previously reported
values [39].
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3.1.4 Parameter Estimation
Model training and estimation of the 15 free parameters in the model were carried out via
our affine-invariant ensemble of samplers with parallel tempering Markov Chain Monte Carlo
(APT-MCMC) algorithm, a C++-implemented, Python-wrapped parameter optimization
tool for systems of ODEs [218]. APT-MCMC is open-source and publicly available online
(https://gitlab.com/liangzha/APT-MCMC). APT-MCMC estimates parameter values by
leveraging the dynamic nature of MCMC algorithms to sample a user-defined parametric
hyperspace. The algorithm deploys distinct, yet parallelly executed, chains of samplers that
explore different temperatures or levels of the models objective space. The samplers are
implemented to efficiently search regions of highly correlated parametric distributions, a
common occurrence in biologically-inspired mathematical models [68]. Each level is defined
with varying thermodynamic energies, and permits the inter-chain exchange of information
regarding goodness of fit, thus providing information about the breadth and depth of the
objective space [70, 83]. APT-MCMC has been successfully implemented for optimization
of a clinically-relevant mathematical model of coagulopathies in trauma patients [154].
In our simulations, a logarithmically-transformed sum-of-squared errors objective func-
tion (χ2) was defined between simulation predictions and ASL volume (fitted in mL) and
DTPA absorption data (fitted as retention in hundreds of thousands of counts to scale it
suitably versus ASL volume), such that:
χ2(θ) =
n∑
x=1
m∑
p=1
d∑
i=1
(
logX∗x,p,i − logXx (θ, ti)
)2
(3.12)
Here, X∗x,p,i refers to the data point recorded for the observable states (ASL or Tc-
DTPA) x, for each individual filter for donor p, measured at time point ti. Xx(θ, ti) is the
corresponding model-simulated value of each state as predicted by a given parameter set, θ.
The objective function was optimized according to equation 3.13.
θˆ =argmin
{
χ2(θ)
}
s. t. Xx = f(X, θ, t,X0)
and θmin ≤ θ ≤ θmax
(3.13)
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Figure 3.3: APT-MCMC uses Markov Chain Monte Carlo techniques to dynamically sample
parameter hyperspace by efficiently searching highly multimodal objective function surfaces
(Top). It implements parallel tempering and affine ensemble sampler techniques to allow for
breadth and depth of parameter space characterization (bottom). Modified from Zhang, et
al [218].
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Here, θˆ represents the parameter values that correspond to the identified solution to the
optimization problem, f is the user-defined ODE system, θ is the set of free parameters, X
and X0 are the states and their respective initial conditions, and θmin and θmax are the set of
lower and upper bounds for all free parameters. It should be noted that predicted parametric
distributions do not have a normality condition imposed on them; hence, they should not be
analyzed as such. This distinction is due to the multidimensional nature of our parameter
set, and to APT-MCMC not requiring a strict statistical prior to all predicted distributions
in order to converge. These conditions then necessitate the use of a non-parametric statistical
test like 2-sample Kolmogorov-Smirnov to compare distributions between the two population
without the need to assume normality.
Since the model is trained with a dataset that primarily informs paracellular fluxes and
transcellular water transport, and in an effort to limit exploration within a biologically-
meaningful parametric region, parameter ranges for ion channels and transporters were es-
timated from a the results of the UC of airway epithelial electrophysiology under flooded
conditions for both non-CF and CF cell cultures shown in Chapter 2 [174]. A list of all free
parameters used in the model, and their respective parametric ranges, can be found in Table
3.2. Constant values for cellular volume regulation, electrolyte-transporter affinities, and
other airway epithelial physiology descriptors were obtained from literature and previously
published models of human airway electrophysiology [54, 62, 123, 138, 169, 181, 209, 210].
3.2 Results
3.2.1 In vitro ASL and Tc-DTPA transport across healthy and CF HNEs
10µL of IR solution and DTPA were added to the apical side of non-CF and CF HNE cell
cultures as described in the Methods section and shown in Figure 3.1 A. Data demonstrated
that CF cultures had decreased ASL volumes (µL) at the start of the experiment (t = 0h)
relative to non-CF cultures (10.01±1.38 vs. 15.35±0.95, respectively; p = 0.0019 by student
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Table 3.2: Model parameters were estimated using APT-MCMC, a separate log-space, non-
linear least-squares objective function for each population (Non-CF, CF), as described in
section 3.1.4. Model includes 15 free parameters describing ion and water permeabilities
through both transcellular and paracellular pathways. The permeability of CFTR was as-
sumed to be negligible in the CF case. ∗: p < 0.05 comparing CF to non-CF through
Kolmogorov-Smirnov test. Initial ranges for ion channels and transporter permeabilities
parametric exploration were based on a previously published model of airway electrophysi-
ology under Ussing Chamber conditions [174].
Parameter Units Non-CF CF Axis Definition
P ∗wca µm/min 1.41x10
4 3.33x104 10200-18000 Water permeability, trans-apical
P ∗wcb µm/min 1.31x10
4 3.46x104 8000-18000 Water permeability, trans-basolateral
Pwab µm/min 0.97x10
5 1.0x105 72000-120000 Water permeability, paracellular
P ∗ENaC µm/min 2.303 3.359 0.6-6 ENaC permeability
PCFTR µm/min 2.209 - 0.6-6 CFTR permeability
P ∗ACC µm/min 2.584 0.759 0.6-6 ACC permeability
PBKCa µm/min 0.862 0.962 0.6-6 BKCa permeability
PbK µm/min 4.094 3.312 0.6-6 bK permeability
PbCl µm/min 3.597 2.821 0.6-6 bCl permeability
Ppna µm/min 2.909 3.199 0.6-6 Na
+ paracellular permeability
Ppcl µm/min 2.597 2.566 0.6-6 Cl
− paracellular permeability
Ppk µm/min 3.151 3.037 0.6-6 K
+ paracellular permeability
P ∗pdt µm/min 7.850 8.485 6-10 Tc-DTPA permeability
JNKCC mmol/m
2min 33.51 32.83 6-60 Max NKCC molar flux
JNaKP mmol/m
2min 29.84 30.44 6-60 Max NaKP molar flux
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t-test), indicative of the characteristic dehydration of CF ASL (Figure 3.3A). CF samples also
showed a significantly depressed ASL volume 24 hours after the initial volumetric challenge
(1.68 ± 0.38 vs. 5.49 ± 0.90, respectively; p = 0.0027). Percent Tc-DTPA absorption over
24 hours was significantly increased in the CF case relative to non-CF (55.40 ± 3.66 vs.
33.51± 3.41, respectively; p = 7.16x10−4), as shown in Figure 3.3 B. Previous studies have
demonstrated increased rates of DTPA absorption in primary CF HBE cell cultures and in
the lungs of CF patients [32, 111, 119]. Previous studies have also shown that there is a
strong correlation between ASL volume and Tc-DTPA absorption in non-CF HBE cultures
[32]. In an effort to further corroborate these observations in HNE, total ASL and Tc-
DTPA absorption were calculated from each subject-specific set of cultures and correlated
(Pearsonss r), see Figure 3.3 C. The analysis confirmed that for non-CF cell cultures, ASL
volume and Tc-DTPA absorption are strongly correlated (r = 0.79). A similar analysis
for CF cell cultures showed the breakdown of this relationship due to increased Tc-DTPA
clearance.
3.2.2 Transcellular water transport drives Cystic Fibrosis pathophysiology
Model simulations were able to capture the absorption dynamics of the ASL and Tc-
DTPA, for both CF and non-CF cell cultures, using identical structure, as shown in Figure
3.5. The model-predicted apical volume and Tc-DTPA trajectories were within the standard
error of the mean for all time points in both cases. Population-level parameter distributions
were generated for all free parameters listed in Table 2, according to the procedure described
in section 3.1.4. Comparisons between the model-predicted distributions of CF and non-CF
cultures were performed using a 2-sample, unpaired Kolmogorov-Smirnov (2-KS) test. The
model predicts that CF cultures, relative to non-CF cultures, have increased apical (Pwac:
3.33x10−4 vs. 1.41x10−4, respectively; p = 4.329x10−9) and basolateral (Pwcb: 3.46x10−4
vs. 1.31x10−4, respectively; p = 7.583x10−8) water permeabilities (Figure 3.6A, B). On the
other hand, paracellular water permeability was similar in CF and non-CF cultures (Pwab:
1.02x10−5 vs. 0.97x10−5; p = 0.936) (Figure 3.5C). These results suggest that transcellular
water transport is responsible for the hyperabsorptive phenotype observed in CF cell cultures.
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Figure 3.4: Summary of ASL and Tc-DTPA absorption profiles for non-CF and CF HNE
cell cultures. (A) Final ASL volume 24 h following the addition of 10 µL of isotonic Ringers
solution and Tc-DTPA. CF cultures demonstrated a significantly decreased final ASL volume
relative to non-CF cell cultures (p = 0.0027). (B) Percent Tc-DTPA absorbed.CF cell
cultures had higher Tc-DTPA absorption rates than non-CF cultures (p = 9.708x10−4). (C)
Comparison plot showing the relationship between Tc-DTPA absorbed (thousands of counts)
and ASL volume absorbed (µL) for both non-CF (13 patients, 72 filters, blue squares) and CF
(9 patients, 36 filters, red squares) 24 h after the initial volumetric challenge. The dashed line
represents the linear regression for non-CF cultures which shows strong correlation between
the measurements. CF cultures show a significant upwards deflection relative to the fitted
line, suggesting an increased rate of Tc-DTPA absorption independent of liquid movement
(diffusive component). Comparisons by unpaired t-test. Statistical significance is indicated
as ∗.
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Furthermore, the model predicted a statistically significant increase in the paracellular
Tc-DTPA permeability for the CF relative to non-CF groups (Ppdt: 8.48 vs.7.85, respectively;
p = 0.0376; Figure 3.6D). It is important to notice that there is significant overlap between
the numerical range of the two distributions. In other words, while the two distributions
have distinct shapes, they will lead to similar transport rates on average. This suggests
that while it is likely for CF individuals to exhibit higher Tc-DTPA diffusion transport rates
than the average non-CF cell culture, the increase is not due to morphological differences
(i.e. permeabilities) in the tight junctions of the two populations. This is further confirmed
by the lack of any statistical difference in the paracellular permeabilities of the electrolytes
(PpNa, PpCl, PpK) predicted between the two groups (Figure 3.7). The model also estimated
that CF cultures exhibit significantly increased ENaC permeability, PENaC , and decreased
constitutively active (i.e. not CFTR) chloride channel permeability, PACC , which correlates
to observations from the literature (Figure 3.7 ) [138, 209].
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Figure 3.5: Best-fit model trajectories (solid lines) and experimental data (error bars; popu-
lation mean ± SEM) from HNE cell cultures following the apical addition of 10µL of Isotonic
Ringers with Tc-DTPA to 12 non-CF (72 filters) and 7 CF (42 filters) lines. (A) CF lines
have lower ASL volumes than non-CF lines at the start and end of the experiment (p<1x10-
4). Total predicted volume absorbed is 9.85 ± 0.934µL (64.2%) in the non-CF lines and
8.33 ± 0.886µL (83.2%) in the CF lines. Non-CF cells rapidly return to homeostatic ASL
volumes (t = 4−12h), whereas CF cells exhibit a more prolonged absorption profile. (B) CF
cultures displayed consistently higher Tc-DTPA absorption rates (p < 1x10−4) vs. non-CF.
Model-estimated DTPA clearance is 37.7% in non-CF cells compared to 61.2% in CF after
24 hrs.
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Figure 3.6: Comparison plot of the model-predicted distributions of water permeability (A:
apical, B: basolateral, C: paracellular) and DTPA permeability (D) for both CF and non-CF
cell cultures. ? denotes significant differences between CF and non-CF distributions by a
2-sample Kolmogorov-Smirnov test. Model predicts that both the apical and basolateral
water permeabilities (Pwac and Pwcb, respectively) are increased in CF cultures vs. non-CF
cultures (p = 4.329x10−9 and p = 7.583x10−8). However, paracellular water permeability is
similar between the two population (p = 0.936). Tc-DTPA permeability is increased in CF
(p = 0.0376).
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Figure 3.7: Summary plot for all model-generated parametric distributions for both the CF and non-CF groups. Combined
distributions’ minima and maxima were obtained for each parameter from both groups, and used to generate normalized
representations for ease of visualization. Distribution difference between the two groups was determined for each parameter by
2-sample Kolmogorov-Smirnov test, and shown as (?) for parameters with a p < 0.05
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The predicted parametric distributions will not all necessarily be normal; and therefore,
should not be analyzed as such. This distinction is due to the multidimensional nature of our
parameter set, and to APT-MCMC not requiring a strict prior to all predicted distributions
in order to converge. These conditions then necessitate the use of a non-parametric statistical
test like 2-sample Kolmogorov-Smirnov to compare distributions between the two population
without the need to assume normality.
3.2.3 Comparison of DTPA Convection and Diffusion
Since Tc- DTPA can only move through the paracellular space, the equation describing
apical Tc-DTPA counts (DTPAAp), contains no active or passive flux terms into or out of
the cell. Thus, the transport equation reduces to:
dDTPAAp
dt
= Jdiff + Jconv = −PDTPAA,B
(
DTPAAp
VAp
− DTPABl
VBl
)
+
DTPAAp
VAp
(
dVAp
dt
)
(3.14)
The equation for basolateral Tc-DTPA counts (DTPABl) has opposite directionality
but equivalent structure to Equation 3.14, as the two are linked by a mass balance. Each
flux term on the right-hand side of Equation 3.14 was integrated individually for the 100
best parameter sets obtained after fitting. The cumulative percent Tc-DTPA absorbed via
diffusion was calculated at every experimentally-measured time point for both CF and non-
CF cultures. The model predicts that over a period of 24 hours, CF cultures on average
clear 61.9% Tc-DTPA through diffusion, a significantly higher amount when compared to
non-CF cultures (49.7%, p = 1.034x10−4; see Figure 3.8). It should be noted that the
percent of Tc-DTPA clearance due to convection will simply be the complementary fraction.
Thus, the ∼ 40%DTPA absorption estimated as due to convection in CF HNE is similar to
experimental values previously reported in CF HBE [110].
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Figure 3.8: Model-predicted percent of Tc- DTPA cleared through diffusion for CF and non-
CF HNE cell cultures following the apical addition of 10µL of isotonic Ringers solutions and
Tc-DTPA (diffusion + convection = 100%). Model predicts CF cultures (red) on average
clear 61.9% Tc-DTPA through diffusion, a significantly higher amount when compared to
non-CF cultures (blue, 50.6%, by student t-test p = 1.034x10−4) over a period of 24h.
Solid lines are the mean percent and dashed lines are the 95% confidence intervals. Both
measures are calculated from simulations generated from the top 100 parameter sets (based
on goodness of fit).
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3.2.4 Experimental Validation: Hypertonic Ringers as a Case Study
In order to test the ability of the model to capture different experimental conditions,
the model was used to simulate the results from a test data set. The test data set con-
sisted of non-CF (6 subjects, 22 filters) and CF (5 subjects, 22 filters) ASL and Tc-DTPA
retention curves over a period of 24 hours following the treatment with HR solution. The
increased osmolarity of HR solution, relative to IR, is due to NaCl. Based on its high NaCl
proportion, HR may be thought of as a surrogate for hypertonic saline which is a common
inhaled osmotic therapy given to CF patients [46]. The addition of HR to both CF and
non-CF HNE reverses liquid hyperabsorption, inducing apical volume swelling and arrest-
ing paracellular convection of Tc-DTPA. Paracellular diffusion of Tc-DTPA does continue
under these circumstances. In the non-CF case, liquid secretion resulted in an initial ASL
increase, and peak volume was reached approximately 2 hours into the experiment, after
which ASL volume began to be absorbed, possibly re-introducing paracellular convection
(Figure 3.9). However, the relatively stable apical Tc-DTPA retention suggests the majority
of water transport occurs transcellularly at this stage (Figure 3.9). ASL volume showed
minimal changes after 8 hours (Figure 3.9. This implies the observed Tc-DTPA profiles over
8 hours represent a strictly diffusive regime (Figure 3.9). In the CF case, HR also induced
epithelial fluid secretion. However, the cultures showed a significantly reduced rate of ASL
reabsorption (Figure 3.9). Tc-DTPA absorption rates were diminished and remained statis-
tically similar to corresponding rates in the non-CF case for most of the experiments (Figure
3.9), further suggesting a change in the diffusive driving force for Tc-DTPA.
Validation simulations were carried out by changing in silico experimental conditions to
match those of the testing data set (initial ASL volume, Tc-DTPA counts and electrolyte
concentrations), while keeping parameter sets the same as those estimated from the training
data set (IR conditions) for each group. The model demonstrates good agreement between
predictions and data, even in the case of ASL volume where transport dynamics are quite
different (fluid secretion instead of absorption) relative to the training set. In particular, the
model successfully captures the initial rise of ASL volume followed by a slower correction
to steady state for both CF and non-CF cultures, as well as the observed increase of apical
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Figure 3.9: Model predictions demonstrate good agreement with experimental data from a
validation data set. Testing data was from non-CF (6 patients, 22 filters, blue squares) and
CF (5 patients, 22 filters, red squares) cultures and included ASL and Tc-DTPA retention
curves following the treatment with HR solution. Validation simulations were carried out by
changing in silico experimental conditions (initial ASL volume, apical electrolyte/Tc-DTPA
concentrations (HR = IR +200mM NaCl)) to match those of the testing dataset, and using
the top 100 parameter sets for CF and non-CF groups estimated from the training data set
(IR conditions). There is good agreement between model prediction and data, even though
transport dynamics are quite different from the training conditions (fluid secretion instead
of absorption). In particular, the model successfully captures the initial rise of ASL volume
with HR followed by a slower correction to steady state for both CF and non-CF cultures and
an observed increase in apical Tc-DTPA retention for CF cultures, relative to the training
data set (IR, Figure 3.5). Error bars represent mean experimental data ± SEM.
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Tc-DTPA retention for CF cultures. However, the model under-predicts the rate of ASL
volume re-absorption immediately following the ASL peak volume (Figure 3.9). The absence
or possible delay of this resorptive behavior suggests a possible shift in water permeability
as a function of osmotic stimuli in the non-CF and CF cultures that cannot be described
without reparametrization. In an effort to validate this we harvested whole cell protein from
both CF and Non-CF HNE cell cultures after 0, 4, and 12hr of apical HR treatments (Figure
3.10). The blot revealed an increase in whole cell AQP5 protein expression for both non-CF
and CF HNE cultures following osmotic stimuli. This type of response to osmotic stimuli has
been observed in other types of epithelial tissues under similar conditions and time frames
[77, 220].
Figure 3.10: (Left) Whole cells western blots obtained from 1 cell line each (6 filters per time
point) from the CF and Non-CF HNE groups with no treatment (time zero) and following 4
and 12 hours of apical treatment with hypertonic Ringer’s. Blots were probed against AQP5,
and β-actin as a reference protein to normalize the results. (Right) Bar plots summarizing
the relative changes in whole cell AQP5 protein expression over time.
3.2.5 ASL dehydration drives increased Tc-DTPA transport in CF HNEs
The training data set was used to compare ASL and Tc-DTPA end point behaviors
between the IR and HR conditions, thus allowing the verification of model predictions. First,
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we compared the percent apical Tc-DTPA cleared 24 hours after the HR osmotic challenge
for both CF and non-CF HNE cultures (Figure 3.11A). HR significantly reduced the percent
of Tc-DTPA absorption relative to IR in CF cultures (p = 2.003x10−4), but HR did not
affect Tc-DTPA retention in the non-CF (p=0.934) cultures. Since the bulk of convective
flux is stopped under these conditions, we explored changes in the diffusive driving force. In
Figure 3.11B, we calculated the fold change in apical Tc-DTPA concentration as a function
of time for HR studies relative to the IR studies. In the CF cultures, apical concentration of
Tc-DTPA was significantly reduced with HR relative to IR, much more so than for non-CF
cultures (maximum fold change: ∼ 7 vs. ∼ 3, CF vs. non-CF; p = 1.092x10−4). This reveals
that the observed hyperabsorption of Tc-DTPA in CF cultures (Figure 3.4A) is likely due
to depressed apical volume, leading to a consistently higher diffusive driving force relative
to non-CF cultures. Lastly, total change in ASL volume and Tc-DTPA absorption were
calculated from each donor in the testing data set (HR conditions) and tested for correlation
(Figure 3.11C). The analysis revealed the loss of the strong correlation previously observed
for non-CF cultures under IR conditions (r=0.09 vs.r=0.86 (Figure 3.11C), p = 0.83). Since
the cornerstone of this relationship is the now osmotically depressed convective Tc-DTPA
transport, its absence further confirms the amplifying effect that ASL dehydration has on
diffusive Tc-DTPA transport in CF cells.
3.3 Discussion
The model presented herein accurately captures ASL and Tc-DTPA dynamics within
biologically-meaningful parametric ranges allowing for a mechanistic exploration of the phys-
iological differences between CF and non-CF epithelia. The trajectories also highlight dif-
ferences in absorption kinetics between the non-CF and CF cultures. Non-CF cells rapidly
reabsorbed liquid and return to homeostasis while CF cells demonstrated a slower rate, but
longer duration, of liquid absorption that ultimately leads to a decreased standing apical
volume. In addition to good dynamic agreement between model output and experimental
data, the parameters agreed well with those found in literature. The total epithelium water
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Figure 3.11: Summary of ASL and Tc-DTPA clearance for non-CF and CF HNE cell cul-
tures following the apical addition of 10µL of Hypertonic Ringers solutions (isotonic +200
NaCl mM) and Tc-DTPA. (A) Percent apical Tc-DTPA cleared 24 h after the HR osmotic
challenge for both CF and non-CF HNE cultures. It shows that HR significantly reduces
the percent of Tc-DTPA absorbed relative to IR in CF (p = 2.003x10−4), but not in non-CF
(p = 0.934) cultures. Comparisons by unpaired t-test, ∗: p < 0.05. (B) Apical Tc-DTPA
concentration as a function of time calculated as the fold change in HR relative to the IR.
This reveals that the observed hyperabsorption of Tc-DTPA in CF cultures is likely due
depressed apical volume, leading to a consistently higher driving force relative to non-CF
cultures (p = 1.092x10−4). (C) Comparison plot showing the relationship between Tc-DTPA
absorbed (thousands of counts) and ASL volume absorbed (µL) for both non-CF (6 patients,
22 filters, blue squares) and CF (5 patients, 22 filters, red squares) at 24 h after the initial
osmotic and volumetric challenge. The dashed line represents the linear regression for non-
CF cultures. The relationship between ASL and DTPA absorption previously demonstrated
with IR (Figure 3.4) is not apparent after HR addition (r = 0.09).
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permeabilities in both the CF and non-CF cases were similar to those reported by Matsui
and colleagues [123].
Because ion transport defects and airway surface liquid dehydration both play key roles
in CF lung disease, it is important to be able to characterize liquid and solute transport.
Our model demonstrates that the main factor contributing to differences in absorption dy-
namics between CF and non-CF epithelia are transcellular hydraulic permeabilities (Figure
3.5A, B; Table 2), which it predicts as being nearly 3-fold higher in CF. The model-predicted
paracellular hydraulic permeabilities were not significantly increased in CF (Figure 3.5C).
This suggests that transcellular permeability has a larger role in the observed decreased
ASL volume in CF than paracellular permeability. Our model also corroborates previous
reports, both in vitro [32] and in vivo [30], that radiolabeled DTPA conjugates absorption
is increased in the CF airway. While ASL can be transported through trans- or paracellular
pathways, Tc-DTPA can only be cleared paracellularly, either through diffusive or convec-
tive transport. Since the convective component of Tc-DTPA absorption is directly driven
by ASL absorption, the relationship between Tc-DTPA and ASL absorption can be used to
illustrate the relative contributions of convection and diffusion. For example, the increased
Tc-DTPA absorption observed in Figure 3.4 C for CF cultures, relative to the non-CF trend-
line, suggests a Tc-DTPA absorption rate increase that is independent of liquid movement
(i.e. through diffusion). Using our mathematical description of Tc-DTPA absorption from
the ASL, we are able to probe the relative contributions of diffusion and convection that lead
to increased solute absorption in CF. The model predicts that diffusive transport accounts
for approximately 60% of all Tc-DTPA absorption seen in CF, a significant increase relative
to the 49% predicted for non-CF cells, which is close to experimentally observed values [110].
It is likely that diffusion transport rates are increased in CF due to the decreased initial ASL
volume and identical added Tc-DTPA counts in both CF and non-CF experiments. Thus,
the concentration, and therefore the diffusive driving force, was slightly increased in CF over
the course of the experiments.
Additionally, the model-determined ion channel permeabilities were within parametric
ranges previously published in a model of HBE under Ussing Chamber conditions [174].
These model-predicted parameters also corroborate previous results describing the function
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of epithelial ion channels. For instance, the model estimated that ENaC permeability is sig-
nificantly increased in CF cell cultures (Figure ??), which is in agreement with the findings
of previous experimental and modeling studies [138, 209]. Furthermore, the model predicted
a significant increase in the constitutively active (i.e. not CFTR) chloride channel perme-
ability in our model, PACC , in non-CF cell cultures (Figure S1). These results are in line with
the findings of Bertrand and colleagues, who have reported that SLC26A9, a constitutively
active Cl− channel expressed in the apical membrane of airway epithelia, shows diminished
expression and functional levels in the presence of dysfunctional CFTR [8, 9]. Overall, our
model describes hyperabsorptive liquid and solute dynamics in CF that are associated with
a loss of CFTR function and the subsequent loss of ENaC flux and decreased constitutive
Cl− transport.
Previous mathematical models of airway epithelia have considered liquid and solute trans-
port in varying degrees of mechanistic detail. The majority of these models have been de-
signed for non-physiological conditions where the extracellular compartment volumes are
static. A more recent model includes dynamic apical and basolateral compartments and
thin film conditions [168]. These conditions recreate the conditions in the human airway,
allowing the modeled epithelium to establish a homeostatic ASL at an air-liquid interface.
Our model further accounts for paracellular transport and includes dynamic apical, basolat-
eral, and cellular compartments under thin-film conditions. Airway epithelia are also known
to transport solutes beyond Na+, Cl−, and K+ that can play a role in the regulation of
ion and liquid transport (e.g., Nucleotides, HCO3−, H+, Ca2+). However, in an effort to
minimize parameter uncertainty and complexity, these were not included herein as explicit
model states. Instead, the model is focused on further developing the description of paracel-
lular solute transport. It is recognized that purinergic, pH and Ca2+ fluctuations can have
meaningful effects on the function of several ion channels, transporters, and consequently,
transepithelial water transport or possibly even MCC [47, 63, 103, 221]. However, previ-
ously published work also suggests that under baseline conditions (i.e. in the absence of
a purinergic/mechanical stimuli) the homeostatic levels of nucleotides and nucleosides are
largely unchanged, even in the presence of large ASL volume differences [63]. As a result,
we postulate that these signaling dynamics do not play a significant role under conditions
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that do not explicitly induce a change in their respective baseline values. As such, they were
not explicitly included in the model structure. Rather, our model considers the effects that
ASL and cell volume have on regulating solute and liquid flux in an HNE culture system. It
is quite possible that both mechanisms (purinergic and volumetric) are related, or a conse-
quence of one another. However, the volumetric effect modeled herein captures the available
experimental data in a structurally simple manner.
Our model also includes a more descriptive understanding of paracellular ion fluxes. Cur-
rent literature describes paracellular ionic transport using Goldmans constant field equation,
the same expression used for transcellular ion channel fluxes [62, 168]. This approximation
fails to account for the contributions of diffusive transport along the entire paracellular path-
way and convective transport due to fluid drag. Previous work from our group has shown
that convective transport can account for approximately 50% of Tc-DTPA transport across
primary HBE cell cultures [110]. This suggests convection could also play a significant role in
the paracellular transport of ionic species. Specifically, we compared predicted paracellular
electrolyte fluxes in the electroosmotic versus the combined convection plus diffusion case.
Our results suggest that electrical contributions are effectively negligible after the inclusion
of convective driving forces (Na+: 9.83x10−9 vs. 2.01x10− 7; Cl−: 8.07x10−9 vs. 1.81x10−7;
K+: 9.59x10−10 vs. 5.18x10−8; respectively, mmol/min). This distinction is particularly
important under conditions of non-homeostatic hydraulic flux, such as those following a
volumetric or tonicity challenge of the ASL. Our group has previously shown that in HBE
cultures, an apical to basolateral osmotic, but not chemical, equilibrium abolished approx-
imately 50% of Tc-DTPA transport in CF HNEs [32]. Furthermore, while electroosmotic
transport is likely representative of charged solute transport across the tight junction, it
does not account for the effects that the inherent paracellular pathway tortuosity and length
of an epithelial membrane are likely to have on the effective solute permeabilities of larger,
uncharged molecules such as Tc-DTPA, or the charge selectivity function that some tight
junction proteins may exert on ionic solutes [217]. A detailed understanding of the dynamic
nature of these effects is a largely underexplored area and could warrant further study.
We validated the model using 6 non-CF and 5 CF cultures from the cell lines included
in the training set but exposed to different experimental conditions. Validation testing
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was performed by measuring ASL and Tc-DTPA response following the addition of 10µL
of HR with Tc-DTPA to the ASL. Model simulations were carried out using line-specific
parameter data obtained during training (IR) experiments. Only initial apical volumes,
Tc-DTPA counts, and ionic concentrations were changed to reflect experimental conditions.
Model predictions obtained from simulations from the top 100 parameter sets of experimental
results recapitulated data within the 95% confidence intervals in both the CF and non-CF
cases overall. The model was able to capture the maximum observed ASL volume increase
following the osmotic challenge, and the final steady state (Figure 3.9 A). However, the model
struggled to recapitulate reabsorption dynamics for non-CF cultures in particular. This
may suggest a possible shift in the expression or functional regulation profile of aquaporins
as a result of the hyperosmotic challenge. This type of behavior has been observed in
epithelial tissues in both the gut and urinary tract [77, 220]. HR reduced the percent of
Tc-DTPA absorbed in CF cultures to levels comparable to those of non-CF cultures under
IR conditions. A similar shift, however, was not observed in non-CF cultures (Figure 3.11
A). Since ASL absorption was largely abrogated with HR, Tc-DTPA absorption under these
conditions is likely caused by diffusion. This is supported by the loss of the correlation
between ASL and Tc-DTPA absorption following HR treatment, which is driven by the
convective transport (Figure 3.11 C). Further investigation revealed that the reduction in
Tc-DTPA absorption observed in CF cultures following HR treatment was primarily driven
by changes in apical Tc-DTPA concentration. Because of their increased transcellular water
transport, CF cultures experience a higher degree of apical solute dilution (∼ 7-fold change)
than non-CF cultures (∼ 2-fold change) under HR conditions relative to IR ones (Figure
3.11 B). The dilution of apical Tc-DTPA leads to a corresponding reduction of chemical
driving force. This loss, alongside the higher Tc-DTPA permeability predicted by the model
(Figure 3.6 D), results in an abrogated Tc-DTPA diffusive transport rates in CF under
hypertonic conditions. This finding is particularly important, because it provides a better
mechanistic understanding of radio-labeled DTPA absorption as a biomarker of CF liquid
hyperabsorptive phenotype both in vitro and in vivo.
HR acts as a direct in vitro surrogate for hypertonic saline (HS) [110]. Inhaled HS is a
vital therapy for patients with CF and is prescribed to approximately 72% of CF patients age
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6 or older [38]. Because of its tonicity when inhaled, HS acts as a mucus thinning agent that
temporarily rescues the airway hyperabsorption phenotype, promoting MCC [31, 46, 48, 82].
Chronic treatment with inhaled HS has also been linked with higher lung function and
reduced rates of pulmonary exacerbation among CF patients [53]. More recently, the FDA
has approved the use of inhaled powder mannitol as an alternative osmotic therapy to HS in
the treatment of CF patients [8]. Mannitol has a similar mechanism of action to HS, but since
it is only transported paracellularly, its residence time in the ASL, and therefore its effective
window thought to be prolonged [11, 20, 26, 120, 162]. Due to its similar transport pathways,
DTPA transport studies in the airway both in vitro, as the ones described here, and in vivo
are vital in order to understand the dynamics of inhaled osmotic therapeutics. This approach
could also be extended to the development of new therapeutics, or the optimization of novel
dosing strategies for other categories of inhaled therapeutics, such a bronchodilators and
antibiotics, both in CF and other airway pathologies [2, 132].
Ultimately, we envision the development of in silico models that are informed by data
relating in vitro cell physiology and therapeutic response to in vivo organ physiology and
therapeutic response, and eventually clinical outcomes. These models could be applied to
develop personalized therapeutic strategies for CF patients. They could also provide new
parameters for phenotyping CF subjects and a better understanding of the physiological ef-
fects of CFTR function and specific genotypes. This notion is particularly relevant because
our model is able to track the different modes of liquid and Tc-DTPA transport in HNE
cultures grown from cells harvested from specific patients. This connection would suggest
the in vitro and in silico descriptors of Tc-DTPA dynamics implemented here could corre-
late with their corresponding In-DTPA absorption (ABS) measurements, a DTPA-based in
vivo biomarker of airway absorption. Current studies are underway to characterize nasal
cell culture physiology, organ level physiology, and clinical outcomes in cohorts of CF sub-
jects, single CFTR mutation Carriers who are parents of CF patients, and healthy controls
(NCT02947126), that are intended to inform such models. These studies include nuclear
imaging studies to measure mucociliary clearance and ABS in the lungs. We have previ-
ously observed and modeled MCC and DTPA absorption in the lungs of subjects with and
without CF [110, 111, 120]. These previous studies provide a quantitative and mechanistic
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description of ABS, and MCC. Similarly, this work represents a mechanistic description of
DTPA and liquid transport that is relevant at a sub-scale of our previous work. Whole-organ
model development based on this scan data is ongoing. Ultimately, the multi-scale linkage
of in vitro models to the whole-organ model, including patient-specific disease mechanism
and clinical performance data, will facilitate the design and use of multi-scale models in
patient-tailored and population-scale interventions for CF patients.
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4.0 A Multi-Scale Study of Cystic Fibrosis Airway Physiology
Therapeutic development is largely dependent on the availability of model systems that
can be used to test and optimize therapies ahead of clinical use. The concept of a model
can be extended to include studies of human disease that describe both the pathogenic
and therapy-related components of a system. Examples of classic biomedical models would
include cell-based assays and animal models of disease. These models often need to span
multiple spatio-temporal scales in order to accommodate different stages of research, dis-
ease progression, and to properly describe changes in pathophysiology through quantifiable
biomarkers. However, the transition from cell or animal-based model experimentation to
clinically meaningful information is rarely simple, and, in fact, is often not practical due to
ethical or logistical limitations.
Multiple physiological processes interact within each of these models. In the case of
CF lung disease, these models include networks of interactive elements that work jointly to
regulate everything from cellular electrophysiology and epithelial hydration to whole organ
absorptive and clearance profiles. These networks tend to inherently be too complex to
exhaustively explore experimentally. However, they can be represented through in silico
models that provide insight into the contribution of individual mechanisms to experimental
outcomes. As shown in the previous chapters, this in silico approach can be applied to
the characterization and validation of experimental models, as well as to identify nuanced,
physiologically-meaningful disease mechanisms that are not easily accessible in the lab.
Similarly, linking cellular level mechanisms to organ or system level therapeutic response
through mathematically-robust and physiologically-inspired models would allow for enhanced
prediction of therapeutic efficacy from in vitro studies. This provides novel opportunities for
personalized medicine, where cells sampled and cultured from individuals could be used to
determine an optimal therapeutic regimen.
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4.1 Study design
The study has recruited 20 subjects ages 12 and older with CF (labeled as CF), 12
subjects who are biological parents of the CF subjects and thus are single CFTR mutation
carriers (labeled as Carriers), and 14 healthy subjects (labeled as Non-CF). All subjects will
undergo a nasal brushing to obtain HNE cells, nuclear imaging studies to measure base-
line mucociliary clearance (MCC) and DTPA absorption (ABS) following treatment with
inhaled isotonic saline, pulmonary function testing (spirogram), and inert gas washout stud-
ies to measure lung clearance index (LCI) and fractional rate clearance (FRC). In addition,
CF subjects will undergo a second imaging day including inhalation of an osmotic therapy
(7% hypertonic saline) to characterize their therapeutic response. CFTR genotyping was
performed in all groups, if not already available. Single mutation carriers were excluded
as controls. Table 4.1 provides a detailed summary of the different measurements included
in the study for each group. Similarly, Tables 4.2, 4.3, and 4.4 provide summaries of the
relevant demographic information for all subjects (Non-CF, Carrier, and CF) enrolled in the
study at the time of writing.
It should be noted that one subject from the CF group, CF 7, was removed from the
analysis due to lack of genetic confirmation of CF. This subject’s genotype includes a CF-
causing variation (3849+10kbc>T) and a non-CF causing CFTR variation (R668C), and
shows normal levels of sweat Cl− (13.2 mmol/L). This CFTR variant combination does not
lead to the development of CF, based on both clinical evaluations of patients with similar
CFTR variant combinations and laboratory experiments performed on this variant as verified
through www.cftr2.org.
4.1.1 In vitro methods and measurements
4.1.1.1 HNE Sampling and Culturing HNE cultures will be developed using previ-
ously described methods developed for HBE and HNE cultures. Briefly, cells are detached
from epithelial tissue in a protease solution, suspended in epithelial growth media, and ini-
tially seeded onto sterile tissue culture flasks pre-coated with human collagen. After several
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Table 4.1: Summary of organ-level, cellular level (in vitro), and clinical endpoints included
in the study protocol. X signals a particular measurement will be performed by a respective
group.
Measurement Non-CF CF Carriers
CFTR Genotype X X X
Clinical Endpoints Pulmonary Function Test X X X
Multi-breath Washout Test X X X
Sweat Chloride X X X
Organ level MCC/ABS (baseline) X X X
Physiology MCC/ABS (hypertonic saline) X
Nasal Sampling X X X
In vitro level Epithelial Resistance X X X
Physiology Ussing Chamber X X X
Thin Film Dynamics X X X
CFTR protein expression X X X
passages, they are seeded onto collagen coated transwell filters at a density of approximately
2 x 106 cells/cm2. When confluent, the cells are maintained at an air-liquid interface and the
differentiation media is added. Cells are allowed to fully differentiate prior to experimenta-
tion. For more detailed please refer to Appendix A. HNE cultures will be characterized
through measurements of: (1) CFTR expression, (2) epithelial electrophysiology, (3) ASL
liquid absorption, and (4) paracellular solute (Tc-DTPA) transport.
4.1.1.2 Measurements of CFTR expression in HNE cells Expression and matu-
ration status of CFTR is performed through Western blotting. A minimum of 6 individual
cultures are required for sufficient total protein. To harvest proteins, cultures are washed
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3x with ice cold PBS, then cells are lysed with addition of RIPA buffer to the apical com-
partment. The lysate is removed from the culture support and centrifuged at 10,000g for
10 min, then quantified for total protein content. ∼100 µg of total protein is subject to
SDS-PAGE, transferred to PVDF membrane, and probed with a CFTR primary antibody
(CFFT 596). After labeling with secondary antibody and chemiluminescent substrate, total
CFTR protein is imaged, and quantified by comparison to total actin protein in the sam-
ple. CFTR typically presents at two molecular weights, consistent with an immature form
(band B, localized to the endoplasmic reticulum), and a mature form (band C, indicative of
complex glycosylation at the plasma membrane). In HBE, the majority of CFTR protein
presents as band C in non-CF, and as band B in CF patients harboring the ∆F508 mutation.
The ratio of band B to C is a marker of CFTR maturation. However, since some CFTR
mutations impact function rather than maturation, functional CFTR expression must be
confirmed with electrophysiology.
4.1.1.3 Measurements of epithelial cell electrophysiology Individual cultures are
placed in the Ussing chamber with Ringers solution aerated with 5% CO2-95% O2 in both
apical and basolateral compartments. The culture is continuously short circuited with an
automatic voltage clamp. Transepithelial resistance is calculated from the current deflec-
tion resulting from a 2-mV pulse applied every 90s via an automated pulse generator. Key
measurements include Na+ absorption via the ENaC channel (increased in CF) and Cl−
secretion through CFTR (generally absent in CF), which together establish the primary
osmotic gradients driving liquid transport across the epithelium. Amiloride-sensitive Na+
current is measured by adding 10µM Amiloride to the apical side of the Ussing chamber.
CFTR-associated Cl− current is measured by first stimulating cAMP production with ad-
dition of 10 µM Forskolin to the basolateral chamber, and then by inhibiting basolateral
NKCC transport through the addition of 100µM Bumetanide.
4.1.1.4 Measurements of ASL and Paracellular Solute Transport Rates HNE
ASL dynamics were assessed under thin film conditions using an optical meniscus method.
Under thin film conditions, the thickness of the meniscus associated with the ASL layer of
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an epithelial culture is visible when examining the apical surface of individual cultures. This
method utilizes an optical scanner to measure the refraction pattern of transmitted light
through that meniscus. Previous studies have demonstrated a robust linear relationship be-
tween the AUC of the gray scale light intensity curve generated by the meniscus and ASL
volume on the cultures [130]. Absorption rate measurements were made by comparing ASL
volume over 24 hours following the addition of 10 µL of Ringer’s solution. Measurements of
paracellular solute absorption can be performed in parallel to measurements of ASL absorp-
tion by adding the radiolabeled small molecule Tc99m-DTPA (Tc-DTPA, ∼ 500Da) to the
Ringers volume challenge. Radioactivity is measured in filters containing the ASL and the
cells after removing it briefly from the basolateral media.
4.1.2 In vivo Methods and Measurements
4.1.2.1 Functionalized Scans of Airway Absorptive and Clearance Dynamics :
This procedure involves the inhalation of a nebulized aerosol containing two radiopharma-
ceuticals, Indium111-DTPA (In-DTPA) and Technetium99m sulfur colloid (Tc-SC). In-DTPA
is a small molecule that is cleared from the lungs by mucociliary clearance and absorption
while Tc-Sc is a particle probe (∼300 nm) that is cleared only by mucociliary clearance.
Tc-SC clearance is used to measure MCC, while the difference in clearance rates between
In-DTPA and Tc-SC is used to measure DTPA absorption (ABS). Previous studies have
demonstrated a relationship between epithelial DTPA and liquid absorption rates [32]. A
very specific breathing pattern is used to deliver the aerosol that provides increased airway
deposition rates and measurement repeatability [7]. Subjects are imaged continuously using
nuclear medicine gamma cameras that allow for independent tracking of the aerosolized parti-
cles for 80 minutes. Use of this dual isotope method is unique to our center [30, 32, 110, 111].
Measurements of MCC using similar methods have received extensive use in CF therapy de-
velopment [46, 162, 165].
4.1.2.2 Multi-breath Washout (Lung Clearance Index) Single and multi-breath
inert gas washout techniques are used to measure of ventilation heterogeneity in the lungs.
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The presence of obstructive disease in the airways increases this heterogeneity and is reflected
in measurements of exhaled gas concentration versus volume or time, which indicate reduced
mixing. Lung clearance index (LCI) is a specific multi-breath measurement representing the
number of ventilations required to clear an inert gas from the lungs. It has been shown to
predict pulmonary exacerbations and to correlate with validated quality of life assessments
[59, 201]. Standardized methods have been established for LCI and devices are available
commercially that allow for its measurement [163].
Table 4.2: Summary of the relevant demographic information for all Non-CF subjects
enrolled in the study. Family ID is an index that relates subjects in the carrier groups with
their respective relative in the CF cohort.
ID Age Gender Family ID CFTR CFTR
Allele 1 Allele 2
NCF 1 23 M - wt wt
NCF 2 20 M - wt wt
NCF 3 20 M - wt wt
NCF 4 20 M - wt wt
NCF 5 22 M - wt wt
NCF 6 23 M - wt wt
NCF 7 23 M - wt wt
NCF 8 22 M - wt wt
NCF 9 20 M - wt wt
NCF 10 25 F - wt wt
NCF 11 22 F - wt wt
NCF 12 23 F - wt wt
NCF 13 21 F - wt wt
NCF 14 19 F - wt wt
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Table 4.3: Summary of the relevant demographic information for all Carrier subjects enrolled in the study. Family ID is an
index that relates subjects in the carrier groups with their respective relative in the CF cohort. CFTR modulator therapy
is coded such that: (0) means no CFTR corrector treatment used (True for all Non-CF), (1) means Kalydeco, (2) means
Orkambi, and (3) means Symdeko. Sputum Culture is classified such that a positive (+) signals the subject has had a verified
Pseudomonas Aeruginosas positive sputum or throat culture within 1 year prior to the day of functional airway testing, and a
negative (-) signals the complementary situation.
ID Age Gender Family ID CFTR CFTR CFTR Sputum
Allele 1 Allele 2 Corrector Culture
P 1 47 F 1 F508del wt 0 -
P 2 36 F 2 P574H wt 0 -
P 3 35 M 3 F508del wt 0 -
P 4 41 F 4 del exon 22,33 wt 0 -
P 5 48 F 5 F508del wt 0 -
P 6 47 M 6 F508del wt 0 -
P 7 48 M 7 F508del wt 0 -
P 8 72 F 8 F508del wt 0 -
P 9 73 M 8 F508del wt 0 -
P 10 64 F 9 F508del wt 0 -
P 11 53 F 10 F508del wt 0 -
P 12 56 F 11 2184insA wt 0 -
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Table 4.4: Summary of the relevant demographic information for all CF subjects enrolled in the study.
Family ID is an index that relates subjects in the carrier groups with their respective relative in the CF
cohort. CFTR modulator therapy is coded such that: (0) means no CFTR corrector treatment used,
(1) means Kalydeco, (2) means Orkambi, and (3) means Symdeko. Sputum Culture is classified such
that a positive (+) signals the subject has had a verified Pseudomonas Aeruginosas positive sputum or
throat culture within 1 year prior to the day of functional airway testing, and a negative (-) signals the
complementary situation.
ID Age Gender Family ID CFTR CFTR CFTR Sputum
Allele 1 Allele 2 Corrector Culture
CF 1 21 M 1 F508del F508del 2 +
CF 2 15 M 2 P574H F508del 0 -
CF 3 13 M 3 F508del N1303K 0 -
CF 4 25 F c.1585-2A>G G551D 1 -
CF 5 26 F 4 del e22,33 F508del 0
CF 6 29 M 5 F508del S549N 1 +
CF 7 61 F 3849+10kbc>T R668C 0 -
CF 8 31 M F508del del e2,3 0 +
CF 9 24 F F508del N1303K 0 -
CF 10 67 M F508del D1152H 1 -
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Table 4.4 (Continued)
ID Age Gender Family ID CFTR CFTR CFTR Sputum
Allele 1 Allele 2 Corrector Culture
CF 11 14 F 6 F508del F508del 2 -
CF 12 39 F F508del W1282X 0 +
CF 13 31 F F508del F508del 0 +
CF 14 40 M F508del F508del 3 +
CF 15 17 M 7 F508del F508del 3 -
CF 16 21 M F508del F508del 2 +
CF 17 25 F 8 F508del F508del
CF 18 39 F 9 F508del F508del 3 +
CF 19 29 F 10 F508del D579G 0
CF 20 18 F 11 F508del 2184insA
CF 21 55 M F508del R117H 1
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4.2 Results
4.2.1 Carriers show mild changes in baseline ion and liquid transport function,
but no significant respiratory impairment
In order to assess the degree to which subjects in the carrier group differed or resembled
both the CF and non-CF groups, we performed Wilcoxon rank sum tests across the three
groups for all clinical endpoint measurements, and both in vivo and in vitro measures of
liquid and solute transport. The Wilcoxon rank sum test is a non-parametric test that
evaluates the likelihood of the population medians of two independent samples of different
sizes to be equal to each other. It is equivalent to a Mann-Whitney U-test.
We first evaluated pulmonary function through the lenses of spirometry and multi-
breath washout measurements. Analysis revealed consistently lower pulmonary function
assessments for the CF group relative to both the Carrier (CF vs. Carrier; %FEV1:
71.27 ± 6.57 vs. 101.09 ± 4.86, p = 0.0053; FVC: 87.72 ± 5.92 vs. 105.72 ± 3.10, p =
0.0364; FEF25%−75% : 50.55± 9.60 vs. 112.72± 18.23, p = 0.003; MBWFRC: 2.07± 0.21 vs.
2.83± 0.17, p = 0.027, MBWLCI: 9.41± 0.8 vs. 7.41± 0.26, p = 0.044) and non-CF groups
(Non-CF; %FEV1:101.83± 3.41, p = 0.0025; FVC: 106.75± 3.67, p = 0.0234; FEF25%−75%:
85.83 ± 6.03, p = 0.005; MBWFRC: 7.16 ± 0.30, p = 0.019, MWBLCI: 7.16 ± 0.30, p =
0.011). All values are shown as percent predicted values ± standard error about the mean.
No meaningful difference was observed between the Carrier and Non-CF groups for any of
the pulmonary functional tests. These results recapitulate well established differences in
pulmonary function between Non-CF and CF individuals, and suggest there is no mean-
ingful signs of airway function impairment in Carriers. However, sweat Cl− measurements
were found to be significantly different among the three different groups (CF: 97.89± 4.68,
Carrier: 39.81± 4.93, Non-CF: 21.62± 3.01; CF vs. Non-CF: p = 0.000721; CF vs. Carrier:
0.000279; Carrier vs. Non-CF: 0.0061). A summary of these results can be found in Figure
4.1.
Results from functionalized scans following the inhalation of isotonic saline provide a
more nuanced perspective regarding liquid absorption and mucocilliary transport in the air-
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Figure 4.1: Boxplots summarizing the observed differences between the three groups in the
study (Non-CF, Carriers, and CF) on the basis of common clinical endpoints used to assess
Cystic Fibrosis disease progression and/or therapeutic responses. Left: (Top) Sweat Cl-,
(Middle) Multi-breath washout functional residual capacity (MBWFRC), (bottom) Multi-
breath washout lung clearance index (MBWLCI). Right: (Top) Percent predicted forced
expiratory volume in one second (%FEV1), (Middle) Forced vital capacity (FVC), (Bottom)
Forced expiratory flow at 25% − 75% (FEF25%−75%). Red cross signifies a measurement
found to be an outlier within its group. Statistical significance was determined through a
non-parametric Wilcoxon rank sum test. *: p-values < 0.05.
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way. Figure 4.2 shows the distributions for whole, central and peripheral ABS and MCC
measurements stratified by subject groups in our study. The CF cohort was modified to
exclude subjects that were taking ivacaftor (Kalydeco), ivacaftor/lumacaftor (Orkambi) or
ivacaftor/tezacaftro (Symdeko) at the time of the study nuclear scans, to account for any pos-
sible effect on ABS measurements [31]. The analysis showed significant differences between
CF and non-CF ABS (% ± SEM) levels in the whole lung (CF: 0.27 ± 0.033 vs. non-CF:
0.106±0.043, p = 0.0083) and central lung (CF: 0.241±0.038 vs. non-CF: 0.0887±0.057, p
= 0.0425), while in the peripheral lung it only approaches significance (CF: 0.27± 0.052 vs.
non-CF: 0.133 ± 0.039, p = 0.064). When comparing ABS measurements between Non-CF
and Carrier groups, statistical significance was only reached for the peripheral lung (Carrier:
0.254 ± 0.0482, p = 0.041). Whole lung (Carrier: 0.236 ± 0.048, p = 0.072) and central
lung (Carrier: 0.218 ± 0.058, p = 0.192) ABS do not reach statistical significance between
these two groups. No meaningful difference was observed between CF and Carrier ABS
measurements in any of the regions of interest.
MCC measurements (% ± SEM) revealed no statistical difference between any of the
groups in any of the regions of interest (Whole Lung; CF: 0.346±0.044; Carrier: 0.342±0.076;
Non-CF: 0.250 ± 0.040; Central Lung; CF: 0.357 ± 0.054; Carrier: 0.369 ± 0.082; Non-CF:
0.272±0.055; Non-CF; CF: 0336±0.040; Carrier: 0336±0.060; Non-CF: 0.265±0.032). These
analyses also excluded patients currently taking Kalydeco, Orkambi or Symdeko during
the imaging day, as well as patients with a Tc99m-Sc percent central deposition above 55
percent, see Figure 4.2. Previous work from our group has shown CF patients with confirmed
Pseudomonas aeruginosa (PA) cultures have significantly lower MCC rates than CF patients
without such a result [31, 111]. In order to further explore this within our study, a CF subset
was created by excluding CF subjects without a positive sputum or throat PA culture within
1 year of the imaging day. These exclusion criteria resulted in only 3 CF subjects remaining
within the analysis subgroup. However, no meaningful change was identified either. We
believe that the relatively small cohort size and the higher percent of subjects under a
CFTR modulator may act as confounding factors in these results.
Given the observed difference between the Carriers and CF groups, we wanted to explore
whether these trends remain true at the cellular level. We performed ASL and Tc-DTPA
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Figure 4.2: Boxplots summarizing the observed differences between the three groups in the
study (Non-CF, Carriers, and CF) on the basis of functionalized scans of airway absorptive
and clearance dynamics. This procedure involves the inhalation of a nebulized aerosol con-
taining two radiopharmaceuticals, Indium111 DTPA (In-DTPA) and Technetium99m sulfur
colloid (Tc-SC). In-DTPA is a small molecule that is cleared from the lungs by mucociliary
clearance (MCC) and absorption while Tc-Sc is a particle probe (∼300 nm) that is cleared
only by mucociliary clearance. Tc-SC clearance is used to measure MCC while the difference
in clearance rates between In-DTPA and Tc-SC is used to measure DTPA absorption (ABS).
Left: (Top) whole lung, (Middle) central, and (Bottom) peripheral ABS, respectively. Right:
(Top) whole lung, (Middle) central, and (Bottom) peripheral MCC, respectively. Red cross
signal a measurement found to be a statistical outlier within its group. Statistical signif-
icance was determined through a non-parametric Wilcoxon rank sum test. *: p-values <
0.05.
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dynamic experiments in HNE cultures treated with 10 µL of either isotonic Ringer’s (IR), or
hypertonic Ringer’s (HR = IR + 200 mM NaCl) from subjects in all groups. In particular,
we calculated the total % Tc-DTPA (± SEM) absorbed over 24 hours (%DTPA24h), the
total change in ASL volume (µL ± SEM) over 24 hours (∆ASL24h), and the baseline ASL
volume prior to the apical volumetric challenge. This last value was used as a measured of
culture quality and baseline control across the different groups and experimental conditions,
see Figure 4.3. No differences were observed between any of the groups for the baseline ASL
volume. CF cultures were found to be slightly drier than either the Carrier or Non-CF groups
in both the isotonic (CF: -3.139± 0.571; Carrier: 1.434± 2.257; Non-CF: 0.165± 1.157) and
the hypertonic cases (CF: -2.451±0.878; Carrier: −1.033±1.619; Non-CF: −3.319±2.751).
Isotonic experiments also showed an increase in %DTPA24h for CF HNE cultures relative
to the Non-CF group (CF: 50.84 ± 2.283 vs. Non-CF: 33.51 ± 3.414, p = 0.000381), but
no change was observed between the Carrier group and either the CF or Non-CF groups
(Carrier: 37.68± 9.05; Carrier vs CF: p = 0.1623; Carrier vs. Non-CF: p = 0.6816) (Figure
4.3). The results suggest that Carriers show a much broader variance than the other groups,
and effectively “split the difference” between healthy and CF. This is further supported by
the results from the hypertonic experiments. HR treatment of the three groups showed no
change in the %DTPA24h between the three groups (CF: 33.38±2.28; Carrier: 21.21±5.72;
Non-CF: 32.50 ± 2.77). However, HR was able to significantly reduce %DTPA24h when
comparing the CF (∼34%, p = 0.0034) and Carrier (∼44%, p = 0.0061) groups across the
two experimental conditions. No meaningful change was observed in %DTPA24h for the
Non-CF group between the two groups (p = 0.894) (Figure 4.3). This suggests that at the
cellular level, cultures derived from carriers of a single CFTR-causing mutation present a
similar, yet milder, version of the liquid transport defect observed for CF cellular cultures,
as described in Chapter 3.
In order to further inform these findings, we also measured ASL24h for all groups under
both IR and HR conditions. For these measurements, it should be mentioned that IR
tends to promote an absorptive phenotype, while HR promotes a secretory phenotype due
to reversal of the transepithelial osmotic gradient. IR experiments showed Carriers reached
similar ASL volume to Non-CF samples after 24 hours (Carriers: 5.63± 1.719 vs. Non-CF:
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Figure 4.3: Boxplots summarizing the observed differences between the three groups in the
study (CF, Carriers, and Non-CF) on the basis of in vitro ASL and paracellular solute trans-
port dynamics. These experiments measure ASL volume and absorption of Technetium99m
DTPA (Tc-DTPA) over 24 hours following a challenge of 10 µL of either isotonic (Left) or
hypertonic (Right, isotonic + 200mM NaCl). Tc-DTPA is an in vitro analogue of In-DTPA
an can only be cleared paracellularly. (Top) percent Tc-DTPA absorption after 24 hours,
(Middle) baseline ASL at time 0, and (Bottom) Change in ASL after 24 hours. Red cross
signifies a measurement found to be an outlier within its group. Statistical significance was
determined through a non-parametric Wilcoxon rank sum test. *: p-values < 0.05.
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5.10± 0.930; p = 0.852), but significantly higher than the CF group (CF: 2.163± 0.289, p =
0.0093). Following the treatment with IR, however, all groups show a significantly increased
ASL24h. The Carrier group was found to be statistically equivalent to both the CF and
Non-CF groups (Carrier: 9.969± 1.59; Non-CF: 22.08± 8.23; CF: 11.08± 1.499). Relative
to their IR levels, Non-CF cells showed the highest increase in ASL24h (∼5-fold), followed
by Non-CF (∼4-fold) and Carriers (∼2-fold). Immediately following the addition of HR, all
groups secreted liquid into the ASL. However, following the ASL peak (∼4-6 h), only the
CF and Carrier groups trend towards their initial baseline levels. Given the similar initial
increase in ASL volume achieved for all three groups, the difference observed at 24 hours
suggests the difference may be due to a longer duration of the osmotic effect of HR. This
could be due to CF, and, to a lesser degree, Carrier cell lines decreased ability to secrete
Cl− or regulate its Na+ intake, possibly leading to a more rapid clearing of the excess salt
ions through diffusion in the paracellular space. It is important to acknowledge the limited
size of the data set in these experiments (Non-CF: N = 3, n = 18; Carrier: N = 4, n = 24;
CF: N = 7, n = 42), since the lower number of Non-CF and Carrier samples may skew the
results. Here N represents the number of subjects, and n is the number of total individual
cultures evaluated. It would be of great interest to examine the response profile as a function
of stimuli with different tonicity levels and longer time points.
4.2.2 Cystic Fibrosis pathophysiology: a study between parent and child
4.2.2.1 CFTR Expression and Functional Levels We have shown so far that car-
riers of a single CF-causing mutation exhibit physiologically meaningful differences versus
both CF and Non-CF individuals at both the cell and organ levels. UC studies in Chapter
2 showed Carriers have statistically different baseline, CFTR, and ENaC associated short
circuit currents in the absence of a transepithelial chemical gradient. Similarly, we have
shown that whole cell protein samples harvested from fully differentiated Carrier HNE cul-
tures expressed approximately two-thirds as much mature CFTR as those obtained from
Non-CF samples (Figure 4.4). This is further supported by a different study that showed
approximately a one-third reduction of CFTR expression Carrier samples vs. Non-CF [3].
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Figure 4.4: Western blot showing the whole-cell CFTR protein expression for two represen-
tative primary HNE cell lines from each group: CF, Carriers, and Non-CF. A minimum of 6
individual filters where harvested for each cell line. Protein samples were probed for CFTR
(middle panel), stripped, and re-probed for GAPDH to use as a reference protein (bottom
panel)
Reduced values for both ∆IForskolin and mature CFTR protein expression suggest that
the lack of a functional CFTR allele does leads to quantifiable changes in cellular electro-
physiology. Results shown in the previous sections also support this claim. In particular,
Carriers showed approximately half as much Forskolin-stimulated (∆IForskolin, µA/cm
2) cur-
rent than non-CF subjects (3.78 ± 0.7 vs. 7.33 ± 0.75). In order to explore this difference,
we tested the ISC of a subset of Carrier HNE primary cultures from the group shown in
Chapter 2 following the treatment with CFTR modulators (Ivacaftor/Lumacaftor) (Figure
4.5).
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Figure 4.5: (Top) Bar plots showing the ∆IForskolin (µA/cm
2) results for CF (red) and
Carriers (green) following treatment with CFTR modulators (lumacaftor/ivacaftor) or no
treatment. (Bottom left) Line plot showing the subject-specific ∆IForskolin at baseline and
following modulator treatment. (Bottom right) Scatter plot showing change of ∆IForskolin
between the two conditions, plotted as child (CF subject) vs. parent (Carrier) pairs.
115
The results revealed that Carrier cultures treated with the modulator combo showed a
5-fold increase in ∆IForskolin response relative to their untreated response. This corresponds
to a total increase of 11.82 ± 0.747 µA/cm2. By comparison, CF cultures exposed to the
same treatment exhibited a nearly 20-fold increase, but with a much lower over all current
change of 4.29 ± 0.57 µA/cm2 (Figure 4.5). When examining the subject-specific response
to the modulator treatment, it was revealed that CF cultures showed a larger inter-subject
variability of treatment response than the Carrier group. This is possibly due to their geno-
types. Out of the three CF lines that exhibited less than 2 µA/cm2 ∆IForskolin , two posses
a genotype not approved for treatment with Orkambi, the clinical version of the modulators
used: ∆F508/D1152H and ∆F508/2184insA. The third line was homozygous for ∆F508.
Similarly, out of the three Carrier cell lines treated with correctors, the one with approxi-
mately 50% lower treatment response also expressed one of these same alleles (2184insA)
(Figure 4.5). We also explored whether a Carrier’s ∆IForskolin response to treatment ex-
hibited any relation with their respective child’s corresponding measurement. No significant
relationship was identified from the the three parent/child pairs studied. However, one of the
pairs studied had the non-responsive allele described above (2184insA). More pairs would
be required in order to establish the existence of any relationship (Figure 4.5C). Lastly, since
Carriers were also shown to have meaningfully elevated levels of sweat Cl− (Figure 4.1), we
also explore a possible correlation between parent and child. However, even after accounting
for pairs where the CF patient is currently on a CFTR modulator therapy, no meaningful
relationship was established (Figure 4.6).
4.2.2.2 Liquid and Solute Transport: in vitro and in vivo In vitro measurements
of ASL volume and Tc-DTPA absorption have been shown to be biomarkers quantifying
important aspects of CF airway pathophysiology in vitro [32, 111]. Results from these
studies in CF and Carriers suggest the two groups share similarities in their water and
solute transport profiles (Figure 4.3). This is also supported by the nominal increase in
ABS values of Carriers relative to Non-CF subjects (Figure 4.2). ABS has been show to
be a reliable indicator of in vivo CF pathophysiology, and acts as an organ-level analogue
to Tc-DTPA absorption [30, 31, 111]. In an effort to explore these observation, parallel
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Figure 4.6: Correlation plots showing the relationship between sweat Cl− in Parents and their
CF children. A linear regression between the two groups was used to established correlation.
Symbols represents current CFTR modulator status for each patient: no treatment (◦),
Kalydeko (square), and Orkambi/Symdeko (). Solid line represents the fitted regression
model, and dashed lines represent the 95% confidence intervals
isotonic (pairs = 7, n = 72) and hypertonic (pairs = 4, n = 48) ASL volume and Tc-DTPA
experiments were performed on CF/carrier matched pairs.
Results revealed a strong correlation between the %Tc-DTPA absorption for the two
groups following the treatment with IR. This relationship is maintained, but somewhat
diminished for the group treated with HR. This relationship suggests that while CF absorbed
Tc-DTPA at higher rates than Carriers, the latter’s paracellular transport rates are not just
nominally similar, but also related to their corresponding partner in the former. This was
further confirmed by calculating the change in %Tc-DTPA in the hypertonic case relative to
the isotonic case, a measure of subject-specific therapeutic response. Plotting this for each
parent/child pair revealed a strong linear correlation between the two groups that nearly
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Figure 4.7: Correlation plots showing the relation between (Left) %DTPA absorption and
(Right) ASL volume in Parents vs. their CF children following treatment with isotonic
Ringer’s (Top), hypertonic Ringer’s (Center), or change from baseline (Isotonic) following
hypertonic Ringer’s (Bottom). A linear regression was used to established correlation. Solid
line represents the fitted regression model, and dashed lines represent the 95% confidence
intervals.
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approached parity (Figure 4.7). Specifically, the decrease in %Tc-DTPA absorbed under
hypertonic conditions relative to isotonic conditions for carriers is nearly equal to that of
their respective children. This suggests that factors beyond disease progression or CFTR
genotype can possibly dictate a CF patient’s response to inhaled osmotic therapies.
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Figure 4.8: Correlation plots showing the relation between MCC (Left) and ABS (Right) in
Parents vs. their CF children 24 hours following treatment with inhaled isotonic saline.
A similar analysis was carried out for ASL volume change following isotonic or hypertonic.
No correlation was found between the two groups in either conditions. However, when we
calculate the ASL volume therapeutic response between the two treatment conditions, we
observed a strong inverse linear correlation (Figure 4.7). In this case, it appears that greater
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improvement in ASL hydration following hypertonic saline for the parent corresponds with
a slightly decreased ASL re-hydration profile in the CF group, with the slope significantly
favoring the CF group. This falls within the predictions established in Chapter 3, which
revealed that CF cells have significantly larger transepithelial hydraulic permeabilities than
Non-CF. It would follow that this trend should also apply to carriers, since CF lines were
shown to absorb more ASL than both Carriers and Non-CF (which were deemed equal to
each other, Figure 4.3). An increased hydraulic permeability, implies that in the presence of
a reverse gradient (i.e. apical hypertonic conditions) CF cells should secrete more ASL and
thus should exhibit a larger total ASL volume change than Carriers. We also performed direct
comparisons between the in vivo MCC and ABS measurements for the same parent/child
pairs following treatment with inhaled isotonic saline. However, no meaningful correlation
was found for either measurement when examining the whole lung, or either its central or
peripheral regions (Figure 4.9).
4.2.3 DTPA Absorption, a Trans-scale Biomarker for Cystic Fibrosis Patho-
physiology
One of the main drivers behind the use of primary HNE cell cultures as an in vitro
model of CF is their potential to serve as a direct bench-scale analogue of a patient’s possible
therapeutic response. In order to fulfill this potential, we must first establish appropriate
means to relate cell level mechanisms to relevant organ-level pathophysiology, and eventually
clinical response. Traditionally, spirometry measurements have been used as assessments of
CF airway disease progression [1, 53]. Similarly, their improvement is used as the primary
endpoint for clinical trials evaluating CF therapeutics [16, 40, 92, 158]. With this in mind,
we explored whether there is any link between ASL volume and Tc-DTPA clearance and
common spirometry measurements: FEV1, FVC, and FEF25%−75%. We have also included
plots showing the same correlation analysis with respect to sweat Cl−, a common method for
CF screening and secondary clinical endpoint. This analysis included measurements from
all three groups (CF, Carriers, and non-CF), and also accounted for CF patients currently
on a CFTR modulator.
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Figure 4.9: Correlation plots between the change in %Tc-DTPA clearance (Top) and ASL
Volume (Bottom) versus (From left to right): Sweat Cl− , FEV1, FVC, and FEF25%−75%
for non-CF (blue), Carrier (green) and CF (red). Symbols represents current CFTR modu-
lator status for each patient: no treatment (◦), Kalydeco (square), and Orkambi/Symdeko
(). Solid line represents the fitted regression model, and dashed lines represent the 95%
confidence intervals
121
Sweat Cl− was found to be directly correlated with %Tc-DTPA absorption (p = 0.017)
and inversely correlated with ∆ASL volume (p = 0.0690). These relationships agree with cur-
rent understanding of CF pathophysiology. It is worthwhile noting that two CF patients with
genotypes linked to mild CF airway disease (3849+10kbc>T/R668C and ∆F508/D1152H)
showed sweat Cl− levels on par with Non-CF subjects. No consistent meaningful improve-
ment was observed among CF subjects on a CFTR modulator. Furthermore, this analysis
revealed that while sweat Cl− is a good measurement for distinguishing between three groups,
it lacks the resolution necessary to serve as a potential link to cell level physiology on its
own.
From the spirometry analysis, FEV1 was found to be directly correlated with ∆ASL
volume (p = 0.0319) and inversely correlated with %Tc-DTPA absorption, although not quite
reaching statistical significance for the latter (p = 0.0556). Both relationships performed
well when capturing the majority of the CF group, but struggle to predict some of the
inter-subject variability observed among the Non-CF and Carrier groups, probably due to
the scaling-related non linearities dominating the relationship between these measurements.
Similar results were observed between FVC and ∆ASL volume (p = 0.0206), and between
FEF25%−75% and %Tc-DTPA absorption (p = 0.0277). As a whole, these results suggest that
while definitely related, ASL volume and Tc-DTPA dynamics struggle to capture system level
physiology with sufficient accuracy on their own.
However, it may possible to overcome this issue through the inclusion of system scale in
vivo analogues of airway absorption dynamics in our analysis. In order to explore this, we
evaluated in vivo absorption profiles for CF patients following treatment with either inhaled
isotonic or hypertonic saline. These measurements track the airway absorption of In-DTPA,
an analogue of Tc-DTPA commonly used for organ level assessments [31, 32, 111, 120]. Using
this information, we calculated each subject’s in vivo and in vitro therapeutic response to
osmotic treatment. These values were plotted against each other, while also accounting for
patients currently on a CFTR modulator.
This analysis revealed that the therapeutic response of both Tc-DTPA absorption and
ASL volume change are highly correlated to the corresponding therapeutic change observed
for ABS across different regions of the lung. In particular, ABS and %Tc-DTPA absorption
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were found to have a very strong direct correlation in the peripheral lung (p = 0.0001,
R2 = 0.7987); this relation was lost in the central lung (p = 0.7883), which obfuscated the
whole lung analysis (p = 0.0633) (Figure 4.10). Previous work in our group has shown that
mucociliary clearance (MCC) dominates the dynamics in the large airway, which account for
the majority of the central lung region of interest [33, 120, 176]. Since In-DTPA can also be
cleared through MCC, it is reasonable to assume that the loss of correlation observed in the
central and whole lung analysis is due to MCC dynamics. The peripheral lung, on the other
hand, is believed to have significantly lower rates of MCC transport and higher absorptive
rates [119, 120, 176], serving as an ideal link to in vitro Tc-DTPA clearance rates.
The opposite behavior was observed when comparing ABS with in vitro ASL volume
change. An inverse correlation was observed between ABS therapeutic response in the whole
lung and the change in ASL volume (p = 0.0078, r2 = 0.4888). This relationship was
abolished in the central (p = 0.0854) and peripheral (p = 0.1459) lung (Figure 4.10). Unlike
Tc-DTPA, ∆ ASL volume is not a direct analogue of ABS. ABS cannot directly account for
in vivo transcellular liquid transport, while ∆ASL volume does. The inverse nature of these
correlations suggests that increased in vitro therapeutic response to osmotic therapies, leads
to a lesser rescue of ABS. Together with findings from Chapter 3, these results suggest that
following osmotic treatment, the larger transcellular water permeabilities lead to rapid, yet
unsustained, hydration of the ASL. The transient increase in ASL volume favors MCC and
decreases the paracellular driving force for the absorption of In-DTPA, lowering ABS. This
behavior is more pronounced in the peripheral lung, which likely has larger rates of hydraulic
permeability than the large airways in the central lung region of interest.
The relations established from this data set have been evaluated through both their sta-
tistical significance, as well as their overall meaning within the context of known CF airway
disease mechanisms. Figure 4.11 shows the results from an univariate, combinatorial, non-
linear ranked correlation matrix illustrating the resulting relations between patient-specific
in vitro, in vivo, clinical measurements, and predicted in silico parameters from both the
cell- and lung-scale models for subjects already enrolled in our trial. The results suggest
there are several measurements with some degree of predictive power. Further analysis is
required in other to identify optimal predictors of clinical measurements of airway function.
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Figure 4.10: Isotonic to hypertonic change in %Tc-DTPA clearance (Top) or ASL Volume
(Bottom) versus the change in In-DTPA absorption (ABS) in the whole (Left), central (Cen-
ter), or peripheral (Right) lung for CF patients. Symbols represents current CFTR modu-
lator status for each patient: no treatment (◦), ivacaftor (square), and lumacaftor/tezacafor
(). Solid line represents the fitted regression model, and dashed lines represent the 95%
confidence intervals.
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Figure 4.11: Ranked correlation matrix showing all inter-parametric correlation coefficients
for all clinical, and in vitro measurements, as well as the in silico estimated parameters
obtained from fitting patient-specific data through our cell-scale models.
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In order to do this, we develop a series of linear regression models that leveraged ASL
and DTPA measurements under isotonic and hypertonic conditions alongside common pa-
tient clinical information such as sweat Cl−, gender, CFTR modulator usage, and airway
microbiology results. The models all followed a similar format as described by Equation 4.1.
y =
k∑
i=1
(αixi) + β (4.1)
Here y represents the vector of predicted variables for all subjects being studied, αi is the
estimated coefficient associated with predictor variable i, xi is the vector of measured values
for all subjects associated with predictor variable i, and β is the predicted model intersect,
a measure of model bias.
These regressions were run following a feature selection analysis that narrowed down
the data set to variables with significant univariate predictive power prior to a full 3-fold
and 5-fold internal cross-validation analysis. This analysis reduced the number of vari-
ables from 55 down to a total of 6 distinct variables including: gender, presence of a
Pseudomonas aeruginosas culture within the last year, CFTR modulator status (no use,
Kalydeco, or Orkambi/Symdeko), percent of Tc-DTPA absorbed following isotonic Ringer’s
stimuli (%DTPAISABS), baseline ASL volume (ASL
IS
0h), and sweat Cl
−. The regression mod-
els for the prediction of MCC and ABS following hypertonic saline treatment, also included
their respective isotonic counterparts as predictive variables. The resulting regression models
for ABS and MCC predictions following either isotonic and hypertonic saline treatment are
shown in Figure 4.12. A summary of all the predicted coefficients, their associated errors and
significance, as well as the over all model statistics and variance are summarized in Table
4.5 for the isotonic case, and Table 4.6 for the hypertonic case.
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Figure 4.12: Adjusted regression models for the prediction of whole lung MCC (Top left)
and ABS (Top right) following inhaled isotonic saline for Non-CF, Carrier, and CF subjects
from in vitro and demographic data. Similarly, regression model for whole lung MCC and
ABS following treatment with hypertonic saline for CF subjects. Predictors, coefficients and
statistical information about model fitness can be found in Table 4.5 for the isotonic saline
case, and Table 4.6 for the hypertonic saline case.
127
Table 4.5: Summary of regressions models developed for the prediction of MCC and ABS
measurements following treatment with inhaled isotonic saline.
Predicted Variable
Treatment MCC ABS
Predictor Coefficient SE p-Value Predictor Coefficient SE p-Value
Intercept -0.7582 0.1710 0.0002 Intercept 0.5622 0.1115 3.36E-5
Gender (F) 0.1215 0.0422 0.0087 Gender (F) -0.1780 0.0436 0.0047
%DTPAISABS 0.0026 0.0012 0.0546 %DTPA
IS
ABS -0.0058 0.0013 0.0002
PA+ -0.1561 0.0549 0.0094 ASLIS0h -0.0154 0.0061 0.0179
Isotonic No Modulator -0.2814 0.0881 0.0042 Sweat Cl− 0.0023 0.0006 0.0018
Saline Ivacaftor 0.0661 0.7815 0.0406
Luma/Teza -0.1530 0.0756 0.0555
Model Statistics Model Statistics
RMSE 0.111 F-stat 9.4 RMSE 0.106 F-stat 18.2
R2 0.741 p-Value 1.74E-5 R2 0.745 p-Value 4.0E-5
5-fold MSE 0.0256 10-fold MSE 0.0291 5-fold MSE 0.0305 10-fold MSE 0.0286
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Table 4.6: Summary of regressions models developed for the prediction of MCC and ABS
measurements following treatment with inhaled hypertonic saline.
Predicted Variable
Treatment MCC ABS
Predictor Coefficient SE p-Value Predictor Coefficient SE p-Value
Intercept -0.5879 0.2829 0.0726 Intercept -0.4415 0.1001 0.0069
%DTPAHSABS -0.0119 0.0045 0.0283 %DTPA
IS
ABS 0.0059 0.0010 0.0023
MCCISWL 0.9249 0.2125 0.00018 ABS
IS
WL 0.7575 0.1254 0.0017
Hypertonic No Modulator 0.3556 0.1123 0.0114 No Modulator 0.0426 0.0605 0.5124
Saline Ivacaftor 0.3777 0.1106 0.0076 Ivacaftor 0.0745 0.0308 0.0603
Luma/Teza 0.1919 0.1131 0.1240 Luma/Teza 0.1073 0.0370 0.0023
Sweat Cl− 0.0023 0.0008 0.0482
Model Statistics Model Statistics
RMSE 0.135 F-stat 5.59 RMSE 0.030 F-stat 54.0
R2 0.756 p-Value 0.012 R2 0.985 p-Value 2.0E-4
3-fold MSE 0.0317 5-fold MSE 0.0302 3-fold MSE 0.0360 5-fold MSE 0.0677
3-fold MCR 0.4807 5-fold MCR 0.4807 3-fold MCR 0.1893 5-fold MCR 0.1786
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4.3 Discussion
The clinical study described above has provided us with a robust data set that we have
then significantly expanded to identify the parametric axes that best describe the aforemen-
tioned link. Patients with CF display a wide range of pathophysiology, even among similarly
genotyped patients. These variations among the patient population are believed to be due
to epigenetic differences in modifier genes of CF disease, as well as the contribution from
multiple environmental influences [35, 115]. As such, developing a mathematically formal-
ized representation of the link between cell-level mechanisms to organ-level dynamics, and
potentially therapeutic response, requires ample knowledge of the physiological processes
that drive these differences.
Analysis of multibreath washout studies and spirometry measurements found no mean-
ingful decrease in airway function in Carriers relative to Non-CF individuals. However,
sweat Cl− measurements were significantly elevated, though not as much as those of CF
individuals. Measurements of DTPA absorption in vivo, ABS, and in vitro, %Tc-DTPAABS,
showed Carriers clear DTPA at nominally higher rates than Non-CF, but not as rapid as
CF subjects. No statistical difference was found between Carrier and either of the other
two groups. No difference was observed in MCC or baseline ASL values between any of the
groups. At the cellular level, however, UC studies showed Carriers have statistically dif-
ferent baseline, CFTR, and ENaC associated short circuit currents. In particular, Carriers
showed approximately half as much Forskolin-stimulated current as non-CF subjects, with
significant changes to their model-predicted channel and transporter permeabilities.
Functional imaging based biomarkers of lung clearance have recently received exten-
sive development in CF. MCC measurements have been used to develop inhaled osmotic
therapies and more recently the CFTR potentiator Ivacaftor [165]. Previous work in our
group developed a nuclear imaging method to measure ASL absorption along with measure-
ments of MCC, based on the absorption rate of a small molecule probe (In-DTPA) from
the lungs. These biomarkers demonstrate a clear, quantifiable signature of CF lung disease
that changes substantially in response to therapy [31, 110]. The multiple variables devel-
oped through this work describe therapeutic response both in vitro and in vivo, and serve to
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develop in silico system models of the organ level physiology depicted through MCC/ABS
scans [119, 120, 176], and the cell level physiology depicted through cell studies [174].
This work has made significant progresses towards the development of a crucial link be-
tween cell and organ level models of airway absorption dynamics, and their dysregulation in
CF. Collection of trans-scale, paired DTPA clearance data has allowed us to evaluate poten-
tial links between cell and organ level physiology. This provides us with a more mechanistic
understanding of therapeutic effects on a cellular level, and allows cell level effects to be
related to organ level outcomes. In particular, this work has identified a direct relationship
between the osmotic effect of hypertonic Ringer’s in CF HNE cultures, and the analogue
therapeutic effect observed in CF individuals after treatment with inhaled hypertonic saline.
This was further validated by statistical models that revealed that both ASL and DTPA can
be used to predict organ-level physiology when combined with common clinical data such as
gender, airway microbiology, and CFTR modulator usage.
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5.0 Summary and Future Work
5.1 Contributions
5.1.1 Model of Airway Electrophysiology for Expediting of Experimental Work-
Flow
The work in this dissertation presented a general model of airway epithelial electro-
physiology capable of meeting both numerical tractability and physiological relevance. This
work required the development of a custom parameter estimation strategy capable of cir-
cumventing the discontinuities observed in the parametric space of the model. This model
was validated through the prediction of known parametric and state changes to complex
experimental stimuli such as CFTR modulator therapies and inflammatory citokines.
Furthermore, the model was used to explore the electrophysiology of primary human
nasal epithelial (HNE) relative to their human bronchial epithelial (HBE) counterparts.
HBE cell cultures have provided a simple and robust model of airway epithelial physiology.
HBEs from CF lungs mimic the epithelial pathophysiology of CF and have received extensive
use in the study of CF lung disease. HNE cell cultures sampled by nasal brushing have been
shown to have similar properties to the HBE cultures, allow for basic studies in cultures from
subjects not undergoing lung transplant. Recent improvements to HNE culture protocols
have allowed their more practical use in research applications [41, 197, 211, 215], however,
little information is currently available about the possible differences between HNE and
HBEs, or the impact that any possible difference may have in CF pathophysiology. The
model was capable of successfully recapitulating the short-circuit dynamics observed for both
types of tissues, and identify potential differences in the homeostatic levels of transepithelial
Cl− transport Non-CF HNE cell cultures relative to HBE ones. In particular, the model
predicted a shift in basolateral Cl− permeability from NKCC to bicarbonate-dependent flux.
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5.1.2 Cell-Scale Model of Airway Liquid and Solute Transport
The thin-film extension of the epithelial transport model accurately captures ASL and
Tc-DTPA dynamics within biologically-meaningful parametric ranges allowing for a mech-
anistic exploration of the physiological differences between CF and non-CF epithelia, high-
lighting differences in absorption kinetics between the non-CF and CF cultures. Non-CF
cells rapidly reabsorbed liquid and return to homeostasis while CF cells demonstrated a
slower rate, but longer duration, of liquid absorption that ultimately leads to a decreased
standing apical volume. The model also predicted the main factor contributing to differ-
ences in absorption dynamics between CF and non-CF epithelia are transcellular hydraulic
permeabilities (∼3-fold higher in CF) and not paracellular permeability.
Our model also corroborates previous reports, both in vitro [32] and in vivo [30], that
radiolabeled DTPA conjugates absorption is increased in the CF airway. While ASL can be
transported through trans- or paracellular pathways, Tc-DTPA can only be cleared para-
cellularly, either through diffusive or convective transport. Since the convective component
of Tc-DTPA absorption is directly driven by ASL absorption, the relationship between Tc-
DTPA and ASL absorption can be used to illustrate the relative contributions of convection
and diffusion. Using our mathematical description of Tc-DTPA absorption from the ASL,
we were able to probe the relative contributions of diffusion and convection that lead to
increased solute absorption in CF. The model predicted that diffusive transport accounts for
approximately 60% of all Tc-DTPA absorption seen in CF, a significant increase relative to
the 49% predicted for non-CF cells, which is close to experimentally observed values [110].
It is likely that diffusion transport rates are increased in CF due to the decreased initial ASL
volume and identical added Tc-DTPA counts in both CF and non-CF experiments.
A significant contribution of the model is the use of a more mechanistic understanding of
paracellular ion fluxes. Current literature describes paracellular ionic transport using Gold-
mans constant field equation, the same expression used for transcellular ion channel fluxes
[62, 168]. This approximation fails to account for the contributions of diffusive transport
along the entire paracellular pathway and convective transport due to fluid drag. Previous
work from our group has shown that convective transport can account for approximately
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50% of Tc-DTPA transport across primary HBE cell cultures [110]. This suggests convec-
tion could also play a significant role in the paracellular transport of ionic species. Specifi-
cally, we compared predicted paracellular electrolyte fluxes in the electroosmotic versus the
combined convection plus diffusion case. Our results suggest that electrical contributions
are effectively negligible after the inclusion of convective driving forces. This distinction
is particularly important under conditions of non-homeostatic hydraulic flux, such as those
following a volumetric or tonicity challenge of the ASL, which are highly relevant for inhaled
osmotic therapies commonly used by CF patients.
5.1.3 Insight into the Physiology of Carriers of a Single CF-Causing Mutations
The work here was able to show that carriers of a single CF-causing mutation exhibit
physiologically meaningful differences with both CF and non-CF individual at both the cell
and organ level. Analysis of showed no meaningful airway function differences in Carriers
relative to Non CF individuals. However, solute absorption rates appeared to be elevated in
both in vivoand in vitro measurements never reaching levels observed in CF.
At the cellular level, this work has shown significant electrophysiological differences be-
tween Carrier sand both CF and non-CF subjects. In particular, Carriers showed approxi-
mately half as much Forskolin-stimulated current than non-CF subjects. Similarly, we have
shown that both whole cell protein and CFTR modulators are statistically lower in Carriers
than Non-CF lines. This study is the first comprehensive look at CFTR function in Carriers,
and the degree to which a single mutation can affect the proper function of airway epithe-
lium. This also provides an avenue to identify just how much CFTR is required in order to
avoid CF pathogenesis.
5.1.4 DTPA as a Multi-Scale Biomarker of CF Pathophysiology
Functional imaging based biomarkers of lung clearance have recently received extensive
development in CF. MCC measurements have been used to develop inhaled osmotic therapies
and more recently the CFTR potentiator Ivacaftor [165]. In order to better understand the
multiple factors contributing to therapeutic response in vitro and in vivo, we have developed
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in silico systems models of the organ level physiology depicted through MCC/ABS scans
[119, 120, 176], and the cell level physiology depicted through cell studies [174].
This work has made significant progresses towards the development of a crucial link be-
tween cell and organ level models of airway absorption dynamics, and their dysregulation
in CF. In particular, identifying direct relationships between the therapeutic effect of hy-
pertonic Ringer’s in CF HNE cultures, and the analogue effect observed in CF individuals
following treatment with inhaled hypertonic saline. Statistical models revealed that both
ASL and DTPA can be used to predict organ-level physiology. This models provide a unique
opportunity to evaluate organ level physiology and therapeutic response a priori through
standard patient demographic information and HNE-based measurements. This measure-
ments could serve as valuable tools for the pre-screening of non-responders for the purposes
of clinical trials.
5.2 Future Work
The above work represents a summary of a project that bridges the quantitative and
design utility of systems medicine with biological and clinical expertise relevant to the field
of CF research. It is intended to serve as a means to improve our understanding of CF patho-
physiology, and as a basis for the further development of novel, patient-specific treatment
options for patients with CF. The following section outlines potential avenues to further
advance this work.
5.2.1 Additional Applications of the Cystic Fibrosis Electrophysiology Model
5.2.1.1 Modeling of Bicarbonate and H+ in Airway Epithelium One of the most
favorable traits of the electrophysiology model presented in this work is its balance between
physiological-relevance and numerical parsimony. As we have described above, the electro-
chemical transport of ionic solutes across biological membranes is an inherently nonlinear
and numerically complex phenomenon. The models described in Chapters 2 and 3 include
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descriptions of most relevant transport pathways for the three major electrolytes: Na+,
Cl−, and K+. However, these models also implement significant assumptions in order to
circumvent the numerical issues described.
There are other ions that also play an important role in epithelial osmolarity, polarization,
cell volume and ASL regulation, both in health and disease. For example, many of the cellular
ion transport pathways are pH dependent [84]. Characterization of pH would require the
addition of H+ and HCO−3 as model states. The inclusion of these components would need
to account for intracellular chemical reactions that facilitate the pH regulation of the cell.
At the same time, it would facilitate the explicit modeling of additional transporters such
as anion exchangers (AEs), Na+-Bicarbonate co-transporter (NBC), Na+-Proton-exchanger
(NHE), the K+-Proton ATPAse (KHP), TMEM16A, and SLC26A9 (Figure 5.1) [1, 8, 9, 60].
Figure 5.1: Diagram of potential Ussing Chamber model structure extension to include the
addition of bicarbonate and proton transport.
Addition of some of these channels would further expand the model’s ability to aid in
in silico experimentation, particularly for the analysis of more nuanced experimental set
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ups and the study of inflammatory responses in both CF or in other disease states like
asthma [116, 117, 178, 212]. However, it should be noted that inclusion of these extra states
would require significant effort in order to ensure model identifiability and numerical stability
alongside physiological state dynamics. The difficulty of this task is evident in simulation
results that used the basic descriptions of ion transport from the cell-scale models in the
literature [54, 75, 135, 207]. However, our groups recent work has led up to developed a data
set rich in Bicarbonate-dependent ion transport mechanisms. Thus providing us with a solid
launching platform for the addition of extra pathways without necessarily compromising the
numerical tractability of our model.
5.2.1.2 Electrophysiology in Cystic Fibrosis-Related Diabetes Pathophysiology
The electrophysiology model could also provide an avenue for the study of CF pathophysi-
ology in other tissues, particularly in pancreatic cells. The recent advances in CFTR modu-
lators and our understanding of airway microbiology and inflammation has led to significant
increases in the life expectancy of CF patients. However, this has also lead to an increase
in the fraction of the CF population with other meaningful comorbidities such as Cystic
Fibrosis related diabetes (CFRD) [91]. This increase has led to a significant push for the
study of CF ”below the diaphragm”.
It has been established that CFTR is widely expressed in both pancreatic α and β cells
in several experimental models, where it appears to contribute to the proper polarization
of islet tissue. [10, 13]. Several studies have hypothesized that CFTR dysfunction gives
way to cellular hyper-polarization due to reduced glucose-sensitive depolarization and in-
sulin release [69, 137, 214] (Figure 5.2). The electrophysiological mechanism behind this
process are largely unknown, and could benefit from a biophysical model capable of tracking
the relationship between transmembrane ionic transport, membrane potential, and insulin
and glucose dynamics. From a model structure point of view, this system could be much
more numerically tractable than airway epithelia, since it would not require the inclusion
of epithelial polarization or Ussing chamber short-circuit constraints. It would also benefit
from a rich library of in silico models of islet cell glucose/insulin dynamics and inflammatory
signals in glucose response [122, 124, 155, 202].
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Figure 5.2: Diagram describing a potential β−cell electrophysiological mechanism leading
to the pathogenesis Cystic Fibrosis-related diabetes.
5.2.2 Optimal Treatment Design at the Cell-Scale
Previous studies of have shown that both ASL reabsorption and ABS begins immediately
following the treatment with isotonic therapies [31, 110]. In this work, we have established
that there exits a direct relationship between in vitro therapeutic response of ASL and
Tc-DTPA dynamics and ABS following a hypertonic stimulus. It is possible that this rela-
tionship can be used to study cell-to-organ dose response behavior. For example, it should
be possible to regulate the degree of ASL hydration in primary cultures as a function of
apical osmolarity challenges. Furthermore, we can assume there is a range of ASL volumes
at which MCC can occur. If a greater than minimum necessary hydration level is achieved
with a given dose, then there will be a period of time that MCC will be improved even as
ASL volume recedes.
We have a mathematical model of the ASL volume regulatory system, a treatment ob-
jective, a body of relevant in vitro and in vivo data, and extensive knowledge and experience
with airway physiology at multiple scales to generate heuristics that can serve as formal
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mathematical constraints in such a way that retains clinical and logistical meaning. Given
this information, a dose scheduling problem can be posed. Equation 5.1 shows a possible
formulation of this problem.
minN,tk,ω
{
t∞∑
t=0
1
σ2tk
(
Vˆ ASLCF (t, θ, u(tk, ω))− V ASLNCF (∞) + λ
)2
+ ΓN
}
dX
dt
= f(x˙, t, θ) + u(tk, ω)
Y (t) = g(x, t, θ)
s. t. λl ≤ λ ≤ λu,
N ≤ dD, N ∈ Z,
tk − tk−1 ≥ dL, t ∈ Q and
ωIS ≤ ω ≤ ω15%HS, ω ∈ Q
(5.1)
Here, Vˆ ASLCF is the control variable, λ is a slack variable that defines the acceptable
therapeutic target as referenced by the Non-CF steady state ASL volume, V ASLNCF (∞), and
delimited by an upper , λl, and an lower, λu, bound. N is the number of treatments per day,
which cannot exceed a certain number, dD. tk is a vector of size N containing the dosage
times, such that a given dose, k, can not be less than dL time units from dose k − 1. ω is
the total osmolarity of the solution being dosed. It is defined such that it cannot be lower
than the osmolarity of isotonic saline, wIS, or higher than the osmolarity of 15% hypertonic
saline, ω15%HS (Figure 5.3). This formulation is similar to the one proposed by Markovetz
et. al [119]. However, this iteration leverages the findings from Chapter 4 regarding our
ability to track DTPA clearance dynamics across multiple physiological scales.
It is important to highlight that the ODE model and its the decision variables relating to
dosage timing and osmolarity are highly nonlinear and continuous in nature. However, the
number of doses is an integer variable, making this a mixed-integer nonlinear programming
problem. It should be possible to leverage the versatility of Pyomo as well as common open
source nonlinear and mix-integer solvers such as IpOpt, GLPK, and CBC to solve problems
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of this class efficiently and rigorously. Kronqvist, et. al. recently published an extensive
review covering both the formulation and implementation of these type of problems [98].
Figure 5.3: Diagram of steps necessary for the development of a therapy design framework
at the cell-scale. The project would required the development of a library of dose-response
osmotic therapy ASL volume changes in vitro, use the responses and the resulting correlations
to inform a non-linear, mix integer optimization problem that can be translate to in vivo-level
response.
5.2.3 Development of a CF Clinical Decision Support System
Current trends in CF therapeutics development indicate that future therapies are likely
to be genotype specific, possibly even patient specific, and that patients may require differ-
ent combinations of medications designed to both potentiate CFTR channels and ameliorate
existing airway damage [16, 40, 64, 92, 158, 164, 191]. In fact, there has been significant
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progress in theratyping of rare CF mutations. Theratyping focuses in evaluating the clini-
cal response to different treatments on an individual basis. This overcomes the limitations
of genotype to predict response to individual therapies and includes all patients regard-
less of CFTR variations. For example, the use of organoids from rectal biopsies in high
throughput screening has allowed numerous compounds to be tested on patient-specific tis-
sue pre-clinically [37, 147]. Similarly, recent work has led to the better understanding of the
pharmacological mechanism different CFTR modulators used to correct distinct CF-causing
variants, including rare combinations [4, 139, 149, 186]. This could lead to the extension
of theratyping beyond CFTR modulators. Specifically, creating a push for the design of
more targeted prophylactic or ameliorative therapies. Recognition of the clinical importance
of CF theratypic variants could potentially extend to the formal definition of CF disease
endotypes.
In fact, there has recently been a concerted effort in the optimization and full char-
acterization of novel in vitro models of CF pathophysiology [147]. Human nasal epithelial
cultures are one of these models, and the work presented in this dissertation provides a strong
foundation for the better understanding of its physiological relevance in CF airway disease.
Furthermore, recent studies have demonstrated the viability of recovering HNE cells from
infants [129]. This provides a glimpse to a future where in vitro samples and clinical mea-
surements are acquired and used to inform computational clinical decision support systems
(DSS) with the ultimate goal of designing prophylactic strategies early in life, before clinical
pathology is demonstrated, potentially stalling disease progression or even pathogenesis.
Furthermore, the availability of more sophisticated, interlinking models that provide a
better indication of therapeutic efficacy based on in vitro studies would facilitate the more
rapid development of these therapies. They could provide a much needed bridge between
exploratory studies performed on sampled nasal cell cultures or through functionalized in
vivo imaging and the design of more optimized and personalized medication choices and
dosing schedules, as described in the previous section. A general framework for such a
platform is depicted in Figure 5.4. The development and integration of the models described
here is a key step in realizing this vision.
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Figure 5.4: Diagram of potential Cystic Fibrosis clinical decision support system (DSS) incor-
porating a combination of genetic, in vitro, in vivo, and in silico physiological measurements
to predict clinical outcomes for individual patients.
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Appendix A
Human Nasal Epithelia (HNE) Cell Cultures
A.1 Protocol
A.1.1 Processing
Ussing a 1000uL pipette tip, scrape pipette tip across the brush to harvested cells. Rinse
brush and pipette tip with 1-2 mL of sterile PBS to remove cells. Centrifuge sample at 300G
at 4C for 5 min. Resuspend cell pellets in 5 mL Accusate, incubate at 37C with occasional
agitation until pellet disperses, approximately 5-10 min. Centrifuge sample at 300G at 4C
for 5 min. Resuspend pellet in 10 mL PBS and centrifuge at 300G at 4C for 5 min. Remove
supernatant and resuspend each cell pellet in media for culture as below.
A.1.2 Expansion: Co-Culture Method
Pre-seed feeder cells (irradiated 3T3-J2, mouse fibroblast cell line) for 24 hours in the
well of a 6 well plate with complete growth media (CGM). Typically, you will seed 400,000
3T3-J2 cells per well the day before receiving the nasal sample. Immediately prior to seed-
ing epithelial cells, aspirate CGM and wash with sterile PBS. Resuspend epithelia cells in
Georgetown media (GM), then place onto feeder cell plate. Use 2.5 mL of GM per well;
seed a minimum of 500,000 epithelial cells per well for initial seed. Leave undisturbed for 48
hours. Co-culture should be checked, and media changed daily, with at least one DPBS wash
per week. For further passages, 1:3 to 1:4 ratio of epithelia to feeder cells yields a co-culture
that is ready for subsequent passage in 3-5 days. Ideally, cells should be passaged when the
epithelial cells reach 70% confluence. If confluence exceeds 70%, multiple trypsinization (see
below, 5-8 minutes each) need to be performed to optimize viability of the cells.
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A.1.3 Trypsinization
Wash the plates with PBS once. Add a 1.5 mL of warm dark trypsin solution per per
well of 6 well plate to remove the feeders. Swirl gently to coat and incubate the 37C for
exactly 2 minute. Observe cells in microscope to verify that feeder cells have fully detached.
Swirl/tap gently, if necessary. GENTLY add PBS, swirl and tilt dish to aspirate feeders.
If performed too forcefully, epithelial cells can be dislodged and lost. Add 3 mL of trypsin
solution per well of 6 well plate and incubate at 37C for 8-10 minutes to detach the remaining
epithelial cells. Add an equal amount of TNS and collect mixture in a labeled 50 mL conical
tube and place on ice. Centrifuge at 900rpm at 4C for 5 minutes. Remove supernatant and
re-suspend cells in GM with a target of 1 x 106 cells per mL. Typical volumes range from
1-5mL. Count and determine the volume of cell suspension needed for plating on filters for
re-differentiation and/or reseeding as co-culture Remaining cells not used for platting can
be centrifuged and resuspended in DMEM/F-12 media to be frozen.
A.1.4 ALI Culture
Coat filters (Transwell) with Human placental collagen. Seed cells on filters at a seeding
density of up to 300-250K cells per cm2 (P3) or 300K cells per cm2 (P4+). Submerged
cultures in GM on filters for 24-48 hours (or until confluent) changing media every 24 hours.
After cells are ¿90% confluent, remove GM media and culture cells submerged UNC media
for 24 hours, then switch to ALI conditions. Culture at ALI for 28 days before evaluating
electrophysiology and/or epithelial transport. Change media as appropriate, minimum is
every other day basolaterally during early stages and 3X times weekly once established, with
weekly sterile DPBS apical wash of approximately 50-100uL per filter.
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A.2 Media Recipes
A.2.1 Complete Growth Media (CGM)
: 500 mL DMEM (H) (Gibco: 11965-092) + 50 mL fetal bovine serum (Gibco: 16140-
071) + 5.5 mL 100x glutamine (Gibco: 25030-081) + 5.5 mL pen/strep (Gibco: 15140-122).
Sterile. Store at 4C.
A.2.2 Georgetown Media (GM)
: 373 mL DMEM (H) (Gibco: 11965-092) + 125mL F12 nutirent mix (Gibco: 11765-
054) + 0.5 mL Hydrocortizone/EGF mix (Dissolve hydrocortisone (Sigma H0888) in 100%
ethanol at 0.5mg/ml. Mix 1mL of this with 19 mL DMEM containing 2.5 ug EGF (Invit-
rogen PHG0311 or PHG0311L)) + 0.5 mL insulin (Dissolve 100 mg insulin (Sigma I5500
or I2643) in 20 mL distilled water containing 200 uL glacial acetic acid) +0.5 mL Fungi-
zone/Amphotericin B (Fisher: BP264550) + 0.5 Gentamicin (Gibco: 15710-064) + 4.3 L
cholera toxin (Dissolve 1 mg vial of cholera toxin (Sigma C8052) in 1 mL distilled water and
filter sterilize) + 0.5 mL Y-27632 (Axxora: ALX-270-333-M025. Dissolve 25 mg with sterile
water to a concentration of 5 mM).
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Appendix B
Ussing Chamber characterization of CF Primary Airway Epithelial Cell
Cultures Following CFTR Modulator treatments
B.1 Protocol
1. Wash the apical side of the membrane for 15 minutes with 20µL of warm (37 degrees)
DPBS solution at least 2 days prior to the experiments. Make sure to not disturb the
monolayer when suctioning the apical wash. DPBS is used in order to minimize any
disruption to the tight junctions during the wash.
2. VX-809 (or VX-661 if applicable) should be added to the basolateral media at a 3µM
final concentration. Filters should be fed with freshly made VX-809 in media 48 and 24
hours prior to the chamber run. Prior testing has shown that in HBEs ∆IForskolin peaks
after 48-72 hours of corrector treatment. However, it also showed longer treatment times
abrogate this effect, possibly due to excessive exposure to DMSO. When using VX-809, I
advise to check the cell line’s genotype before starting the treatment. Experience suggest
that filters with even a single nonsense or frameshift mutation (those producing no CFTR
at all) tend to show negligible to no response to the treatment.
3. The potentiator, VX-770, is added acutely during the Ussing chamber run. It is prepared
in DMSO and added to obtain a final chamber concentration of 100 nM. Stock solution
is usually prepared at a 1000x concentration in order to facilitate addition during the
run. For the purposes of data incorporation into the model, try to add VX770 at the
same time as Forskolin.
4. The bath solutions should be normal Ringers with Bicarb on both the apical and baso-
lateral sides of the cell. Some experiments will be run on the presence of a Cl− gradient
(High Cl- Ringers basolaterally and Normal Cl− Ringers apically). 5 mL of solution
should be added to both the apical and the basolateral chambers and bubbled with 5%-
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CO2 95% air bubbled through for mixing purposes. In cases were the experiments are
ran in the absence of Bicarbonate, use the fish pump to bubble the chambers. This will
remove the CO2 and make sure the chambers solutions do not produce bicarbonate from
it.
5. It is important to allow sufficient time in between different drug additions during the
run, so the filter can re-stabilize and reach a new steady state. 5 minutes is typically
sufficient. Similarly, it is important to allow the baseline current to stabilize prior to the
addition of any drugs. This process varies across cell-lines and can take as long as 30
minutes.
6. Please verified the specific drug additions for each experiment. A traditional corrector
Ussing Chamber uses the following addition order: Amiloride→ Forskolin→ VX-770→
CFIhn172 → Bumetanide
B.1.1 Other chemicals used
• Amiloride: 5 L at 10mM concentration, to achieve a chamber concentration of 10 M
is added directly to the apical chamber once the current has stabilized. The stock is
prepared and kept in aluminum foil to eliminate exposure to light.
• Forskolin: 5 L at 10 mM concentration to achieve a chamber concentration of 10 M
is added directly to the basolateral after the current has stabilized from the Amiloride
addition usually 5 minutes after the Amiloride addition.
• CF Inh 172: 5 L at 20 mM concentration to achieve a chamber concentration of 20 M
is added directly to the apical chamber after the current has stabilized from the VX-
770/Forskolin addition.
• Bumetanide: 5 L at 50 mM concentration to achieve a chamber concentration of 50 M
is added directly to the basolateral chamber after the current has stabilized from the
CF172 addition usually 5 minutes.
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Appendix C
Experimental Protocol to Assess Apical ASL and Tc-DTPA Retention
C.1 DTPA Experimental Protocol
1. Day before the experiment, call Cardinal Health to order radioactive material (412-227-
0911), tell them its for the Corcoran Lab. Order 5 mCi sodium pertechnetate in a 1mL
solution and 1 DTPA cold kit. There are a few spares in the hot lab if needed (quite
rarely). Replace the spares every couple of months as they do expire.
2. Day of experiment, collect your radioactive material and DTPA cold kit from nuclear
medicine in Presby.
3. In the hot lab, over an absorbent blue pad, carefully add the 1mL of 5mCi sodium
pertechnetate to the DTPA cold kit vial.
4. Add 4mL of saline to the DTPA cold kit vial. The final volume of DTPA-Tc to be
5mL so if they give you the sodium pertechnetate at a different volume, just adjust the
amount of saline to add so you have a final volume of 5mL (which is 1mCi/mL).
5. Allow the DTPA and sodium pertechnetate to bind for 15 minutes.
6. While you are waiting, scan the plates of cells for time point = -1.
7. After 15 minutes, remove a small sample of the DTPA-Tc into a separate microtube.
8. Perform QC by obtaining one red and one black chromatography strip. Place a 1.5uL
drop of DTPA-Tc at the bottom line of the strip. Place the red strip in a glass vial
with a small amount of acetone and the black strip in a glass vial with a small amount
of saline. NOTE: you do not want the strip to touch the sides of the glass vial, simply
place the strip in the vial so that the bottom is in the solution and the top of the strip
leans against the top of the glass vial (if the strip touches the sides, it can throw off your
result).
9. Place microtube with DTPA-Tc in a lead container to test the QC.
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10. Cut the strips so each number is separate.
11. Check the radioactivity for each strip 1 and 4 should be high, 2 and 3 should be low. If
your results are not correct, your kit failed and you must start again with fresh sodium
pertechnetate.
12. Mix 10µL of the DTPA-Tc with 990µL of ringers made the previous day.
13. Add 10µL of the ringers + DTPA-Tc to the apical side of each filter
14. At the start of reading each plate, check the background (place the plate behind the lead
sheet).
15. Read the radioactivity on each filter keeping the remainder of the plate behind the lead
sheet.
16. Once complete, scan the plate for ASL volume.
17. Keep the plate in the incubator between time points.
18. Repeat read/scan for time 2, 4, 6, 8, 12, 24 hours.
C.1.1 Tips and Tricks
• When starting the experiment, treat one plate at a time. So treat a plate, do the
reading/scan, then start the next one. Otherwise, your first time point is not truly time
zero.
• When taking the plates out of the incubator, take one plate at a time. The change in
temperature and gas does have an affect.
• When adding the Ringers + DTPA-Tc to the cells, you want to slowly dispense the
solution to form a ball at the end of the pipet. That way only the ball of solution
touches the cells and it will help to avoid disturbing the cell layer.
• Ringers should be used warm, so if you stored in the fridge overnight, place it in the
water bath prior to use.
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C.2 Using the Scanner for ASL volume measurement
1. Open the Scanner program on the computer
a. EPSON scan
b. bottom left icon on desktop
2. When the screen pops up, under SETTING Name Setting 2
3. Click Preview
4. Once the preview happens, click on Scan
5. A third screen will pop up
a. Navigate to location→ other→ browse, and select the folder for which you want to
place your images
b. File name: Cell type prefix + 3 digit line number→ Prefix→ how you want to save
your images. The standard lab practice for labeling is ”date−cell line−experimental
conditions−timepoint−”.
c. Place the plate on the scanner with the rounded edges toward you
d. Slide the plate down and to the right within the template
e. OK
6. When the scanner is done scanning the image, the folder you saved the image in will pop
up and you can check your image.
C.2.1 Tips and Tricks
• Clean the condensation off the top of the filter plate (in the hood if you are keeping the
cells sterile).
• Wipe any unnecessary smudges off the top and bottom of the plate.
• If the scanner stops connecting with the computer, check the connections in the back of
the scanner. Tighten them and then restart the program.
• Check the images after scanning to ensure they are of good quality.
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Appendix D
Code for Models
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D.1 Thin Film Model of Airway Epithelial Liquid and Solute Transport
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D.2 Code for Ussing Chamber Electrophysiology Model
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D.3 Driver for Ussing Chamber Model
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